Abstracts

 
 
  • Bernstein V, Ellard S, Dent SF, Gelmon KA, Dhesy-Thind SK, Mates M, Salim M, Panasci L, Song X, Clemons M, Tu D, Hagerman LJ, Seymour L. A randomized (RCT) phase II study of oncolytic reovirus (pelareorep ) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC). Proc Am Assoc Cancer Res . 2017.
  • Bradbury PA, Ding K, Ellis PM, Seymour L, De Kievit F, Jones G, Morris CD, Green E, Goss GD, Tsao MS, Shepherd FA. Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 35[Suppl; abstr 9024]. 2016.
  • Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn K, Albain KS, Chew HK, Von Burton G, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow J, Hortobagyi GN. SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy. J Clin Oncol 35[Suppl; abstr 521]. 2017.
  • Chen EX, Jonker DJ, Kennecke HF, Koski SL, Wei AC, Magoski NM, Tu D, O'Callaghan CJ. The CCTG CO.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies. J Clin Oncol 35[Suppl; abstr TPS3621]. 2017.
  • Daaboul N, Gauthier I, Tu D, Brown-Walker P, Sun X, Hao D, Juergens RA, Bradbury PA, Mates M, Tehfe MA, Kollmannsberger CK, Ellis PM, Robinson AG, Wheatley-Price P, Laurie SA, Seymour L. Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) ± tremelimumab (T): CCTG IND226. J Clin Oncol 35[Suppl; abstr 3058]. 2017.
  • de Boer SM, Powell ME, Mileshkin LR, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles AW, Baron M-H, Kitchener HC, Nijman H, Kruitwagen RFPM, Jurgenliemk-Shultz IM, Nout RA, Smit VTHBM, Putter H, Creutzberg CL. Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer. J Clin Oncol 35[Suppl; abstr 5502]. 2016.
  • Eigl BJ, Winquist E, Tu D, Hotte SJ, Canil CM, Gregg RW, Zulfiqar M, North SA, Ellard S, Ruether JD, Le LH, Kakumanu AS, Theis A, Booth CM, Potvin KR, Chi KN, Seymour L. A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209. J Clin Oncol 35[Suppl; abstr 5021]. 2017.
  • Ghate K, Parulekar WR, Chen BE, Montenegro A, Khaouam N, McCarthy JS, Walker J, Waldron J, Siu LL, Johnson A. Resource utilization in patients with head and neck cancer: Analysis of CCTG HN6 (NCT00820248). J Clin Oncol 35[Suppl; abstr 6067]. 2017.
  • Jiang DM, Sim H-W, Siu LL, Shapiro JD, Liu G, Price TJ, Jonker DJ, Karapetis CS, Strickland A, Zhang W, Jeffery M, Tu D, Ng S, Sabesan SS, Shannon J, Townsend AR, Morgen E, Xu W, O'Callaghan CJ, Chen EX. Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 35[Suppl; abstr 3600]. 16 A.D.
  • Jonker DJ, Hotte SJ, Razak ARA, Renouf DJ, Lichty B, Bell JC, Powers J, Breitbach CJ, Stojdl DF, Stephenson KB, Bramson JL, Hummel J, Lemay CG, Cutz J-C, Wells J, Eady R, Sun X, Tu D, Dancey J. Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214. J Clin Oncol 35[Suppl; abstr e14637]. 2017.
  • Karim S, Ding K, Bradbury P, Ellis P, Mittmann N, Sun XX, Millward M, Liu G, Sun S, Stockler MR, Cohen V, Blais N, Sangha R, Boyer M, Sasidharan R, Lee C, Shepherd FA, Goss G, Seymour L, Leighl NB. Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26. Ann Oncol 28[Supplement 5], 398. 2017.
  • Kuruvilla J, Crump M, Villa D, Aslam M, Prica A, Scott DW, bdel-Samad N, Couban S, Doucet S, Dudebout J, Fleury I, Fraser G, Larouche J, Shafey M, Skrabek P, Skamene T, Winch C, Shepherd L, Chen BE, Hay AE. Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B Cell Lymphoma (RR-DLBCL) - Outcome of Ibrutinib+R-GDP. Hematological Oncology 35, 88. 2017.
  • Ledermann JA, Embleton AC, Perren T, Jayson GC, Rustin GJS, Kaye SB, Hirte HW, Oza AM, Vaughan MM, Freidlander M, Martin AG, Clark E, Popoola BO, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MK. Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer. J Clin Oncol 35[Suppl; abstr 5506]. 2016.
  • Litère S, Isaac G, de Vries E, Bogaerts J, Chen AP, Dancey J, Ford R, Gwyther SJ, Hoekstra OS, Huang E, Lin NU, Liu Y, Mandrekar SJ, Schwartz LH, Shankar L, Therasse P, Seymour L. Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database. J Clin Oncol 35[Suppl; abstr 2534]. 2017.
  • Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle FM, Hillman DW, Korde LA, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Lang I, Xu B, Smith IE, Barrios CH, Gelber RD, Baselga J, Piccart-Gebhart MJ. Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer. J Clin Oncol 35[Suppl; abstr 502]. 2017.
  • Newcomb PA, Sun W, Hua X, Banbury BL, Phipps AI, Kocarnik J, Harrison TA, Shi Q, Sinicrope FA, Thibodeau SN, Chan E, Gill S, Goldberg RM, Kahlenberg MS, Nair S, Shields AF, Jahagirdar BN, Peters U, Alberts SR, Chan AT. Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance). J Clin Oncol 35[Suppl; abstr 3604]. 2017.
  • Renouf DJ, Kavan P, Dhani NC, Jonker DJ, Wei AC, Hsu T, Tang PA, Graham B, Tu D, O'Callaghan CJ. The CCTG PA.7 trial: A randomized phase II study of gemcitabine and nab-paclitaxel vs. gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab as 1st line therapy in metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol 35[Suppl; abstr TPS4149]. 2017.
  • Ruppert AS, Byrd JC, Heerema NA, Smith MR, Godwin JE, Couban S, Fehniger TA, Thirman M, Halvorson AE, Tallman MS, Appelbaum FR, Stone RM, Robinson S, Chang JE, Mandrekar S, Larson RA. A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance). J Clin Oncol 35[Suppl; abstr 7503]. 2017.
  • Sahgal A, Myrehaug S, Dennis K, Liu M, Chow E, Wong R, Butler JB, Greenspoon JN, Fehlings MG, Maralani P, Masucci L, Lee Y, Brundage MD, Liu SK, Ding K, Hum M, Parulekar WR. A randomized phase II/III study comparing stereotactic body radiotherapy (SBRT) versus conventional palliative radiotherapy (CRT) for patients with spinal metastases (NCT02512965). J Clin Oncol 35[Suppl; abstr TPS10129]. 2017.
  • Sinicrope FA, Shi Q, Hermitte F, Heying EH, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair S, Shields AF, Sargent DJ, Galon J, Alberts SR. Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance). J Clin Oncol 35[Suppl; abstr 3579]. 2017.
  • Sinicrope FA, Shi Q, Smyrk TC, Goldberg RM, Heying EH, Cohen SJ, Gill S, Kahlenberg MS, Nair S, Shields AF, Sargent DJ, Jahagirdar BN, Pollak MN, Alberts SR. Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance). J Clin Oncol 35[Suppl; abstr 3516]. 2017.
  • Sjoquist KM, Pavlakis N, Martin AJ, Tsobanis E, Yip S, Bang Y-J, Alcindor T, O'Callaghan CJ, Bekaii-Saab TS, Grothey A, Chen L-T, Simes J, Zalcberg JR, Goldstein D. Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG). J Clin Oncol 35[Suppl; abstr TPS4136]. 2017.
  • Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Sondak VK, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Kirkwood JM. A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms. J Clin Oncol 35[Suppl; abstr 9500]. 2017.
  • Torres CH, Cheung WY, O'Callaghan CJ, Hsu T. Accrual of older adults to Canadian Cancer Trials Group (CCTG) led trials: A retrospective analysis from 1990 to 2015. J Clin Oncol 35[Suppl; abstr 10031]. 2017.
  • Von Minckwitz G, Procter MJ, de Azambuja E, Zardavas D, Knott A, Viale G, Suter TM, Arahmani A, Rouchet N, Clark E, Benyunes M, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart-Gebhart MJ, Baselga J. APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). J Clin Oncol 35[Suppl; abstr LBA500]. 2017.
  • Wells C, Siu LL, Shapiro JD, Tu D, Jonker DJ, Karapetis CS, Simes J, Liu G, Price TJ, Tebbutt NC, O'Callaghan CJ. Age as a predictive and prognostic factor for targeted therapy treatment in metastatic chemorefractory colorectal cancer (CRC): An analysis of NCIC CTG CO.17 and CO.20. J Clin Oncol 35[Suppl; abstr 3555]. 16 A.D.
  • Abou-Alfa GK, Niedzwiecki D, Knox JJ, Kaubisch A, Posey J, Tan BR, Kavan P, Goel R, Murray JJ, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, Siegel A, Balletti J, Harding JJ, Schwartz LH, Goldberg RM, Bertagnolli MM, Venook AP. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). J Clin Oncol 34[suppl 4S abstr 192]. 2016.
  • Benson AB, Zhao F, Meropol NJ, Catalano PJ, Chakravarthy B, Flynn PJ, Catalano RB, Giantonio BJ, Mitchell EP, Haller DG, Leichman CG, Petrelli NJ, Sinicrope FA, Tepper JE, Brierley JD, Sigurdson ER, Whittington RM, O'Dwyer PJ. Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/ III rectal cancer receiving pre-operative chemoradiation. J Clin Oncol 34[Suppl; abstr 3616]. 2016.
  • Brown PD, Ballman KV, Cerhan J, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NN, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG, II, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D. N107C/CEC.3: A Phase III Trial of Post-Operative Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease. Int J Radiat Oncol Biol Phys 96[5], 937. 2016.  Elsevier
  • Cairns J, Ingle J, Dudenkov T, Kalari K, Buzdar A, Kubo M, Robson M, Ellis M, Goss P, Shepherd L, Goetz M, Weinshilboum R, Wang L. CSMD1 SNPs selectively affect anastrozole response in postmenopausal breast cancer patients. San Antonio Breast Cancer Symposium . 2016.
  • Cheung WY, Mittmann N, Leighl NB, Cheung MC, Bradbury PA, Ng RCH, Chen BE, Ding K, Pater JL, Tu D, Hay AE. The economic impact of the transition from branded to generic oncology drugs. J Clin Oncol 34[Suppl; abstr 6520]. 2016.
  • Courneya KS, Vardy JL, O'Callaghan CJ, Friedenreich C, Campbell KL, Prapavessis H, Crawford JJ, O'Brien P, Dhillon HM, Jonker DJ, Chua NS, Lupichuk SM, Sanatani MS, Gill S, Meyer RM, Begbie S, Bonaventura A, Burge ME, Tu D, Booth CM. Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial. J Clin Oncol 34[suppl; abstr 3621]. 2016.
  • Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Ahmed MA, Link BK, Hay AE, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek JS, Go WY, Gisselbrecht C. Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. J Clin Oncol 34[Suppl; abstr 7516]. 2016.
  • Davis ID, Stockler MR, Martin AJ, Hague W, Coskinas X, Yip S, Tu E, Lawrence NJ, Chan H, McDermott R, Chowdhury S, Marchesin V, Deignan O, Vera-Badillo F, North SA, Montenegro A, Sweeney C. Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304). J Clin Oncol 34[Suppl; abstr TPS5090]. 2016.
  • Dent SF, Aseyev O, Levine MN, Pritchard KI, Parulekar WR, Chen BE, O'Brien P, Burnell MJ, Shepherd LE. Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The Canadian cancer trials group (NCIC CTG) MA.21 experience. J Clin Oncol 34[Suppl; abstr 1016]. 2016.
  • Djurfeldt MS, Brown T, Wilson CF, Elliott C, Fisher B, Sadura A. Launching the Canadian Cancer Trials Group Site Training Initiative. Controlled Clin Trials. 2016.
  • Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin RM, Mohammed N, O'Brien MER, Pantarotto JR, Surmont V, Van Meerbeeck J, Woll PJ, Lorigan P, Blackhall FH. CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). J Clin Oncol 34[Suppl; abstr 8504]. 2016.
  • Garcia-Manero G, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow M, Savoie ML, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton DF, Essell J, Luger S, Mohan SR, Moseley A, Appelbaum FR, Erba HP. SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). Blood 128[22], 901. 16 A.D.
  • Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon KA, Whelan TJ, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer EP, Hudis CA, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. J Clin Oncol 34[suppl; abstr LBA1]. 2016.
  • Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howson-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Chen BE, Djurfeldt M, Reiman T. A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 126. 2016.
  • Hansen AR, Tannock I, Prawira A, Knox JJ, Templeton AJ, Vera-Badillo F, Chen EX, Zavitz M-B, Wang L, Evans A, Tan S, Wouters B, Sridhar SS, Joshua AM. Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): a phase II trial in men with castration resistant prostate cancer (mCRPC). J Clin Oncol 34[Suppl; abstr e16502]. 2016.
  • Hao D, Juergens R, Laurie S, Mates M, Tehfe M, Bradbury P, Kollmannsberger C, Ellis P, Hilton J, Brown-Walker P, Seymour L. A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226). EORTC-NCI-AACR Symposium 2016.
  • Juergens RA, Hao D, Laurie SA, Mates M, Tehfe M, Bradbury P, Kollmannsberger C, Ellis PM, Hilton JF, Brown-Walker P, Seymour L. Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226. J Thoracic Oncol . WCLC 2016.
  • Kanakry JA, Hong F, Martinez-Maza O, Horning SJ, Gordon LI, Gascoyne RD, Gellert LL, Lemas MV, Cheson B, Advani RH, Pohlman B, Kenkre VP, Winter JN, Stiff PJ, Tuscano J, Friedberg J, Dreosti L, Fisher RI, Laneuville P, Kahl BS, Ambinder RF. Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. Blood 128[22], 2992. 2016.
  • Kang A, Hupp M, Ho D, Huang J, Leitzel K, Ali S, Shepherd L, Parulekar WR, Ellis CE, Rocco CJ, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon KA, Truica C, Al-Marrawi Y, Rizvi S, Vasekar M, Nagabhairu V, Polimera H, Marks E, Richardson A, Ali AS, Krecko L, Carney WP, Downs S, Chen BE, Lipton A. Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31. San Antonio Breast Cancer Symposium . 2016.
  • Lemieux J, Goss PE, Parulekar WR, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Strasser-Weippl K, Brundage MD, Whelan K, Tu D, Whelan TJ. Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. J Clin Oncol 34[Suppl; abstr LBA506]. 2016.
  • Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon K, Nielsen T. Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with CCTG MA.31. San Antonio Breast Cancer Symposium . 2016.
  • Mackay H, Gallagher CJ, Parulekar WR, Ledermann JA, Armstrong DK, Gourley C, Romero I, Feeney A, Bessette P, Hall M, Weberpals JI, Hall G, Lau SK, Gauthier P, Fung-Kee-Fung M, Eisenhauer EA, Winch C, Tu D, Provencher DM. OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). J Clin Oncol 34[Suppl; abstr LBA5503]. 2016.
  • McDonald G, O'Brien P, Chen B, Zhu L, Richardson H, Shepherd L, Parulekar W. Patient Retention in Clinical Trials – The Canadian Cancer Trials Group (CCTG) Group Experience with Withdrawal of Consent and Lost to Follow Up. Controlled Clin Trials. 2016.
  • McDonald R, Ding K, Brundage M, Meyer RM, Nabid A, Chabot P, Coulombe G, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JS, Dennis K, DeAngelis C, Wong RK, Zhu L, Chow E. B06-C Improved Pain and Quality of Life as Early as Day 10 Following Radiotherapy for Painful Bone Metastases: A Secondary Analysis of the NCIC CTG SC.23 Randomized Trial. J Pain Symp Man 52: e17-e18, 2016.
  • Monreal M, Brodeur-Robb K, Djurfeldt M, Morrison E, Urton A, Halton J, Sadura A, Fisher B, Smith S, Hay A. Development of a Collaborative Approach to Accrual of Adolescents and Young Adults with Cancer to Clinical Trials in Canada: A Joint Report from the Pediatric C17 Council and the Adult Canadian Cancer Trials Group. Controlled Clin Trials. 2016.
  • Morris D, Tu D, Tehfe MA, Nicholas GA, Goffin JR, Gregg RW, Shepherd FA, Murray N, Wierzbicki R, Lee CW, Kuruvilla S, Keith B, Ahmed A, Blais N, Goss GD, Korpanty G, Sederias J, Laurie SA, Seymour L, Bradbury PA. A Randomized Phase II study of Reolysin in Patients with Previously Treated Advanced or Metatstatic Non Small Cell Lung Cancer (NSCLC) receiving Standard Salvage Chemotherapy – Canadian Cancer Trials Group IND 211. J Clin Oncol 34[Suppl; abstr e20512]. 2016.
  • Needham J, Nomikos D, Stanton H. Integrating Patient/Public Involvement in the Canadian Cancer Trials Group. Controlled Clin Trials. 2016.
  • Niravath PA, Chen BE, Chapman JA, Agarwal SK, Welschhans RL, Bongartz T, Kalari KR, Shepherd LE, Bartlett J, Pritchard KI, Gelmon KA, Hilsenbeck SG, Rimawi MF, Osborne CK, Goss PE, Ingle JN. Vitamin d and aromatase inhibitor-induced arthralgia: Analysis of Canadian cancer trial group MA.27 data. J Clin Oncol 34[Suppl; abstr 10020]. 2016.
  • Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, Litzow M, Savoie ML, Spellman SR, Confer DL, Chell J, Brown M, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton DF, Essell J, Luger S, Mohan SR, Moseley A, Erba HP, Appelbaum FR. Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. Blood 128[22], 1166. 2016.
  • Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay MF, Nishikawa R, Cairncross GJ, Roa W, Osoba D, Sahgal A, Hirte HW, Wick W, Laigle-Donadey F, Franceschi E, Chinot OL, Winch C, Ding K, Mason WP. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). J Clin Oncol 34[suppl; abstr LBA2]. 2016.
  • Reiman T, Savage KJ, Crump M, Cheung M, Macdonald DA, Buckstein R, Couban S, Piliotis E, Imrie KR, Spaner D, Shivakumar S, Kuruvilla J, Villa D, Shepherd LE, Skamene T, Winch C, Chen BE, Hay AE. A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15. Blood 128[22], 4162. 16 A.D.
  • Skamene T, Jiang W, Meyer RM, Crump M, Kuruvilla J, Kouroukis CT, Luminari S, Couban S, Cheung MC, Rizzieri DA, Bardy PG, Pater J, Djurfeldt MS, Shepherd LE, Chen BE, Hay AE. Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Blood 128[22], 690. 2016.
  • Stewart D, Chen B, Mansoor A, Akhter A, Lebrn D, Crump M, Shepherd L, Bosch M. A Bioclinical Prognostic Model Incorporating MYC And BCL2 Predicts Outcome to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An NCIC CTG LY12 Correlative Science Study. European Hematology Association. 2016.
  • Stiff PJ, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus D, Barton K, Mills GM, LeBlanc M, Rimsza L, Forman SJ, Leonard JP, Fisher RI, Friedberg J. Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis. Blood 128[22], 4651. 2016.
  • Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd LE, O'Shaughnessy J, Chen BE, Parulekar WR, Liedke PER, Goss PE. Outcomes of invasive ductal (ID) or invasive lobular (IL) early stage breast cancer in women treated with anastrozole or exemestane in the Canadian cancer trials Group MA.27. J Clin Oncol 34[Suppl; abstr 521]. 2016.
  • Sud S, O'Callaghan CJ, Jonker C, Karapetis CS, Price TJ, Tebbutt NC, Shapiro JD, van Hazel GA, Pavlakis N, Gibbs P, Jeffery M, Siu LL, Gill S, Wong R, Jonker DJ, Tu D, Goodwin RA. Hypertension as a predictor of outcome and treatment response to cetuximab: A retrospective analysis of NCIC CTG CO.17. J Clin Oncol 34[No 4 suppl: 256]. 2016.
  • Sud S, O'Callaghan CJ, Karapetis CS, Jonker C, Price TJ, Tebbutt NC, Shapiro JD, van Hazel GA, Pavlakis N, Gibbs P, Jeffery M, Siu LL, Gill S, Wong R, Jonker DJ, Tu D, Goodwin RA. Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: A retrospective analysis of NCIC CTG CO.17. J Clin Oncol 34[suppl; abstr e15025]. 2016.
  • Sweeney C, Xie W, Regan MM, Nakabayashi M, Buyse ME, Clarke NW, Collette L, Dignam JJ, Fizazi K, Habibian M, Halabi S, Kantoff PW, Parulekar WR, Sandler HM, Sartor O, Soule HR, Sydes MR, Tombal BF, Williams SG. Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP). J Clin Oncol 34[Suppl; abstr 5023]. 2016.
  • Tang PA, Jonker DJ, Kennecke HF, Welch S, Cripps MC, Asmis TR, Chalchal HI, Tomiak AT, Ko Y-J, Chen E, Alcindor T, Goffin JR, Theis A, Gill GM, Tu D, Seymour L. IND.210: A randomized phase 2 trial of FOLFOX6/bevacizumab with or without reovirus (Reo) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 34[Suppl; abstr 3546]. 2016.
  • Tinker A, Hirte H, Provencher D, Butler M, Ritter H, Tu D, Paralejas P, Grenier S, Hahn S, Ramsahai J, Seymour L. Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221. EORTC-NCI-AACR Symposium . 2016
  • van den Bent MJ, Erridge S, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Wick W, Clement PM, Baurain J-F, Mason WP, Wheeler H, Chinot OL, Weller M, Golfinopoulos V, Aldape K, Dinjens WNM, Wesseling P, Gorlia T, Kros JM, Baumert BG. Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. J Clin Oncol 34[Suppl; abstr LBA2000]. 2016.
  • Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Butts CA, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott RS, Perez-Soler R, Traynor AM, Evans TL, Horn L, Ramalingam SS, Schiller JH. E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—Outcomes based on chemotherapy subsets. J Clin Oncol 34[Suppl; abstr 8507]. 2016.
  • Wilson CF, Parker EL, Casey J, O'Brien P, O'Callaghan CJ. Implementation of a web-based screen failure log with real-time data collection and assessment facilitated timely modification of eligibility criteria in an adjuvant lung cancer immunotherapy trial. Controlled Clin Trials. 2016.
  • Winch C, Chen B, Fisher B, Snyder J, Broekhoven M, Djurfeldt M, Shepherd L, Hay A. Practical Implementation of an Adaptive Clinical Trial Design in a Multi-Stage Randomized Phase II Study of Novel Combination Therapy for the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma: Canadian Cancer Trials Group LY.17. Controlled Clin Trials. 2016.
  • Arts KE, Kato D, Dancey J. Establishment of a baseline to measure academic clinical trial activity in Canada. J Clin Oncol 33[suppl; abstr e17547].
  • Baumert BG, Hegi ME, Mason WP, Ryan G, Hoang-Xuan K, Bromberg JE, van den Bent MJ, Hassel MB, Marosi C, Brandes AA, Rees J, Von Deimling A, Hartmann C, Kros JM, Lacombe DA, Gorlia T, Capper D, Kurscheid S, Stupp R. Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma. J Clin Oncol 33[suppl; abstr 2006].
  • Becerra C, Stephenson J, Jonker DJ, Cohn AL, Asmis TR, Bekaii-Saab TS, Conkling PR, Garbo LE, Lenz H-J, Richards DA, Spira AI, Mikhail S, Goodwin RA, Yoon HH, Hume S, Hitron M. Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol 33[suppl; abstr 4069].
  • Booth CM, Vardy JL, O'Callaghan CJ, Gill S, Jonker DJ, Friedenreich C, Meyer RM, Brundage MD, Wong R, Dhillon HM, O'Brien P, Baylock B, Chua NS, Lipichuk S, Sanatani MS, Begbie S, Bonaventura T, Burge ME, Tu D, Courneya KS. A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). J Clin Oncol 33[suppl; abstr TPS3620].
  • Bosse D, Mercer J, Raissouni S, Dennis K, Goodwin RA, Jiang M, Powell ED, Kumar A, Lee-Ying RM, Price Hillier JA, Chin Heng DY, Tang PA, MacLean A, Cheung WY, Vickers MM. PROSPECT eligibility and clinical outcomes: Results from the pan-Canadian rectal cancer consortium. J Clin Oncol 33[suppl; abstr 6594].
  • Creutzberg CL, de Boer SM, Putter H, Powell M, Mileshkin LR, Katsaros D, Bessette P, Haie-Meder C, Ledermann JA, Ottevanger PB, Khaw P, Colombo A, Fyles AW, Baron M-H, Nijman HW, Nout RA, Smit VTHBM, Verhoeven-Adema K, Kruitwagen RFPM, Kitchener HC. Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial. J Clin Oncol 33[suppl; abstr 5501].
  • Dancey J, Krzyzanowska MK, Provencher DM, Cheung WY, Macfarlane RJ, Alcindor T, Ghatage P, Gupta AA, Laurie SA, Sawyer MB, Welch S, Salim M, Ellard S, Wall DA, Tsao MS, Sederias J, Xu H, Nielsen TO, Asa SL, Hirte HW. NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers. J Clin Oncol 33[suppl; abstr 2594].
  • Davis ID, Stockler MR, Martin AJ, Marchesin V, Deignan O, McDermott R, Parulekar WR, North SA, Graham B, Long AP, Roncolato FT, Yip S, Hague W, Dazo C, Coskinas X, Sweeney C. Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304). J Clin Oncol 33[suppl; abstr TPS5077].
  • DeAngelo DJ, Stevenson K, Neuberg DS, Silverman LB, Ballen KK, Asch JD, Mourad YA, Paulson K, Seftel MD, Avigan D, Bergeron J, Couban S, Blum W, Storring J, Wadleigh M, Steensma D, Supko J, Sallan SE, Stone RM. A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. Blood (ASH Annual Meeting Abstracts) 126. 2016.
  • Gralow J, Barlow WE, Paterson AHG, Lew D, Stopeck A, Hayes DF, Hershman DL, Schubert M, Clemons MJ, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Livingston RB, Hortobagyi GN. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. J Clin Oncol 33[suppl; abstr 503].
  • Haas NB, Manola J, Uzzo RG, Atkins MB, Wilding G, Pins M, Jewett MAS, Kane CJ, Cella D, Wagner LI, Coomes B, Wood CG, Dutcher JP, Flaherty K, DiPaola RS. Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. J Clin Oncol 33[suppl 7; abstr 403]. 2015
  • Ho M, Wang L, Ingle J, Goss P, Mushiroda T, Kubo M, Nakamura Y, Shepherd L, Weinshilboum R, Bongartz T. Aromatase inhibitor-induced arthralgia associated with TCL1A SNP and estrogen-dependent variation in cytokine expression: possible links between estrogen and arthritis. Clinical Pharmacology & Therapeutics 97[Supplement S1], S11-S18. 2015.
  • Hotte SJ, Joshua AM, Torri V, Macfarlane RJ, Basappa NS, Powers J, Winquist E, Mukherjee S, Gregg RW, Kollmannsberger CK, Finch DL, Xu H, Hausman DF, Seymour L, Eisenhauer EA, Chi KN. IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone. J Clin Oncol 33[suppl 7;abstr 279]. 2015.
  • Jonker DJ, Laurie SA, Cote GM, Flaherty K, Fuchs CS, Chugh R, Smith DC, Edenfield WJ, Conkling PR, Mier JW, Goodwin RA, Kwak EL, Abrams TA, Goel R, Cleary JM, Li W, Li Y, Jemison J, Hitron M, Li C. Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer. J Clin Oncol 33[suppl; abstr 3615].
  • Nicholas GA, Goffin JR, Laurie SA, Robinson AG, Goss GD, Reaume MN, Mates M, Wheatley-Price P, Ellis PM, Juergens RA, Tomiak AT, Gregg RW, Melosky BL, Tu D, Ritter H, Seymour L, Bradbury PA. A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197. J Clin Oncol 33[suppl; abstr 8046].
  • Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].
  • Pavlakis N, Sjoquist KM, Tsobanis E, Martin AJ, Kang Y-K, Bang Y-J, O'Callaghan CJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Burnell MJ, Alcindor T, Strickland A, Kim JW, Yip S, Simes J, Zalcberg JR, Goldstein D. INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results. J Clin Oncol 33[suppl; abstr 4003].
  • Penniment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(suppl 3; abstr 6)]. 2015.
  • Qu MXL, Ramjeesingh R, Ogundimu O, Ren K, Hurlburt D, Biagi JJ, Mahmud A. Predictive factors and prognostic significance of tumor regression grade in rectal cancer. J Clin Oncol 33[suppl; abstr e14628].
  • Ramjeesingh R, Kankesan J, Chen BE, Pater JL, Han L, O'Brien P, Burnell MJ, Shepherd LE, Parulekar WR. Clinical predictors of failure of granulocyte colony stimulating factor (G-CSF) prophylaxis in patients with breast cancer treated with dose dense epirubicin (E), cyclophosphomide (C) + paclitaxel (T) Adjuvant chemotherapy: Subgroup analysis of the NCIC CTG MA.21 study (NCT00014222). J Clin Oncol 33[suppl; abstr 1033].
  • Richardson H, Goss PE, Walker M, Jabs D, King W. Abstract B46: The influence of exemestane on breast density in postmenopausal women: A cohort study nested within the NCIC CTG MAP.3 chemoprevention trial. Cancer Prevention Research 8[10 Supplement], B46. 2015.
  • Ringash J, Waldron JN, Siu LL, Marino R, Winquist E, Wright JR, Nabid A, Hay JH, Hammond A, Sultanem K, Hotte S, Leong C, El-Gayed AAH, Naz F, Ramchandar K, Owen TE, Montenegro A, O'Sullivan B, Chen BE, Parulekar WR. Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248). J Clin Oncol 33[suppl; abstr 6053].
  • Sederias J, Dancey J, Hirte H, Le A, Xu H. Reducing Adverse Events Reporting For Commercially Available Agents  (Sunitinib And Temsirolimus) Can Improve Phase II Trial Execution. Controlled Clin Trials . 2015.
  • Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, Childs TJ, Montenegro A, O'Sullivan B, Parulekar WR. Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. J Clin Oncol 33[suppl; abstr 6000].
  • Sridhar SS, Blais N, North SA, Tran B, Chi KN, Robinson JW, Reaume MN, Liu G, McDonald GT, Ding K, Parulekar WR. A multicenter randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen: NCIC Clinical Trials Group BL 12 (NCT02033993). J Clin Oncol 33[suppl; abstr TPS4573].
  • Stone RM, Mandrekar S, Sanford BL, Geyer S, Bloomfield CD, Dohner K, Thiede C, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Dohner H. The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). Blood (ASH Annual Meeting Abstracts) 126[23]. 2015.
  • Zlobinsky Rubinstein MM, Gray RJ, Sparano JA, Zujewski J, Whelan TJ, Albain KS, Hayes DF, Geyer CE, Dees EC, Perez EA, Keane MM, Vallejos C, Goggins TF, Mayer IA, Brufsky A, Toppmeyer D, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. J Clin Oncol 33[suppl; abstr 533].
  • Abbott LS, Hay AE, Willman C, Urton A, Pater JL, Dancey J, Eisenhauer EA, Seymour L. Accrual of adolescents and young adults with cancer to eligible clinical trials: A report from the NCIC Clinical Trials Group (NCIC-CTG). J Clin Oncol 32:5s[suppl; abstr 6543]. 2014.
  • Abbott LS, Pater JL, Friel KT, Kato D, Dancey J. Improving cancer clinical trial accrual in Ontario, Canada: The clinical trials infrastructure fund (CTIF) experience. J Clin Oncol 32:5s[suppl; abstr 6602]. 2014.
  • Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Coates AS, Gelber RD, Goldhirsch A, Walley B. Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). J Clin Oncol 32:5s[suppl; abstr 557]. 2014.
  • Bonomi M, Xu H, Laurie SA, Eisenhauer EA, Tu D, Pater JL, Seymour L, Bradbury PA. The association of treatment-emergent proteinuria (TEP) with baseline/treatment variables in patients (pts) treated with antiangiogenic tyrosine kinase inhibitors (AA-TKIs): A pooled analysis of NCIC Clinical Trial Group (NCIC CTG) trials. J Clin Oncol 32:5s[suppl; abstr 11126]. 2014.
  • Booth CM, Vardy JL, Gill S, Jonker DJ, O'Callaghan CJ, Friedenreich C, Meyer RM, Brundage M, Wong R, Dhillon HM, O'Brien P, Goddard E, Chua NS, Lipichuk S, Sanatani MS, Beale PJ, Begbie S, Ackland SP, Tu D, Courneya KS. A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). J Clin Oncol 32:5s[suppl; abstr TPS3663]. 2014.
  • Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Albain KS, Rinn K, Chew HK, Von Burton G, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew D, Gralow J, Hortobagyi GN. Outcome of male patients and black patients enrolled in S0221, an intergroup chemotherapy study. J Clin Oncol 32:5s[suppl; abstr 1016]. 2014
  • Chan KK, Tu D, O'Callaghan CJ, Au H, Leighl NB, Brundage MD, Jonker DJ, Karapetis CS, Ringash J, Zalcberg JR, Hoch JS, Tebbutt NC, Shapiro J, Price TJ, Pavlakis N, van Hazel GA, Mittmann N. A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer. J Clin Oncol 32[suppl 3; abstr 547]. 2014.
  • Chapman J-AW, Liu S, Leung S, Nielsen TO. Competing risks of mortality by PAM50 intrinsic subtype: BC tamoxifen-treated cohort. J Clin Oncol 32:5s[suppl; abstr 562]. 2014.
  • Cuffe S, Hon H, Tobros K, Espin-Garcia O, Brhane Y, Harland L, Fadhel E, Eng L, LaDelfa A, Waldron JN, Chen BE, Xu W, Simmons CE, Kassam Z, Siu LL, Montenegro A, Parulekar WR, Liu G. Cancer patients' acceptability of incorporating an epidemiology questionnaire within a clinical trial: A patient preference study and subanalysis of the NCIC clinical trials group HN.6 clinical trial. J Clin Oncol 32:5s[suppl; abstr 1586]. 2014.
  • Ellis PM, Liu G, Millward M, Perrone F, Shepherd FA, Sun S, Cho BC, Morabito A, Stockler MR, Wierzbicki R, Cohen V, Blais N, Sangha RS, Favaretto AG, Kang JH, Wilson CF, O'Connell J, Ding K, Goss GD, Bradbury PA. NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. J Clin Oncol 32:5s[suppl; abstr 8036^]. 2014.
  • Gelmon KA, Chapman J-AW, Liu S, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, Rugo HS, Albain KS, Perez EA, Virk S, O'Brien P, Shepherd LE, Nielsen TO. Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. J Clin Oncol 32:5s[suppl: abstr 11019]. 2014.
  • Gralow JR, Barlow WE, Paterson A, Lew DL, Stopeck A, Hayes DF, Hershman D, Schubert M, Clemons M, van Poznack C, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino M, Margolis J, Dakhil S, Chew H, Livingston RB, Hortobagyi GN. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery. J Clin Oncol suppl; abstr 558. 2014.
  • Hay AE, Monzon JG, McDonald GT, Pater JL, Meyer RM, Chen EX, Chen BE, Dancey J. Correlation between phase 2 clinical trial design and subsequent phase 3 outcome. J Clin Oncol 32:5s[suppl; abstr 2549]. 2014.
  • Hay AE, Savage KJ, Crump M, Reiman A, Meyer RM, Good D, LeBrun D, Djurfeldt M, Kuruvilla J, Chen BE, Shepherd LE. Outcomes of patients with peripheral T cell lymphoma: a subset analysis of the NCIC Clinical Trials Group LY.12 Phase III clinical trial. BSH 165[suppl1; abstr 124], 53-54. 2014.
  • Hay AE, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman TJ, Roy J, Shustik C, Kovacs MJ, Sussman J, Reece DE, Lacy M, Meyer RM, Shepherd LE, Whelan K, Zhu L, Chapman J-AW, Stewart AK. A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial. J Clin Oncol 32:5S[suppl; abstr 8591]. 2014.
  • Ho D, Huang J, Chapman J-AW, Leitzel K, Ali SM, Shepherd LE, Parulekar WR, Ellis CE, Crescenzo RJ, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon KA, Carney WP, Lipton A. Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31. J Clin Oncol 32:5s[suppl; abstr 617]. 2014.
  • Jonker DJ, Nott LM, Yoshino T, Li C, Gill S, Shapiro JD, Ohtsu A, Zalcberg JR, Vickers MM, Simes J, Wei AC, Mittmann N, Magoski NM, Murray Y, Tsobanis E, Tu D, Kerstein D, O'Callaghan CJ. The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC). J Clin Oncol 32:5s[suppl; abstr TPS3660]. 2014.
  • Kangarloo SB, Ng ESM, Bramwell VHC, Pritchard KI, Shepherd LE, Tu D, Magliocco AM, Tang PA. Pharmacokinetic analysis of tamoxifen metabolites in premenopausal women with early breast cancer: A substudy of NCIC CTG MA.12 randomized clinical trial. J Clin Oncol 32:5s[suppl; abstr 1524]. 2014.
  • Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee S, Chalchal HI, Bernstein V, Stambolic V, Chen BE, Goodwin PJ. Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl). J Clin Oncol 32:5s[suppl; abstr 542]. 2014.
  • Lohmann AE, Chapman J-AW, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, Gelmon KA, O'Brien P, Han L, Rugo HS, Albain KS, Perez EA, Vandenberg TA, Chalchal HI, Sawhney RPS, Shepherd LE, Goodwin PJ. Prognostic associations of 25OH vitamin d in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high risk breast cancer (BC). J Clin Oncol 32:5s[suppl: abstr 504]. 2014.
  • Pagani O, Regan MM, Walley B, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Rabaglio-Poretti M, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol 32:5s. 2014.
  • Parulekar WR, Aparicio S, Chapman J-AW, Gao D, Shepherd LE, Boyle FM, Kaufam B, Yelle L, Vandenberg TA, Salim M, Lorette J, Crescenzo RJ, Zhu L, Murray Y, Huntsman D, Gelmon KA. Lapatinib or trastuzumab with taxane therapy as first line treatment in metastatic breast cancer (MBC): A biomarker analysis in NCIC CTG MA.31. J Clin Oncol 32:5s[suppl; abstr 601]. 2014.
  • Penniment MG, Harvey JA, Wong R, Stephens S, Au H-J, O'Callaghan CJ, Kneebone A, Ngan S, Ward IG, Roy R, Sullivan TR, Nijjar T, Biagi JJ, Mulroy LA. A randomized phase III study in advanced esophageal cancer (OC) to compare the quality of life (QoL) and palliation of dysphagia in patients treated with radiotherapy (RT) or chemoradiotherapy (CRT) TROG 03.01 NCIC CTG ES.2. J Clin Oncol 32:5s[suppl; abstr 4009]. 2014.
  • Piccart-Gebhart MJ, Holmes AP, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Santillana S, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith IE, Boyle F, Xu B, Gomez HL, Gelber RD, Perez EA. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T->L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 32:5s[suppl; abstr LBA4]. 2014.
  • Rouette J, Blazeby JM, King M, Calvert M, Peng Y, Meyer RM, Ringash J, Walker M, Brundage MD. The use of health-related quality of life outcomes in oncology practice: An international study. J Clin Oncol 32:5s[suppl; abstr 6524]. 2014.
  • Shultz D, Pai J, Graber MS, Heestand GM, Chang DT, Parulekar WR, Tu D, Moore MJ, Koong A. A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3. J Clin Oncol 32:5s[suppl; abstr 4133]. 2014.
  • Sternberg CN, Skoneczna IA, Kerst JM, Fossa SD, Albers P, Agerbaek M, Dumez H, De Santis M, Theodore C, Leahy MG, Chester JD, Verbaeys A, Caty A, Daugaard G, Marreaud S, Cambier S, Sylvester R. Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder. J Clin Oncol 32:5s[suppl; abstr 4500]. 2014.
  • Tang PA, Hay AE, O'Callaghan CJ, Mittmann N, Chambers C, Pater JL, Leighl NB. Estimation of drug cost avoidance (DCA) and pathology cost avoidance (PCA) through participation in NCIC clinical trials group (NCIC-CTG) phase III clinical trials in Canada. J Clin Oncol 32:5s[suppl; abstr 6560]. 2014.
  • Wilson SM, Zheng Y, Chapman J-AW, Burnell MJ, Speers C, Baxter E, Tyldesley S, Shepherd LE, Gelmon KA, Lohrisch CA. Outcomes of 3-weekly doxorubicin and cyclophosphamide followed by Paclitaxel (AC/T) in a randomized trial (RCT), compared to a case-control matched British Columbia (BC) breast cancer population. J Clin Oncol 32:5s[suppl; abstr 1037]. 2014.
  • Wong R, Au H-J, Ding K, Harvey JA, Stephens S, O'Callaghan CJ, Kneebone A, Ngan S, Ward IG, Roy R, Sullivan TR, Nijjar T, Biagi JJ, Penniment MG. Quality of life (QoL) in patients with malignant dysphagia: An international randomized trial comparing radiotherapy alone (RT) versus chemoradiotherapy (CRT)—TROG03.01 NCICCTG ES2. J Clin Oncol 32[suppl 31; abstr 163]. 2014.
  • Bar J, Ding K, Zhao H, Laurie SA, Han L, Shepherd FA, Addison CL, Goss GD, Dimitroulakos J, Bradbury PA. Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial. J Clin Oncol 31[suppl; abstr 8048], 2013.
  • Baumert BG, Mason WP, Ryan G, Bromberg JE, van den Bent MJ, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Rees J, Wick W, Von Deimling A, Hartmann C, Kros JM, Hegi ME, Dif N, Lacombe DA, Gorlia T, Stupp R. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). J Clin Oncol 31[suppl; abstr 2007], 2013.
  • Booth CM, Courneya KS, Vardy JL, Jonker DJ, Gill S, Brundage M, van der Ploeg H, Dhillon HM, O'Brien P, Goddard E, Pollak MN, Friedenreich C, Tu D, Wong R, Meyer RM. A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). J Clin Oncol 31[suppl; abstr TPS3647], 2013.
  • Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. J Clin Oncol 31[suppl; abstr 3528], 2013.
  • Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn K, Albain KS, Chew HK, Von Burton G, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew D, Gralow J, Hortobagyi G. S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. J Clin Oncol 31[suppl; abstr CRA1008], 2013.
  • Cervantes-Ruiperez A, Hoskins P, Vergote I, Eisenhauer EA, Ghatage P, Carey M, Katsaros D, Poveda A, Provencher DM, Tu D, Stuart G. Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first line chemotherapy for advanced epithelial ovarian cancer (EOC): A GCIG study of NCIC CTG, EORTC-GCG and GEICO. J Clin Oncol 31[suppl; abstr 5502], 2013.
  • Chapman J-A. Personal Environment: Design and Analysis of Breast Cancer Trials. Statistical Society of Canada, 2013.
  • Chapman J-AW, Shepherd LE, Ingle JN, Muss HB, Pritchard KI, Gelmon KA, Whelan TJ, Elliott C, Goss PE. Competing risks of death in NCIC CTG MA.27 adjuvant exemestane vs anastrozole. J Clin Oncol 31[suppl; abstr 564], 2013.
  • Chapman J-A, Shepherd L, Ingle J, Muss H, Pritchard K, Gelmon K, Whelan T, Elliott C, Goss P. Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole. Canadian Cancer Research Alliance 2013.
  • Chia SKL, Ellard S, Mates M, Welch S, Mihalcioiu CLD, Miller WH, Gelmon KA, Lohrisch CA, Kumar V, Taylor SK, Hagerman L, Eisenhauer EA, Bradbury PA. A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198. J Clin Oncol 31[suppl; abstr 518], 2013.
  • Chow E, van der Linden Y, Roos D, Hartsell W, Hoskin P, Wu J, Brundage M, Meyer R, Chen B, Wong R. Response and Quality of Life (QOL) Outcomes in a Randomized Trial of Single Versus Multiple Fractions (Fx) for Re-irradiation (RE-RT) of Painful Bone Metastases (PBM): NCIC CTG SC.20. International Journal of Radiation Oncology*Biology*Physics 87: S6, 2013.
  • Chow E, van der Linden Y, Roos D, Hartsell WF, Hoskin P, Wu JSY, Brundage M, Nabid A, Wilson CF, Meyer RM, Chen BE, Wong R. A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20. J Clin Oncol 31[suppl; abstr 9502], 2013.
  • Crump M, Kuruvilla J, Couban S, Macdonald D, Kukreti V, Kouroukis T, Meyer R, Rubinger M, Buckstein R, Imrie K, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Sussman J, Hay A, Djurfeldt M, Chen B, Shepherd L. Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Salvage Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed And Refractory Aggressive Lymphomas: Final Result of the Phase III NCIC CTG Study LY12. Hematolological Oncology 31[Suppl 1], 96-150. 2013.
  • Davison K, Chen B, Kukreti V, Couban S, Benger A, Berinstein N, Kaizer L, Desjardins P, Mangel J, Le A, Djurfeldt M, Shepherd L, Crump M. Treatment Outcomes for Older Patients With Relapsed/Refractory Aggressive Lymphoma Receiving Salvage Chemotherapy and Autologous Stem Cell Transplantation (ASCT) are Similar to Younger Patients: A Subgroup Analysis from the Phase III NCIC CTG LY12 Trial. Hematolological Oncology 31[suppl 1], 96-150. 2013.
  • Ding K, He Z, Xu J. Discovery of Pre-Post-Treatment Predictive Biomarker. Statistical Society of Canada, 2013.
  • Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis. J Clin Oncol 31[suppl; abstr 7510], 2013.
  • Goodwin PJ, Parulekar W, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Oja CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V. Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC). J Clin Oncol 31[suppl; abstr 1033], 2013.
  • Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz M, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dörken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM. An Individual Patient-Data Comparison of German Hodgkin Study Group HD10 and HD11 Combined Modality Therapy and NCIC Clinical Trials Group HD.6 ABVD Alone. Canadian Conference On Lymphoproliferative Disorders, 2013.
  • Hotte SJ, Eisenhauer EA, Joshua AM, Kumar V, Ellard S, Gregg RW, Macfarlane RJ, Winquist E, Torri V, Ruether JD, Basappa NS, Kakumanu AS, North SA, Kollmannsberger CK, Tinker A, Mirchandani D, Tassignon A, Hausman DF, Allan AL, Chi KN. NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 31[suppl; abstr 5042], 2013.
  • Kuruvilla J, Chen B, Macdonald D, Kouroukis T, Cheung M, Olney H, Turner R, Anglin P, Seftel M, Hay A, Shepherd L, Crump M. Salvage Chemotherapy (SC) and Autologous Stem Cell Transplantation (ASCT) for Transformed Indolent Lymphoma (TR): A Subgroup Analysis of NCIC CTG LY12. Hematolological Oncology 31[Suppl 1], 96-150. 2013.
  • Ledermann JA, Perren T, Raja FA, Embleton AC, Rustin GJS, Jayson G, Kaye SB, Swart A, Vaughan M, Hirte H. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. NCRI Cancer Conference, UK [abstr LB80]. 2013.
  • Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.
  • Pavlakis N, Goldstein D, Sjoquist KM, Martin A, Tsobanis E, Yip S, Shannon J, Burge ME, Cronk MF, Tebbutt NC, Strickland A, Lipton LR, Price TJ, Nott LM, Harris DL, Burnell MJ, Alcindor T, Bang Y-J, Kang Y-K, O'Callaghan CJ. INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG). J Clin Oncol 31[suppl; abstr TPS4157]. 2013.
  • Petrella TM, Mihalcioiu CLD, McWhirter E, Belanger K, Savage KJ, Song X, Hamid O, Cheng T, Davis ML, Lee CW, Spatz A, Monzon JG, Hagerman L, Chen BE, Dancey J. Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM). J Clin Oncol 31[suppl; abstr 9032], 2013.
  • Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Macdonald DR, Easaw JC, Eisenstat DD, Kakumanu AS, Squire J, Tsao MS, Kamel-Reid S, Tassignon A, Hausman DF, Mason WP. Phase II study of PX-866 in recurrent glioblastoma. J Clin Oncol 31[suppl; abstr 2053], 2013.
  • Pritchard K, Goss PE, Ingle JN, Muss HB, Dent SF, Vandenberg TA, Findlay B, Gelmon KA, Wilson CF, Shepherd LE, Pollak MN. Competing risks of death in NCIC CTG MA.14 patients treated with Tamoxifen +/- Octreotide LAR. San Antonio Breast Cancer Symposium, 2013.
  • Raja FA, Perren TJ, Embleton A, Rustin GJS, Jayson G, Swart AM, Vaughan M, Hirte H, Stark DP, Ledermann JA. Randomised Double-Blind Phase III Trial Of Cediranib (AZD2171) in Relapsed Platinum Sensitive Ovarian Cancer: Results of the ICON6 Trial. Int J Gynecol Cancer 23[8], Supplement 1. 2013.
  • Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.
  • Trudeau M, Chapman J-A, Guo B, Clemons M, Dent R, Jong R, Kahn H, Shepherd L, Pritchard K, Xu J, O'Brien P, Parissenti A. Microarray data analysis and long term outcomes of NCIC-CTG MA.22: Neoadjuvant epirubicin and docetaxel with pegfilgrastim support for locally advanced breast cancer. San Antonio Breast Cancer Symposium 2013.
  • Vickers MM, Tu D, Lee C, Wheatley-Price P, Parulekar W, Brundage MD, Moore MJ, Au HJ, O'Callaghan CJ, Jonker DJ, Ringash J, Goldstein D. Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. J Clin Oncol 31[suppl; abstr 4053], 2013.
  • Yoganathan P, Wang A, Lian E, Ding K, Tron VA, Mulligan LM. Characterization of the functional roles of RET isoforms in breast cancer. Proc Am Assoc Cancer Res [abstr 539], 2013.
  • Bradbury P, Eisenhauer E, Rayson D, Lupichuk S, Chia S, Leighl N, Ho C, Seymour L. A Pooled Analysis to Evaluate the Incidence of Proteinuria, Hypoalbuminemia, and Edema Secondary to MET and VEGFR Inhibition. EORTC-NCI-AACR Symposium [abstr 313], 2012.
  • Brundage M, Parulekar W, Chen B, Bezjak A, Sydes M, Mason M, Hiltz A, Warde P. The impact of radiotherapy (RT) on quality of life (QOL) when given in combination with androgen deprivation therapy (ADT) for locally advanced prostate cancer: QOL results from NCIC CTG PR3 / Medical Research Council MRC PR07 randomized trial. Canadian Assoc Rad Oncol [abstr 184], 2012.
  • Burnell MJ, Shepherd L, Gelmon K, Bramwell V, Walley B, Vandenberg E, Chalchal H, Pritchard K, Whelan TJ, Albain K, Perez EA, Rugo H, O'Brien PS, Chapman J-A, Levine M. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of the final relapse free survival analysis. Cancer Res 72[24 Suppl 3, abstr P1-13-01], 2012.
  • Carde P, Karrasch M, Fortpied C, Brice P, Khaled HM, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg P, Morschhauser F, Aurer I, Coiffier B, Cantin G, Seftel MD, Wolf M, Glimelius B, Sureda A, Mounier N. ABVD (8 cycles) vs. BEACOPP (4 escalated cycles => 4 baseline) in Stage III - IV high risk Hodgkin Lymphoma (HL): First Results of EORTC 20012 Intergroup Randomized Phase III Clinical Trial. J Clin Oncol 30[suppl, abstr 8002], 2012.
  • Chapman J-AW, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE, Gelmon KA, Wolmark N, Pollak MN. Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29. J Clin Oncol 30[suppl, abstr 538], 2012.
  • Chapman J-AW, Sgroi D, Goss PE, Richardson E, Binns SN, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Pollak MN. Prognostic relevance of statistically standardized estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in tamoxifen(TAM)-treated NCIC CTG MA.14 patients. Cancer Res 72[24 Suppl 3, abstr P1-07-13], 2012.
  • Cheang M, Martin M, Nielsen T, Prat A, Rodriguez-Lescure A, Simon AR, Chia S, Shepherd L, Voduc D, Bernard P, Ellis M, Perou C, Di Leo A, Carey LA, on behalf of BIG-NABCG investigators. Quantitative hormone receptors, triple negative breast cancer (TNBC), and molecular subtypes: a collaborative effort of the BIG-NCI NABCG. J Clin Oncol 30[suppl, abstr 1008], 2012.
  • Cheung P, Faria S, Ahmed S, Chabot P, Greenland J, Kurien E, Mohamad I, Wright J, Ding K, O'Callaghan C. A phase II study of accelerated hypofractionated 3-dimensional conformal radiotherapy for inoperable T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25. Canadian Assoc Rad Oncol [abstr 171], 2012.
  • Cheung P, Faria S, Ahmed S, Chabot P, Greenland J, Kurien E, Mohamad I, Wright J, Ding K, O'Callaghan C. A Phase II Study of Accelerated Hypofractionated 3-Dimensional Conformal Radiotherapy for Inoperable T1-3 N0 M0 Non-Small Cell Lung Cancer: NCIC CTG BR.25. Chicago Multidisciplinary Symposium in Thoracic Oncology [abstr 20], 2012.
  • Crump M, Kuruvilla J, Couban S, MacDonald D, Kukreti V, Kouroukis CT, Meyer RM, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner RA, Sussman J, Hay AE, Djurfeldt M, Chen BE, Shepherd L. Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12. Blood (ASH Annual Meeting Abstracts) 120[21, abstr 745], 2012.
  • Eigl BJ, North S, Winquist E, Powers J, Good J, Sharma M, Squire J, Cox M, Eisenhauer EA, Chi K. A phase II study of SB939 in patients (pts) with castration resistant prostate cancer (CRPC). Ann Oncol 23[suppl 9, abstr 922], ix304, 2012.
  • Eisenhauer EA. Antiangiogenics in ovarian cancer: where are we now? Ann Oncol 23[suppl 9, abstr 54IN], ix40-ix41, 2012.
  • Ellis PM, Shepherd FA, Laurie SA, Goss GD, Olivo MS, Powers J, Walsh W, Seymour L, Bradbury PA. NCIC IND.190: A phase I trial of MK-0646 in combination with cisplatin and etoposide in extensive stage small cell lung cancer (ES SCLC). J Clin Oncol 30[suppl, abstr 7093]. 2012.
  • Fehringer G, Liu J, Pintilie M, Sykes J, Liu N, Cheng D, Chen Z, Seymour L, Der SD, Shepherd FA, Tsao M-S, Hung RJ. Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue. Proc Am Assoc Cancer Res [abstr 4210], 2012.
  • Gelmon KA, Boyle F, Kaufman B, Huntsman D, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Dent SF, Ellard S, Tonkin KS, Nagarwala YM, Pritchard KI, Whelan TJ, Nomikos D, Chapman J-AW, Parulekar W. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 30[suppl, abstr LBA671], 2012.
  • Goldhirsch A, Piccart-Gebhart MJ, Procter M, de Azambuja E, Weber HA, Untch M, Smith I, Gianni L, Jackisch C, Cameron D, Bell R, Dowsett M, Gelber RD, Leyland-Jones B, Baselga J. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Cancer Res 72[24 Suppl 3, abstr S5-2], 2012.
  • Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz M, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dorken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM. Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone. Blood (ASH Annual Meeting Abstracts) 120[21, abstr 548], 2012.
  • Higgins MJ, Chapman J-AW, Ingle JN, Sledge G, Budd GT, Ellis MJ, Pritchard KI, Clemons M, Crnjevic TB, Han L, Gelmon K, Rabaglio M, Elliott C, Shepherd LE, Goss PE. Effect of aspirin (ASP) or celecoxib (CC) use on outcomes in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27. Cancer Res 72[24 Suppl 3, abstr P2-13-02], 2012.
  • Jamal R, Chen BE, Hristova G, Seymour L, Assouline SE. Predictive model for survival and toxicity in early-phase trials in hematology. J Clin Oncol 30[suppl, abstr 2547], 2012.
  • Jonker DJ, Karapetis CS, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Daneshmand M, Hanson J, Shapiro JD, Pavlakis N, Gibbs P, van Hazel GA, Yu Min Lee UJ, Virk S, Tu D, Lorimer I. BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17. J Clin Oncol 30[suppl, abstr 3515], 2012.
  • Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA. A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29. J Clin Oncol 30[suppl, abstr 7511], 2012.
  • Leighl NB, Tsao MS, Ho C, Shepherd FA, Murray N, Goffin J, Nicholas G, Seymour L, Goss GD, Bradbury P. NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC. EORTC-NCI-AACR Symposium [abstr 607], 2012.
  • Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.
  • Litière S, de Vries E, Seymour L, Sargent DJ, Shankar L, Bogaerts J. The components of progression as explanatory variables for overall survival in the RECIST database. J Clin Oncol 30[suppl, abstr 10602]. 2012.
  • Mackay H, Eisenhauer EA, Kamel-Reid S, Clarke B, Walsh W, Karakasis K, Salvesen HB, Oza AM. Molecular Determinants of Outcome with mTOR Inhibition in Endometrial Cancer (EC). J Clin Oncol 30[suppl, abstr 5010], 2012.
  • Mason MD, Parulekar W, Sydes MR, Parmar M, Anderson J, Barber J, Brundage MD, Cowan R, Gospodarowicz MK, Hayter C, Hetherington J, Hiltz AC, Kirkbride P, Kostashuk E, Sanders K, Sathya J, Swanson GP, Chen BE, Warde PR. Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110). J Clin Oncol 30[suppl, abstr 4509], 2012.
  • Masucci GL, Wong R, Brundage M, Stanton H, Wilson C, Meyer R, Sahgal A. Developing the NCIC-CTG SC24 randomized phase II spine SBRT (stereotactic body radiation therapy) study for complex spinal metastases: what should the control group be? Canadian Assoc Rad Oncol [abstr 61], 2012.
  • Pitz MW, MacNeil MV, Macdonald DR, Kakumanu AS, Thiessen B, Tsao MS, Kamel-Reid S, Squire J, Sederias J, Walsh W, Eisenhauer EA, Mason WP. PhaseII study of PX-866 in recurrent glioblastoma. J Clin Oncol 30[suppl, abstr 2051], 2012.
  • Rayson D, Lupichuk SM, Chia SKL, Potvin KR, Dent S, Tsao MS, Prady C, Ellard S, Salim M, Allo G, Ludkovski O, Goodwin RA, Wainman N, Walsh W, Farmer P, Eisenhauer EA. A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484). J Clin Oncol 30[suppl, abstr 1036], 2012.
  • Ringash J, Au H-J, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland AH, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan SS, Easaw JC, Shannon JA, El-Tahche F, Walters IB, Tu D, O'Callaghan CJ. Quality of life (QoL) assessment in patients (pts) with K-RAS wild-type (WT) chemotherapy refractory metastatic colorectal cancer (mCRC) treated with cetuximab (CET) plus brivanib alaninate (BRIV) or placebo: Results of the NCIC Clinical Trials Group and AGITG CO.20 trial. J Clin Oncol 30[suppl 4; abstr 542]. 2012.
  • Sgroi D, Goss PE, Chapman J-AW, Richardson E, Binns SN, Zhang Y, Schnabel C, Erlander MG, Pritchard KI, Han L, Shepherd LE, Pollak MN. Assessment of the prognostic and predictive utility of the breast cancer index (BCI): A NCIC CTG MA.14 study. J Clin Oncol 30[suppl, abstr 561], 2012.
  • Shepherd FA, Bourredjem A, Brambilla E, Domerg C, Douillard J-Y, Filipits M, Graziano SL, Hainaut P, Janne PA, Le Chevalier T, Le Teuff G, Pignon J-P, Pirker R, Seymour L, Soria J-C, Taron M, Tsao MS. Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study. J Clin Oncol 30[suppl, abstr 7007], 2012.
  • Shepherd LE, Chapman J-AW, Ali SM, Zhu L, Leitzel K, Goss PE, Lipton A. Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27. J Clin Oncol 30[suppl, abstr 501], 2012.
  • Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer M, Jefford M, Magoski NM, Haydon A, Walters I, Tu D, O'Callaghan CJ, on behalf of NCIC CTG and AGITG. Final Analysis of the Phase III randomized trial of cetuximab (CET) + either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. J Clin Oncol 30[suppl, abstr 3504], 2012
  • Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw WS, Sawyer MB, Jefford M, Magoski NM, Haydon AM, Walters IB, Tu D, O'Callaghan CJ. Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. J Clin Oncol 30[suppl 4, abstr 386], 2012.
  • Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.
  • Vogl SE, Altwairgi AK, Chapman J-AW, Zhu L, Shepherd LE, Goss PE. Characterization of patients who received further adjuvant endocrine therapy after 5 years of aromatase inhibitors (AIs): NCIC CTG MA 27. J Clin Oncol 30[suppl, e11005], 2012.
  • Waldron JN, Parulekar W, O'Sullivan B, Chen BE, Montenegro A, Nabid A, Winquist E, Wright JR, Hay J, Ringash J, Martino R, Johnson A, Liu G, Breen S, Gilbert RW, Shenouda G, Siu LL. A phase III study off standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6). J Clin Oncol 30[suppl, abstr TPS5600], 2012.
  • Walker M, Richardson H, Goss P, Jabs D, Jones D, Kaufmann M, Wactawski-Wende J, Cheung A, Winquist E, Spadafora S, Ellard S, Hey A, Cooke A, Eisen A, Verma S, Lickley L, Tu D, Gelmon K, Meyer RM, King WD. Vitamin D and Mammographic Density in Postmenopausal Women: A Cohort Study Nested Within the NCIC CTG MAP.3 Chemoprevention Trial. 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research, 2012
  • Warde P, Parulekar W, Parmar M, Andersen J, Barber J, Brundage M, Chen B, Cowan R, Gospodarowicz M, Hayter C, Hetherington J, Hiltz A, Kirkbride P, Kostashuk E, Sanders K, Sathya J, Swanson G, Sydes M, Mason M. Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) +/- radiation therapy (RT) in locally advanced prostate cancer (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633). Canadian Assoc Rad Oncol [abstr 185], 2012.
  • Zorzi AP, Bernstein M, Samson Y, Wall DA, Desai S, Wainman N, Eisenhauer E, Baruchel S. A Phase I Study of Histone Deacetylase Inhibitor, SB939, in Pediatric Patients with Refractory Solid Tumors. EORTC-NCI-AACR Symposium [abstr 344], 2012.
  • Advani R, Hong F, Gordon LI, Gascoyne RD, Wagner H, Hoppe RT, Fisher RI, Bartlett NL, Kahl BS, Stiff P, Cheson BD, Belch AR, Friedberg JW, Kassis J, Blum KA, Habermann TM, Tuscano J, Horning SJ. Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V regimen in the Randomized Phase III North American Intergroup trial: E2496. Blood (ASH Annual Meeting Abstracts) 118[21, abstr 1603], 2011.
  • Agarwala SS, Lee SJ, Flaherty LE, Smylie M, Kefford RF, Carson WE, Cohen G, Kirkwood JM. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697). J Clin Oncol 29[suppl; abstr 8505], 2011.
  • Aguilar-Mahecha A, Basik M, Chapman JW, Jahan K, Hassan S, Zhu L, Wilson CF, Pritchard KI, Shepherd LE, Pollak MN. Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. J Clin Oncol 29[suppl; abstr 577]. 2011.
  • Alberts SR, Thibodeau SN, Sargent DJ, Mahoney MR, Sinicrope F, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Nair SG. Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. J Clin Oncol 29[suppl; abstr 3607]. 2011.
  • Basik M, Keilty D, Aleynikova O, Tu D, Li X, Shepherd LE, Bramwell V. Measurement of Pax2, TC21,CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer. J Clin Oncol 29[suppl; abstr 560]. 2011.
  • Bouganim N, Dong B, Hilton JF, Chapman J-AW, Arnaout A, O'Malley F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Bramwell V, Whelan T, Pritchard KI, Shepherd L, Clemons M. How Should We Assess Tumour Size (T Stage) in Patients with Multicentric/Multifocal Breast Cancer? Results from the NCIC CTG MA.5 Randomized Trial of CEF vs. CMF in Pre-Menopausal Women with Node Positive Breast Cancer. Cancer Res 71[24, Suppl 3, abstr P2-12-23], 114s, 2011.
  • Bramwell VH, Tuck AB, Chapman J-A, Anborgh PH, Postenka CO, Shepherd L, Pritchard KI, Han L, Wilson C, Pollak M, Chambers AF. Studies of a Malignancy-Associated Protein, Osteopontin, in NCIC CTG MA.14, a Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR in Adjuvant Treatment of Women with Early Breast Cancer. Cancer Res 71[24 Suppl 3, abstr P2-12-28], 302s, 2011.
  • Chapman J-AW, Shepherd LE, Le Maître A, Pritchard KI, Graham BC, Gelmon KA, Bramwell VH. Effect of Treatment Emergent Symptoms on Relapse Free Survival: NCIC CTG MA.12 a Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-menopausal Women in Early Breast Cancer. Cancer Res 71[24 Suppl 3, abstr P1-06-08], 178s, 2011.
  • Chapman J-AW. Efficacy Estimation Using Parametric (Log-Normal) Framework for Meta-Analyses. Joint Statistical Meetings [abstr 300162], 2011.
  • Chapman JW, O'Callaghan C, Hu N, Ding K, Yothers GA, Catalano PJ, Shi Q, Gray RG, O'Connell MJ, Sargent DJ, for the ACCENT collaborative group. Comparison of innovative estimation of efficacy to standard using the ACCENT database. J Clin Oncol 29[suppl; abstr 3616]. 2011.
  • Cheang M, Voduc D, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Vickery T, Davies S, Stijleman IJ, Davis C, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen TO. The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. J Clin Oncol 29[suppl; abstr 1032]. 2011.
  • Chi KN, Eigl BJ, North S, Squire J, Eisenhauer E. A Phase II Study of SB939 in Patients with Recurrent or Metastatic Castration Resistant Prostate Cancer (CRPC). Canadian Cancer Research Conference, 2011.
  • Crook JM, O'Callaghan CJ, Ding K, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde PR, Corbett TB, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Schellhammer PF, Klotz L. A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013). J Clin Oncol 29[suppl; abstr 4514]. 2011.
  • Cuffe S, Graziano S, Bourredjem A, Pignon J-P, Ezzalfani M, Seymour L, Strevel E, Burkes R, Capelletti M, Janne PA, Tsao MN, Shepherd FA. A pooled exploratory analysis of the impact of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC). J Thoracic Oncol 6[6 suppl 2, abstr O42.01], S462, 2011.
  • De Ruysscher D, Paris E, Le Péchoux C, Turrisi AT, Pang H, Murray N, Lebeau B, Takada M, Skarlos D-V, Blackstock A, O'Brien MER, Spiro S, Pignon J-P. A meta-analysis of randomised trials using individual patient data on the timing of chest radiotherapy in patients with limited stage small cell lung cancer. J Thoracic Oncol 6[6 suppl 2, abstr MO19.03], S641, 2011.
  • Dong B, Chapman J-AW, Yerushalmi R, Goss PE, Pollak MN, Burnell MJ, Bramwell VH, Levine MN, Pritchard KI, Whelan TJ, Ingle JN, Parulekar W, Shepherd LE, Gelmon KA. Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis. Cancer Res 71[24, Suppl 3, abstr P5-14-01], 559s-560s, 2011.
  • Dong B, Chapman JW, Yerushalmi R, Shepherd LE, Gelmon KA. Differences in efficacy by assessment method: NCIC CTG adjuvant breast cancer trials MA.5, MA.12, MA.14, MA.21, MA.27 meta-analysis. Canadian Cancer Research Conference, 2011.
  • Douer D, Zickl L, Schiffer CA, Appelbaum FR, Feusner JH, Shepherd LE, Willman CL, Bloomfield CD, Rowe JM, Wiernik PH, Tallman MS. Late Relapses Following ALL-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129. Blood (ASH Annual Meeting Abstracts) 118[21, abstr 83], 2011.
  • Eigl BJ, North S, Murray N, Heng DYC, Winquist E, Powers J, Walsh WR, Eisenhauer E, Squire J, Cox M, Chi KN. A Phase II Study of SB939 in Patients with Recurrent or Metastatic Castration Resistant Prostate Cancer (CRPC). AACR Mol Cancer Ther 10[11 Suppl; abstr A211], 2011.
  • Elimova E, O'Callaghan CJ, Tu D, Karapetis CS, Price TJ, Zhu L, Zalcberg JR, Simes J, Jonker DJ. Cetuximab (CET) -related hypersensitivity reactions (HSRs): An analysis of timing, demographics, and outcomes from the AGITG/NCIC CTG CO.17 trial. J Clin Oncol 29[suppl; abstr 3624]. 2011.
  • Fuchs CS, Tepper JE, Niedzwiecki D, Hollis D, Mamon HJ, Swanson R, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett C, Enzinger PC, Goldberg RM, Venook AP, Mayer RJ. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol 29[suppl; abstr 4003]. 2011.
  • Goodwin RA, Jamal R, Tu D, Oza AM, Elit L. Predictors of Response and Progression to Temsirolimus in Women with Recurrent or Metastatic Endometrial Cancer. Canadian Cancer Research Conference, 2011.
  • Goss GD, Addison CL, Ding K, Zhao H, Le Maître A, Laurie S, Shepherd FA, Bradbury PA, Seymour L. Circulating plasma angiogenic factors and soluble receptors in NCIC CTG BR.24. J Thoracic Oncol 6[2 suppl 2, abstr MO22.12], S673, 2011.
  • Goss PE, Richardson H, Ingle JN, Chlebowski RT, Fabian CJ, Garber JE, Sarto GE, Hiltz A, Tu D, Cheung AM. Influence of Two Years of Exemestane on Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer; a Companion Study to the NCIC CTG MAP.3 Trial. Cancer Res 71[24 Suppl 3, abstr P4-11-13], 480s-481s, 2011.
  • Goss PE, Ingle JN, Alés-Martinez J, Cheung A, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson K, Martin L, Winquist E, Sarto G, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3 - A randomized placebo-controlled clinical trial. J Clin Oncol 29[suppl; abstr LBA504]. 2011.
  • Goss PE, Ingle JN, Chapman JW, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Gelmon K, Shepherd L, Pritchard KI. Final results of NCIC CTG MA.27: adjuvant exemestane versus anastrozole in primary breast cancer. 12th St Gallen International Breast Cancer Conference, 2011.
  • Hammel P, Huguet F, Van Laethem J, Goldstein D, Glimelius B, Moore MJ, Chibaudel B, Bonnetain F, Louvet C. Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib-LAP 07 study. J Clin Oncol 29[suppl; abstr e14619]. 2011.
  • Hershman DL, Cheung AM, Chapman JW, Ingle JN, Ahmed F, Hu H, Scher J, Leeson S, Elliott C, Le Maître A, Shepherd LE, Goss PE. Effects of adjuvant exemestane versus anastrozole on bone mineral density: Two-year results of the NCIC CTG MA.27 bone companion study. J Clin Oncol 29[suppl; abstr 518]. 2011.
  • Hertel PB, Tu D, Ejlertsen B, Jenson M-B, Balslev E, Jiang S, O'Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO. TIMP-1 in Combination with HER2 and TOP2A for Prediction of Benefit from Adjuvant Anthracyclines in High Risk Breast Cancer Patients. Cancer Res 71[24 Suppl 3, abstr P1-06-07], 178s, 2011.
  • Hilton JF, Dong B, Bouganim N, Chapman J-AW, Arnaout A, O'Malley F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Bramwell V, Whelan T, Pritchard KI, Shepherd L, Clemons M. Simply Adding Together the Diameters of Tumor Foci in Patients with Multicentric or Multifocal Disease Does Not Add Any Additional Prognostic Information: An Analysis from NCIC CTG MA.12 Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women with Early Breast Cancer. Cancer Res 71[24 Suppl 3, abstr P2-12-27], 301s-302s, 2011.
  • Hilton JF, Seymour L, Le Maître A, Tu D, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib. J Clin Oncol 29[suppl; abstr 7523]. 2011.
  • Huang J, Sargent DJ, Mahoney MR, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Sinicrope F, Nair SG, Alberts SR. Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147. J Clin Oncol 29[suppl; abstr 3522]. 2011.
  • Klotz L, O'Callaghan CJ, Ding K, Dearnaley DP, Higano CS, Horwitz EM, Malone S, Goldenberg SL, Gospodarowicz MK, Crook JM. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. J Clin Oncol 29[suppl 7; abstr 3]. 2011.
  • Kristensen G, Perren T, Qian W, Pfisterer J, Ledermann JA, Joly F, Carey MS, Beale PJ, Cervantes A, Oza AM. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol 29[suppl; abstr LBA5006]. 2011.
  • Kurzeder C, Zhao L, Eisenhauer EA, Vergote IB, du Bois A, Tai D, Wang Y, Gill JF, Hirte HW, Richter B, Hanker LC, Bentley J, Wagner UA, Plante M, Kimmig R, Pfisterer J. The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. J Clin Oncol 29[suppl; abstr 5088]. 2011.
  • Lee C, Simes J, Gebski V, Wollschlaeger K, Plante M, Vergote I, Mäenpää J, Ferrero A-M, Pisano C, Parma G, Berton-Rigaud D, Schröder W, Bentley J, Reinthaller A, Schmalfeldt B, Hirte H, Pfisterer J, Pujade-Lauraine E, Friedlander M. Development and validation of a nomogram to predict survival in CALYPSO and AGO-2.5 patients with platinum sensitive recurrent ovarian cancer. Int J Gynecol Cancer 21[12 Suppl 3, abstr 365], 2011.
  • Lee C, Gurney H, Brown C, Friedlander M, Tulunay G, Belau A, Maenpaa J, Bacon M, Vasey P, Wolfram G, Reed N, Sorio R, Donadello N, Gebski V, Pujade-Lauraine E, Lord S, Simes J. Carboplatin-paclitaxel induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer patients treated in the CALYPSO GCIG trial. Int J Gynecol Cancer 21[12 Suppl 3, abstr 368], 2011.
  • Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.
  • Mackay H, Welch S, Tsao MS, Biagi JJ, Elit L, Ghatage P, Martin L, Tonkin KS, Ellard S, Lau SK, McIntosh L, Eisenhauer EA, Oza AM. Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192. J Clin Oncol 29[suppl; abstr 5013]. 2011.
  • Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Ferrero A, Cretin J, Havsteen H, Bessette P, Angleitner-Boubenizek L, Vergote IB, Vasey PA, Gebski V, Slama B, Herrstedt J, Kaizer L, Georgoulopoulos A, Reed N, Wagner U. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very palatinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial. J Clin Oncol 29[suppl; abstr 5059]. 2011.
  • Mahoney MR, Sloan JA, Hubbard JM, Liu H, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Nair SG, Sargent DJ, Alberts SR. Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. J Clin Oncol 29[suppl; abstr 3541]. 2011.
  • Marth C, Alexandre J, Hanker LC, Brown C, Kaern J, Heywood M, Bonaventura A, Vergote IB, Pignata S, Ferrero A, Gebski V, Gropp M, Skeie-Jensen T, Giede C, Vasey PA, Schauer C, Reed N, Ferrandina G, Fossati R, Pujade-Lauraine E. Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial. J Clin Oncol 29[suppl; abstr 5052]. 2011.
  • Mauguen A, Michiels S, Burdett S, Tierney JF, Sause W, Mandrekar SJ, Dahlberg SE, Shepherd FA, Parmar M, Perry MC, O'Brien M, Le Péchoux C, Pignon J-P. Evaluation of progression-free survival as a surrogate endpoint for overall survival when evaluating the effect of chemotherapy and radiotherapy in locally advanced lung cancer using data from four individual patient data meta-analyses. J Thoracic Oncol 6[6 suppl 2, abstr O42.05], S464, 2011.
  • Maunsell E, Richardson H, Ingle JN, Ales-Martinez JE, Chlebowski RT, Fabian CJ, Sarto GE, Garber JE, Pujol P, Hiltz A, Tu D, Goss PE. Menopause-Specific and Health-Related Qualities of Life among Post-Menopausal Women Taking Exemestane for Prevention of Breast Cancer: Results from the NCIC CTG MAP.3 Placebo-Controlled Randomized Controlled Trial. Cancer Res 71[24 Suppl 3, abstr S6-1], 113s-114s, 2011.
  • Mehta RS, Barlow WE, Albain KS, Vandenberg T, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB. A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226. Cancer Res 71[24, Suppl 3, abstr S1-1], 2011.
  • Meyer RM, Gospodarowicz M, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE. Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6. Blood (ASH Annual Meeting Abstracts) 118[21, abstr 590], 2011.
  • Michiels S, Mauguen A, Fisher D, Burdett S, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Le Péchoux C, Pignon J. Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. J Clin Oncol 29[suppl; abstr 7004]. 2011.
  • Moy B, Shepherd LE, Chapman J-AW, Le Maître A, Gelmon KA, Elliott C, Ingle JN, Goss PE. NCIC CTG MA.27: Clinical Tolerability and Overall Survival of Racial and Ethnic Minority Women on Aromatase Inhibitor Therapy. Cancer Res 71[24 Suppl 3, abstr P2-14-02], 309s, 2011.
  • Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, Mcdonald A, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Coxon FY, Lacaine F, Middleton MR, Ghaneh P, Bassi C, Halloran C, Oláh A, Rawcliffe CL, European Study Group for Pancreatic Cancer, Buchler MW. Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater. J Clin Oncol 29[suppl; abstr LBA4006]. 2011.
  • O'Callaghan CJ, Tu D, Karapetis CS, Au H, Moore MJ, Tebbutt NC, Trudeau MG, Price TJ, Yip D, Jonker DJ. The relationship between the development of rash and clinical and health-related quality of life outcomes by KRAS mutation status patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17. J Clin Oncol 29[suppl; abstr 3588]. 2011.
  • Parulekar W, Chen BE, Elliott C, Shepherd LE, Gelmon KA, Pritchard KI, Whelan TJ, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Rastogi P, Lemieux J, Ganz PA, Stambolic V, Goodwin PJ. A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32). J Clin Oncol 29[suppl; abstr TPS103]. 2011.
  • Parulekar W, Chapman JW, Aparicio S, Murray Y, Boyle FM, di Leo A, Kaufmann B, Levy C, Manikhas A, Martin M, Pritchard KI, Schwartzberg LS, Burnell MJ, Dent S, Ellard S, Tonkin KS, Whelan TJ, Lemieux J, Bordeleau L, Gelmon KA. Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG) MA.31/ GSK EGF 108919). J Clin Oncol 29[suppl; abstr TPS108]. 2011.
  • Powell BL, Moser BK, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre SE, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. Blood (ASH Annual Meeting Abstracts) 118[21, abstr 258], 2011.
  • Scott DW, Chan FC, Hong F, Rogic S, Tan K, Meissner B, Farinha P, Horning SJ, Fisher RI, Bartlett NL, Shepherd LE, Connors JM, de Sousa AB, Kahl BS, Gordon LI, Steidl C, Gascoyne RD. A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma - a Correlative Study From the E2496 Intergroup Trial. Blood (ASH Annual Meeting Abstracts) 118[21, abstr 430], 2011.
  • Shapiro JD, Siu LL, Zalcberg JR, Moore MJ, Ringash J, Mittmann N, Simes J, O'Callaghan CJ, Tu D, Walters IB, Magoski N, Smith P, Nomikos D, Zhu L, Savoie M, Virk S, El-Tahche F, Gill R, Price TJ, Jonker DJ. A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial. J Clin Oncol 29[suppl; abstr TPS163]. 2011.
  • Shepherd L, Virk S, Zeltser F, Shepherd F, Tsao M-S. Impact of Biorepositories in Clinical Trials: The NCIC Clinical trials Group Experience. Canadian Cancer Research Conference, 2011.
  • Sloan JA, Mahoney MR, Sargent DJ, Hubbard JM, Liu H, Basch EM, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Alberts SR. Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. J Clin Oncol 29[suppl; abstr 6122]. 2011.
  • Song H, Peng P, Tu D. A New Approach for Joint Modeling of Longitudinal Measurements and Survival Times with a Cure Fraction. Statistical Society of Canada, 2011.
  • Soria J-C, Brambilla E, Le Teuff G, Tsao M-S, Janne P, Hainaut P, Taron M, Kratzke RA, Shepherd F, Pignon J-P. A pooled analysis to evaluate the prognosis and predictive value of EGFR mutation on survival in patients with KRAS wild-type lung adenocarcinoma. J Thoracic Oncol 6[6 suppl 2, abstr MO16.06], S617, 2011.
  • Stearns V, Chapman JW, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maître A, Kundapur J, Shepherd LE, Goss PE. Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. J Clin Oncol 29[suppl; abstr 525]. 2011.
  • Stiff PJ, Unger M, Cook J, Constine LS, Couban S, Shea TC, Winter JN, Miller TP, Tubbs RR, Marcellus DC, Friedberg JW, Barton K, Mills GM, LeBlanc ML, Rimsa L, Forman SJ, Fisher RI. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin's lymphoma (NHL). J Clin Oncol 29[suppl; abstr 8001]. 2011.
  • Tinker A, Mackay H, Ellard S, Welch S, Eisenhauer E. Preliminary Activity of Temsirolimus, an mTOR Inhibitor, in Patients with Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix: a NCIC-CTG Phase II Clinical Trial. AACR Mol Cancer Ther 10[11 Suppl; abstr C69], 2011.
  • van Hazel GA, Tu D, Tebbutt NC, Jonker DJ, Price TJ, O'Callaghan C, Zalcberg JR, Taylor M, Strickland AH, Tomiak AT, Yip D, Simes J, Yadav SK, Links M, Burnell MJ, Jefford M, Karapetis CS. Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study. J Clin Oncol 29[suppl; abstr 3602]. 2011.
  • Van Loon K, Wigler D, Niedzwiecki D, Hollis D, Venook AP, Blanke CD, Saltz L, Goldberg RM, Fuchs CS, Meyerhardt JA. A comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients. J Clin Oncol 29[suppl; abstr e14026]. 2011.
  • Venook AP, Niedzwiecki D, Lopatin M, Lee M, Friedman PN, Frankel W, Clark-Langone K, Yoshizawa C, Milward C, Shak S, Goldberg RM, Mahmoud NN, Schilsky RL, Bertagnolli MM. Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581. J Clin Oncol 29[suppl; abstr 3518]. 2011.
  • Vickers MM, Karapetis CS, Tu D, O'Callaghan CJ, Price TJ, Tebbutt NC, van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Yu Min Lee UJ, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ. The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17. J Clin Oncol 29[suppl; abstr 3601]. 2011.
  • Wagner LI, Zhao F, Chapman J-AW, Cella D, Shepherd LE, Sledge GW, Goss PE. Patient-Reported Predictors of Early Treatment Discontinuation: NCIC JMA.27/E1Z03 Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole. Cancer Res 71[24 Suppl 3, abstr S6-2], 114s, 2011.
  • Walker M, Szeto A, Meng Z, Chen BE, Meyer RM. Sponsor / Research Ethics Boards (REB) Communications About Informed Consent (IC) and Time to Local Activation (LA): An NCIC CTG Pilot Study. Canadian Cancer Research Conference, 2011.
  • Walker M, Szeto A, Meng Z, Chen BE, Meyer RM. Sponsor/research ethics boards (REB) communications about informed consent (IC) and time to local activation (LA): An NCIC CTG pilot study. J Clin Oncol 29[suppl; abstr 6131]. 2011.
  • Whelan TJ, Olivotto I, Ackerman I, Chapman JW, Chua B, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Craighead P, Nolan MC, Bowen J, McCready DR, Pritchard KI, Levine MN, Parulekar W. NCIC-CTG MA.20: An integroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol 29[suppl; abstr LBA1003]. 2011.
  • Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Bramwell VH, Levine MN, Pritchard KI, Whelan TJ, Ingle JN, Parulekar W, Shepherd LE, Gelmon KA. Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer. J Clin Oncol 29[suppl; abstr 513]. 2011.
  • You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Fossati R, Emons G, Rehman KL, Steffensen KD, Petru E, Gebski V, Burges A, Tubiana-Matthieu N, Hansen M, Vasey PA, Denison U, De Bruyne P, Oza AM. Mathematical modeling of CA125 kinetics in recurrent ovarian cancer patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial: A GCIG study. J Clin Oncol 29[suppl; abstr 5065]. 2011.
  • Advani R, Hong F, Fisher RI, Bartlett NL, Robinson S, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl B, Friedberg JW, Blum KA, Habermann TM, Tuscano J, Hoppe R, Horning SJ. Randomized phase III trial comparing ABVD + radiotherapy and the Stanford V regimen in patients with stage I/II bulky mediastinal Hodgkin lymphoma: A subset analysis of the US Intergroup Trial E2496. Blood (ASH Annual Meeting Abstracts) 116[21, abstr 416], 2010.
  • Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuxiumab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.
  • Ali SM, Aguilar-Mahecha A, Chapman J-AW, Lipton A, Leitzel K, Jahan K, Hassan S, Shepherd LE, Han L, Wilson CF, Pritchard KI, Pollak MN, Basik M. Serum SDF-1: biomarker of bone relapse in the NCIC MA.14 adjuvant breast cancer trial. Cancer Res 70[24 Suppl, abstr P4-09-09], 341s, 2010.
  • Basik M, Aguilar-Mahecha A, Chapman JW, Jahan K, Hassan S, Han L, Wilson CF, Pritchard KI, Shepherd LE, Pollak MN. Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. J Clin Oncol 28[15s, abstr 551], 2010.
  • Brambilla E, Bourredjem A, Lantuejoul S, Tsao MS, Pignon JP, Kratzke R, Stahel R, Douillard JY, Seymour L, Soria JC. Bax expression as a predictive marker of survival benefit in non-small cell lung carcinoma treated by adjuvant cisplatin-based chemotherapy. Chicago Multidisciplinary Symposium in Thoracic Oncology, 2010.
  • Browne R, Chapman J-A. SAS general parametric step-wise regression macro. 38th Annual Meeting of the Statistical Society of Canada [Abst MS194], 153, 2010.
  • Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S, Ferrero A. Health related quality of life and progression-free survival in patients with recurrent ovarian cancer: Results from the CALYPSO trial. J Clin Oncol 28[15s, abstr 5044], 2010.
  • Carbone DP, Seymour L, Ding K, Roder H, Tsao M, Shepherd FA. Serum proteomic prediction of outcomes in advanced NSCLC patients treated with erlotinib/placebo in the NCIC Clinical Trials Group BR.21 trial. J Thoracic Oncol 5[5 Suppl 1], S80, 2010.
  • Chapman J-AW, Nielsen T, Ellis MJ, Bernard P, Chia S, Gelmon K, Pritchard KI, Le Maître A, Shepherd L, Bramwell V. Effect of continuous statistically standardized qPCR and IHC ER and PR on disease-free survival in NCIC CTG MA.12. Cancer Res 70[24 Suppl, abstr P2-09-16], 214s, 2010.
  • Chapman JW, Ali SM, Lipton A, Leitzel K, Pritchard KI, Han L, Carney WP, Wilson CF, Shepherd LE, Pollak MN. Obesity, patient characteristics, and TIMP-1: Effects on non-bone RFS in NCIC CTG MA.14. J Clin Oncol 28[15s, abstr 562], 2010.
  • Chia SK, Ung K, Bramwell VH, Tu D, Perou CM, Ellis MJ, Bernard PS, Vickery T, Shepherd LE, Nielsen TO. Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial. J Clin Oncol 28[15s, abstr 508], 2010.
  • Cuffe S, Ezzalfani M, Graziano S, Pignon J, Seymour L, Strevel E, Burkes R, Shepherd FA. A pooled exploratory analysis of the effect of tumor size on survival benefit from adjuvant platinum-based chemotherapy in node negative non-small cell lung cancer. Chicago Multidisciplinary Symposium in Thoracic Oncology, 2010.
  • Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.
  • Gelmon K, Dent S, Chi K, Jonker D, Wainman N, Simpson R, Capier K, Chen E, Squires MS, Seymour L. NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion. EORTC-NCI-AACR Symposium [abstr 512], 2010.
  • Goodwin RA, Jamal R, Tu D, Walsh W, Dancey J, Oza AM, Elit L, Eisenhauer EA. Temsirolimus in endometrial cancer: Predictors of response and progression. OICR 3rd Annual Scientific Meeting, 2010.
  • Goodwin RA, Jamal R, Booth CM, Goss PE, Eisenhauer EA, Tu D, Shepherd LE. Effects of diabetes, hypertension and coronary artery disease on prognosis after 5 years of adjuvant tamoxifen and on treatment outcomes with the use of extended letrozole: NCIC CTG MA.17. Cancer Res 70[24 Suppl, abstr PD03-04], 103s, 2010.
  • Goodwin RA, Jamal R, Tu D, Walsh W, Dancey J, Oza AM, Elit L, Eisenhauer EA. Temsirolimus in endometrial cancer: Predictors of response and progression. J Clin Oncol 28[15s, abstr 3090], 2010.
  • Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl B, Friedberg JW, Blum KA, Habermann TM, Tuscano J, Hoppe R, Horning SJ. A randomized phase III trial of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Blood (ASH Annual Meeting Abstracts) 116 [21, abstr 415], 2010.
  • Goss PE, Ingle JN, Chapman J-AW, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Gelmon K, Shepherd L, Pritchard KI. Final analysis of NCIC CTG MA27: A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. Cancer Res 70[24 Suppl, abstr S1-1], 75s, 2010.
  • Goss GD, Lorimer I, Tsao MS, O'Callaghan CJ, Ding K, Masters GA, Gandara DR, Jett JR, Edelman MJ, Shepherd FA. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor, gefitinib in completely resected stage IB-IIIA non small cell lung cancer, NCIC CTG BR.19. J Clin Oncol 28[18s, abstr LBA7005], 2010.
  • Gryfe R, Minoo P, Baker K, Tu D, Ribic C, Marsoni S, Moore MJ, Shepherd LE, Jass J, Gallinger S. Colon cancer O6-methylguanine DNA methyltransferase gene methylation and survival in fluorouracil-treated patients. ASCO Gastrointestinal Cancers Symposium, 2010.
  • Hotte SJ, Chen EX, McIntosh L, Hirte HW, Turner S, Jarvi A, Squires MS, Seymour L. NCIC CTG IND.177: Phase I study of AT7519M given as a short infusion twice weekly. EORTC-NCI-AACR Symposium [abstr 491], 2010.
  • Hu N, Li W. Metabolism of Bradykin and Endogenous des-Arg9-Bradykinin in Human Plasma: Contribution to the Pathophysiology of Angioedema Associated with ACE Inhibitors. 38th Annual Meeting of the Statistical Society of Canada, 2010.
  • Jamal R, Goodwin RA, Tu D, Walsh W, Eisenhauer EA. Application of multinomial phase II designs in trials of targeted agents. J Clin Oncol 28[15s, abstr 3074], 2010.
  • Jamal R, Goodwin RA, Tu D, Walsh W, Eisenhauer EA. Application of multinomial phase II designs in trials of targeted agents. OICR 3rd Annual Scientific Meeting, 2010.
  • Karp DD, Lee SJ, Wright GL, Johnson DH, Johnston MR, Goodman GE, Clamon GH, Okawara GS, Marks R, Ruckdeschel JC. A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium supplementation in resected stage I non-small cell lung cancer. J Clin Oncol 28[18s, abstr CRA7004], 2010.
  • Kurtz J, Hilpert F, Dorum A, Veillard A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N. Can elderly patients with recurrent ovarian cancer be treated with a platinum-based doublet? Results from the CALYPSO trial. J Clin Oncol 28[15s, abstr 5031], 2010.
  • Lee CK, Guardiola E, Hogberg T, Friedlander M, Bentley J, Denison U, Vergote IB, Pisano C, Parma G, Wimberger P. Development of a nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer based on the CALYPSO trial. J Clin Oncol 28[15s, abstr 5105], 2010.
  • Liu G, Cheng D, Le Maître A, Liu N, Chen Z, Seymour L, Ding K, Shepherd FA, Tsao MS. EGFR and ABCG2 polymorphisms as prognostic and predictive markers in the NCIC CTG BR.21 trial of single-agent erlotinib in advanced non-small cell lung cancer. J Clin Oncol 28[15s, abstr 7538], 2010.
  • Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S, Foo A, Leber B. Phase I/II study of low-dose cytarabine with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome. J Clin Oncol 28[15s, abstr 6564]. 2010.
  • Mason MD, Warde PR, Sydes MR, Gospodarowicz MK, Swanson GP, Kirkbride P, Kostashuk E, Hetherington J, Ding K, Parulekar W. Intergroup Randomized Phase 3 Study of Androgen Deprivation Therapy (ADT) + Radiation Therapy (RT) in Locally Advanced Prostate Cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, and INT: T94-0110; NCT00002633). Int J Radiat Oncol Biol Phys 78[3, Suppl, abstr 3], S2, 2010.
  • Mason MD, Warde PR, Sydes MR, Ding K, Gospodarowicz MK, Swanson GP, Kirkbride P, Kostashuk E, Hetherington J, Hiltz A, Sanders K, Anderson D, Barber J, Parmar MKB, Parulekar W. Intergroup randomized controlled phase III trial of androgen deprivation therapy +/- radiation therapy in locally advanced prostate cancer (NCIC-CTG, SWOG, MRC, INT: T94-0110; NCT00002633). NCRI Cancer Conference, UK [abstr C15], 2010.
  • Murawski N, Kuhnt E, Grass S, Hiddemann W, Cavallin-Stahl E, Hess G, Witzens-Harig M, Vasova I, Jäger U, Osowiecki M, North S, Pettengell R, Pöschel V, Löffler M, Pfreundschuh M. The role of the rituximab partner chemotherapy regimen in young patients with good-prognosis diffuse large B-cell lymphoma: Results of the 6-year follow-up of the Mint study of the Mabthera International Trial (MInT) Group. Blood (ASH Annual Meeting Abstracts) 116[21, abstr 2826], 2010.
  • Perren T, Swart AM, Pfisterer J, Ledermann J, Lortholary A, Kristensen G, Carey M, Beale P, Cervantes A, Oza A, on behalf of GCIG ICON7 collaborators. ICON7: A phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Ann Oncol 21[Suppl 8, abstr LBA4], viii2, 2010.
  • Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Kamel-Reid S, Tron V, Chen B, Hunder NN, Eisenhauer EA. Interleukin-21(IL-21) activity in patients with metastatic melanoma. J Clin Oncol 28[15s, abstr 8507], 2010.
  • Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Tmeny M, Shepherd L, Gill SD, Walewski J, Pettengell R, Jäger U, Zinzani P-L, Shpilberg O, Kvaloy S, Hansen M, Stahel R, Milpied N, Lopez-Guillermo A, Grass S, Murawski N, Pöschel V, Löffler M. Randomised intergroup trial of first line treatment for young low-risk patients (<61 years) with diffuse large B-cell non-Hodgkin's lymphoma with a CHOP-like regimen with or without the anti-CD20 antibody rituximab - 6-year follow-up of the Mint Study of the Mabthera International Trial (MInT) Group. Blood (ASH Annual Meeting Abstracts) 116[21, abstr 111], 2010.
  • Pirker R, Rousseau V, Paris E, Tsao MS, Aviel-Ronen S, Taron M, Kratzke R, Brambilla E, Seymour L, Filipits M. LACE-Bio: Cross-validation and pooled analyses of the putative prognostic/predictive biomarkers p27, p16 and cyclin E in IALT, ANITA, JBR10 and CALGB 9633. Chicago Multidisciplinary Symposium in Thoracic Oncology, 2010.
  • Pollak MN, Chapman JW, Pritchard KI, Krook JE, Dhaliwal HS, Vandenberg TA, Whelan TJ, O'Reilly SE, Wilson CF, Shepherd LE. Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial. J Clin Oncol 28[15s, abstr 542], 2010.
  • Radich JP, Kopecky KJ, Kamel-Reid S, Stock W, Paietta E, Wadleigh M, Larson RA, Emanuel PD, Tallman MS, Lipton J, Couban S, Deininger MW, Appelbaum FR, Druker BJ. A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial. Blood (ASH Annual Meeting Abstracts) 116[21, LBA 6], 2010.
  • Sgroi DC, Finkelstein DM, Shepherd L, Ingle JN, Rimm DL, Sasano H, Porter P, Pins M, Paik S, Ristimaki A, Pritchard KI, Tu D, Goss PE. Quantitative protein and gene expression biomarkers of tamoxifen and letrozole recurrence in the NCIC CTG MA.17 cohort. Cancer Res 70[24 Suppl, abstr P3-10-26], 270s, 2010.
  • Simes RJ, Lee CK, Mirza MR, Sauthier P, Georgopoulos A, Vergote IB, Ferrandina G, Donadello N, Schmalfeldt B, Delva R. The value of early decrease in CA125 levels as a prognostic or surrogate marker for disease progression in patients with recurrent ovarian cancer: Results from the CALYPSO study. J Clin Oncol 28[15s, abstr 5080], 2010.
  • Sinicrope F, Foster NR, Sargent DJ, Gallinger S, Benatti P, Marsoni S, Monges G, Labianca R, O'Connell MJ, Allegra CJ. DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials. J Clin Oncol 28[15s, abstr 3519], 2010.
  • Sinicrope F, Foster NR, Sargent DJ, Thibodeau SN, Gallinger S, Moore MJ, Tu D. Evaluation of recurrence rate, time-to-recurrence, and hepatic metastases in patients with colon cancers with defective DNA mismatch repair. ASCO Gastrointestinal Cancers Symposium, 2010.
  • Soulieres D, Fortin B, Winquist E, Charpentier D, Harnett E, Walsh W, Parulekar W. HN5: A phase I/II study of erlotinib as adjuvant therapy in patients treated by chemoradiation therapy (CRT) for locally advanced SCCHN. J Clin Oncol 28[15s, abstr 5562], 2010.
  • Stewart AK, Trudel S, Bahlis NJ, White DJ, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Sussman J, Meyer RM, Harnett EL, Oana D, Chapman JA, Shepherd L. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation in patients with multiple myeloma: the NCIC CTG MY.10 trial. Blood (ASH Annual Meeting Abstracts) 116[21, abstr 39], 2010.
  • Tonkin KS, Bramwell V, Vandenberg T, Pritchard KI, Shepherd L, Ghosh S. Tamoxifen in osteoporosis protection in the spine and femur for breast cancer patients rendered postmenopausal by adjuvant chemotherapy: 10-year results of NCICCTG MA12 study. ASCO Breast Cancer Symposium [abstr 220], 2010.
  • Trudeau ME, Clemons MJ, Dent RA, Kahn HJ, Parissenti AM, Chapman JW, O'Brien P, Jong RA, Pritchard KI, Shepherd LE. A phase I-II study of increasing doses of epirubicin and docetaxel plus pegfilgrastim for locally advanced or inflammatory breast cancer: NCIC CTG MA.22. J Clin Oncol 28[15s, abstr 629], 2010.
  • Tsao MS, Hainaut P, Bourredjem A, Janne PA, Pignon J-P, Douillard J-Y, Soria J-C, Seymour L, Shepherd FA. LACE-Bio pooled analysis of the prognostic and predictive value of KRAS mutation in completely resected non-small cell lung. Ann Oncol 21[Suppl 8, abstr 156], viii63, 2010.
  • Tsvetkova EV, Chapman JW, Baetz TD, Burnell MJ, Gelmon KA, Pu N, O'Brien P, Shepherd LE, Goodwin PJ. Characterization of 25-OH vitamin D and factors associated with obesity in patients with high-risk breast cancer: NCIC CTG MA.21. J Clin Oncol 28[15s, abstr 1578], 2010.
  • Twumasi-Ankrah P, Ding K, Seymour L, Shepherd FA, Tsao M-S. A sparse prognostic gene signature for stage IB and II patients with completely resected non-small cell lung cancer. Proc Am Assoc Cancer Res 51[abstr 1998], 485-6, 2010.
  • Vachon CM, Brandt KR, Suman VJ, Weinshilboum R, Kosel ML, Wu F, Serie DJ, Olson JE, Buzdar AU, Shepherd LE, Goss PE, Ingle JN. Mammographic density response to aromatase inhibitor therapy. Cancer Res 70[24 Suppl, abstr P2-09-03], 208s-209s, 2010.
  • Verleye L, Ottevanger PB, Amant F, Kristensen GB, van der Burg MEL, Verheijen R, Johnson N, Gaarenstroom KN, Read NS, Seoane JM, Mosgaard B, Ehlen T, van der Velden J, Lotocki R, Rustin G, Sandvei R, Eisenhauer E, Coens C, Vergote I, EORTC-GOG and NCIC-CTG. Quality of surgery in advanced ovarian cancer: Validation of the EORTC-GCG quality indicators. Int Gyn Cancer Soc [abstr 1369], 2010.
  • Vickers MM, Powell ED, Asmis TR, Jonker DJ, O'Callaghan CJ, Tu D, Parulekar W, Moore MJ. Comorbidity and overall survival in patients with advanced pancreatic cancer: Results from NCIC CTG PA.3-A phase III trial of erlotinib plus gemcitabine versus gemcitabine alone. J Clin Oncol 28[15s, abstr 4079], 2010.
  • Warde PR, Mason MD, Sydes MR, Gospodarowicz MK, Swanson GP, Kirkbride P, Kostashuk E, Hetherington J, Ding K, Parulekar W. Intergroup randomized phase III study of androgen deprivation therapy plus radiation therapy in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633). J Clin Oncol 28[18s, abstr CRA4504], 2010.
  • Weberpals JI, Tu D, Squire J, Islam S, Amin S, Pelletier L, O'Brien A, Hoskins P, Eisenhauer EA. Breast cancer protein expression as a prognostic marker in sporadic epithelial ovarian cancer: an NCIC CTG OV.16 correlative study. J Clin Oncol 28[15s, abstr 5018], 2010.
  • Ali SM, Chapman J-AW, Lipton A, Leitzel K, Pritchard KI, Pu X, Wilson C, Carney WP, Shepherd L, Pollak M. Examination of TIMP-1 levels and relapse-free survival for patients in NCIC CTG MA.14 who received adjuvant tamoxifen +/- octreotide LAR. Cancer Research 69[24 Suppl], 653s, 2009.
  • Ali SM, Chapman JW, Demers L, Shepherd L, Han L, Wilson C, Pritchard K, Leitzel K, Pollak M, Lipton A. Effect of adjuvant chemotherapy on bone resorption marker beta C-telopeptide in post-menopausal women. J Clin Oncol 27[15s], 2009.
  • Bradbury PA, Addison CL, Goss G, Shepherd FA, Seymour L, Le Maître A, Ding K. Baseline TGF- and amphiregulin levels in non small cell lung cancer patients treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 clinical trial. J Thoracic Oncol 4[9 suppl 1, abstr PD9.2.4], S537-S538. 2009.
  • Bradbury PA, Twumasi-Ankrah P, Ding K, Shepherd FA, Goss G, Leighl NB, Laurie S, Seymour L. Known Brain Metastases: A valid exclusion criterion in non-small cell lung cancer (NSCLC) clinical trials? An audit of the eligibility criteria in NSCLC trials, and an evaluation of treatment delivery, toxicity and survival experienced by patients with brain metastases in NCIC clinical trial group trials. J Thoracic Oncol 4[9 suppl 1, abstr A1.7], S288. 2009.
  • Bradbury PA, Twumasi-Ankrah P, Ding K, Leighl NB, Goss GD, Laurie S, Shepherd FA, Seymour L. The impact of brain metastases on overall survival in National Cancer Institute of Canada Clinical Trials Group clinical trials in advanced non-small cell lung cancer. J Clin Oncol 27[15s], 2009.
  • Buckstein R, Kuruvilla J, Chua N, Lee C, Macdonald DA, Al-Tourah AJ, Foo A, Walsh W, Ivy SP, Crump M, Eisenhauer E. Sunitinib in relapsed or refractory diffuse large B cell lymphoma: results of a phase II multi-center study of the NCIC Clinical Trials Group. Blood (ASH Annual Meeting Abstracts) 114[22, abstr 2729], 2009.
  • Cheang M, Chia SK, Tu D, Jiang S, Shepherd LE, Pritchard KI, Nielsen TO. Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 27[15s], 2009.
  • Chen B, Graubard,B, Flegal K, Gail M. Evaluating strategies to estimate the association of obesity with mortality via a Markov model. Statistical Society of Canada, 2009.
  • Chen J C-H, Chapman J-A, Rajput A, Mak H, Perry A, Feilotter H, SenGupta S, Elliott BE. Differential localization of ezrin expression in normal and neoplastic mammary tissues. United States and Canadian Academy of Pathology, 2009.
  • Chia SK, Ung K, Bramwell V, Tu D, Perou CM, Ellis MJ, Bernard PS, Vickery T, Mardis E, Cheang M, Pritchard K, Shepherd L, Nielsen TO. Prognostic and predictive impact of intrinsic biological classification by immunohistochemistry (IHC) and QPCR for adjuvant tamoxifen in pre-menopausal breast cancer: results from the NCIC CTG MA.12 trial. Cancer Research 69[24 Suppl], 725s, 2009.
  • Chi KN, Hotte SJ, Yu E, Tu D, Eigl B, Tannock I, Saad F, North S, Powers J, Eisenhauer E. Final results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer. Eur J Can Supplements 7[2], 406, 2009.
  • Chi KN, Hotte SJ, Yu E, Tu D, Eigl B, Tannock I, Saad F, North S, Powers J, Eisenhauer E. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 27[15s], 2009.
  • Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.
  • da Cunha Santos G, Ding K, Cutz J-C, Le Maître A, Squire JA, Shepherd FA, Tsao MS, Seymour L. A novel algorithm for the EGFR fluorescence in situ hybridization (FISH) assay in non-small cell lung cancer: an analysis of the NCIC Clinical Trials Group Study BR.21. J Thoracic Oncol 4[9 suppl 1, abstr P3.171], S924-S925. 2009.
  • Dancey JE. Testing for biomarker driven therapy (ERCC1 and EGFR). J Thoracic Oncol 4[9 suppl 1, abstr GR3.3], S172-S173. 2009.
  • Dhani NC, Tu D, Parulekar W, Seymour L, Moore MJ. A retrospective analysis of tumor size as a continuous rather than discrete variable in advanced pancreatic cancer. J Clin Oncol 27, 2009.
  • Ding K, Shepherd FA, Tsao MS, Le Maître A, Seymour L. P53 IHC protein expression and tumor size predict survival benefit from adjuvant chemotherapy in stage IB non small cell lung cancer patients. BIT's 2nd Annual World Cancer Congress, 2009.
  • Ding K, Nourijelyani K, Twumasi-Ankrah P. Prognostic and predictive biomarker model building for time to event outcomes. Statistical Society of Canada, 2009.
  • Eisenhauer EA, Verweij J. New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1. Eur J Can Supplements 7[2], 5, 2009.
  • Fleshner N, Kapusta L, Hersey K, Farley A, Lawrentschuk N, Donnelly B, Chin J, Gleave M, Klotz L, Trypkov C, Tu D, Parulekar W. Randomized trial of combination vitamin E, selenium and soy protein among men with high grade prostatic intraepithelial neoplasia. J Urol 181[4], 263, 2009.
  • Gelmon KA, Parulekar W, Rappold E, Voskoglou-Nomikos T, Guerrera S, Ledger D, Chapman JW, Shepherd L. COMPLETE: Phase III study of taxane-based chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu positive metastatic breast cancer (NCIC CTG MA.31/EGF108919). ASCO Breast Cancer Symposium, 2009.
  • Goodwin RA, Seymour L, Ding K, Gauthier I, Le Maître A, Frymire E, Arnold A, Shepherd FA, Goss GD, Laurie SA. Hypertension in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of carboplatin and paclitaxel with either daily oral cediranib, an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer. J Clin Oncol 27[15s], 2009.
  • Gore EM, Bae K, Wong S, Bonner J, Sun A, Schild S, Gaspar LE, Bogart J, Werner-Wasik M, Choy H. A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214. J Clin Oncol 27[15s Part 1; abstr 7506], 383s, 2009.
  • Goss PE, Mamounas EP, Jakesz R, Markopoulos C, Dowsett M, Peto R, Godwin J, Davies C. Aromatase inhibitors (AIs) versus not (placebo/observation) as late extended adjuvant therapy for postmenopausal women with early stage breast cancer: overviews of randomized trials of AIs after ~ 5years of tamoxifen. Cancer Research 69[24 Suppl], 733s, 2009.
  • Goss PE, Ingle JN, Martino S, Robert N, Muss H, Shepherd L, Pritchard KI, Livingston RB, Davidson N, Perez EA, Cameron D, Whelan T, Palmer M, Tu D. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. Cancer Research 69[24 Suppl], 487s, 2009.
  • Goss GD, Addison C, Shepherd F, Seymour L, Le Maître A, Ding K. TGF-alpha and amphiregulin levels in non-small cell lung cancer patients treated with erlotinib/placebo in the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21. J Clin Oncol 27[15s], 2009.
  • Heywood M, Fabbro M, Staehle A, Gebski V, Nordal R, Vasey P, Schauer C, Vergote I, Pignata S, Ferrero A. Carboplatin & pegylated liposomal doxorubicin vs carboplatin & paclitaxel in relapsed platinum-sensitive ovarian cancer: CALYPSO phase III study of GCIG. Eur Soc Gyn Oncol, 2009.
  • Ingle J, Schaid D, Goss P, Mushiroda T, Chapman J-A, Kubo M, Jenkins G, Batzler A, Liu M, Shepherd L, Ellis M, Flockhart D, Nakamura Y, Weinshilboum R. A genome-wide association study in patients experiencing musculoskeletal adverse events on aromatase inhibitors as adjuvant therapy in early breast cancer entered on NCIC CTG trial MA.27. A Pharmacogenetics Research Network-RIKEN Collaboration. Cancer Research 69[24 Suppl], 488s, 2009.
  • Isogai P, Cheung M, Lathia N, Leighl N, Mittmann N, Working Group on Economic Analysis. Validity of a model mapping quality of life scores to utility scores in lymphoma. Can J Clin Pharmacol 16: 210, 2009.
  • Jonker DJ, Karapetis C, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, Xu L, Moore MJ, Zalcberg JR, Khambata-Ford S. High epiregulin gene expression plus K-ras wild-type status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer: Results from NCIC CTG CO.17 - A phase III trial of cetuximab versus best supportive care. J Clin Oncol 27[15s], 2009.
  • Kouroukis CT, Hafid T, Wong J, Kovacs MJ, Barr R, Findlay B, Shepherd L, Djurfeldt M, Ding K, Zhu L, Shustik C, Meyer R. Comorbidity, age and performance status are important predictors of outcome in older multiple myeloma patients treated with melphalan and corticosteroids; subgroup analysis from the National Cancer Institute of Canada MY7 trial. International Society of Geriatric Oncology, 2009.
  • Laurie SA, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, Goss G, Ding K, Seymour L. Overall survival results of NCIC Clinical Trials Group BR.24: A randomized, double-blind trial of carboplatin + paclitaxel with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine ki. J Thoracic Oncol 4[9 suppl 1, abstr C1.1], S353. 2009.
  • Lee CW, Ding K, Laurie SA, Goss G, Ellis P, Arnold A, Frymire E, Le Maître A, Seymour L, Shepherd FA. Subject blinding in a placebo-controlled randomized trial and its relationship to overall survival and quality of life: results from NCIC CTG BR.24. International Society for Quality of Life Research, 2009.
  • Lee CW, Ding K, Le Maître A, Han L, Laurie SA, Goss G, Shepherd FA, Arnold A, Frymire E, Seymour L. Quality of life outcomes with cediranib/placebo in combination with carboplatin/paclitaxel in advanced non-small cell lung cancer: results from NCIC CTG BR.24. J Thoracic Oncol 4[9 suppl 1, abstr A1.6], S288. 2009.
  • Lerner SP, Stein JP, Stadler W, Groshen S, Tuazon E, Skinner DG, Raghavan D, Esrig D, Steinberg GD, Klotz LH, Hall C, Cote RJ. Variability in surgical quality in a randomized clinical trial of adjuvant chemotherapy following radical cystectomy and pelvic lymphadenectomy. J Urol 181[4 Suppl], 630-631, 2009.
  • Lipton A, Chapman JW, Demers L, Shepherd L, Han L, Wilson CF, Pritchard KI, Leitzel K, Ali SM, Pollak M. Elevated bone resorption predicts shorter recurrence-free survival for bone metastasis in breast cancer. Primary Therapy of Early Breast Cancer 11th International Conference 18[Suppl 1]: S35, 2009.
  • Mackay H, Gallinger S, Tsao M, McLachlin CM, Kieser K, Eisenhauer E, Tu D, Oza A. Microsatellite instability and loss of PTEN expression in early versus late-stage endometrial cancer: Results from studies of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 27[15s], 2009.
  • Mason WP, MacNeil M, Easaw J, McIntosh L, Lwin Z, Chen E, Eisenhauer E. A phase I study of temozolomide and RAD001 in patients with glioblastoma multiforme. J Clin Oncol 27[15s], 2009.
  • Mittmann N, Au H-J, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ, Working Group on Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group, Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial (ONLINE). J Natl Cancer Inst 2009.
  • Mittmann N, Evans WK, Rocchi A, Rocchi A, Longo CJ, Au HJ, Husereau D, Isogai PK, Krahn M, Coyle D. Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document. J Clin Oncol 27, 2009.
  • Ohorodnyk P, Eisenhauer EA, Booth CM. Clinical benefit in oncology trials: Is this a patient-centered or tumor-centered endpoint? J Clin Oncol 27[15s], 2009.
  • Oza AM, Kollmannsberger C, Hirte H, Welch S, Siu L, Mazurka J, Sederias J, Doyle LA, Eisenhauer E. Phase I study of temsirolimus (CCI-779), carboplatin and paclitaxel in patients with advanced solid tumours: NCIC CTG IND 179. J Clin Oncol 27[15s], 2009.
  • Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.
  • Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, Slovak ML, Tallman MS, Willman CL, Erba H, Appelbaum FR. Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 114[22, abstr 790], 2009.
  • Petrella T, Savage K, Tozer R, Belanger K, Tron V, Sederias J, Hunder N, Royer N, Eisenhauer E. Phase II study of Interleukin-21 in patients with metastatic or recurrent melanoma. ECCO 15 - ESMO 34 Multidisciplinary Congress, 2009.
  • Petrella T, Savage K, Tozer R, Belanger K, Tron V, Sederias J, Hunder N, Royer N, Eisenhauer E. Phase II study of Interleukin-21 in patients with metastatic or recurrent melanoma. World Conference on Melanoma, 2009.
  • Piura E, Chapman JW, Lipton A, Zhu L, Leitzel K, Wilson CF, Pritchard KI, Shepherd L, Pollak MN. Serum 1-OH vitamin D and prognosis of postmenopausal breast cancer patients: NCIC CTG MA14 trial. J Clin Oncol 27[15s], 2009.
  • Powell ED, Asmis T, Jonker D, Tu D, Karapetis C, Jeffery M, O'Callaghan C. Comorbidity and overall survival in cetuximab-treated patients with advanced colorectal cancer - Results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care. J Clin Oncol 27[15s], 2009.
  • Pujade-Lauraine E, Mahner S, Kaern J, Gebski V, Heywood M, Vasey P, Reinthaller A, Vergote I, Pignata S, Ferrero A. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer: CALYPSO study of the Gynecologic Cancer Intergroup. J Clin Oncol 27[18s], 2009.
  • Reiman T, Seve P, Veillard A-S, Soria J-C, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd F, Pignon J-P, Lai R. Validation of the prognostic and predictive value of class III beta tubulin for adjuvant chemotherapy in completely resected non-small cell lung cancer: results from four randomized trials. J Thoracic Oncol 4[9 suppl 1, abstr A4.2], S298, 2009.
  • Richardson F, Young D, Wolf J, Sennello G, Wacker B, Davies A. Comparison of E-cadherin IHC status with clinical outcomes from erlotinib in the non small cell lung cancer clinical trial NCIC CTG BR.21. J Thoracic Oncol 4[9 suppl 1, abstr PD7.2.5], S504-S505. 2009.
  • Sehn LH, Macdonald DA, Rubin SH, Cantin G, Rubinger M, Lemieux B, Basi S, Imrie KR, Gascoyne RD, Chen B, Djurfeldt M, Shepherd L, Couban S, Crump M. Bortezomib added to CVP-R is safe and effective for previously untreated advanced stage follicular lymphoma: a phase II study by the NCIC Clinical Trials Group. Blood (ASH Annual Meeting Abstracts) 114[22, abstr 407], 2009.
  • Shustik C, Harding S, Ding K, Zhu L, Rassenti LZ, Kipps TJ, Shepherd L, Robson M. Analysis of the serum free light chain ratio and its prognostic value in a cohort of patients with chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 114[22, abstr 2631], 2009.
  • Stadler WM, Lerner SP, Groshen S, Stein JP, Skinner DG, Raghavan D, Steinberg GD, Wood D, Klotz LH, Hall C, Cote R. Randomized trial of p53 targeted adjuvant therapy for patients with organ-confined node-negative urothelial bladder cancer. J Clin Oncol 27[15s], 2009.
  • Stearns V, Chapman J-A, Ma C, Ellis MJ, Ingle J, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maître A, Elliott C, Shepherd L, Goss P. Treatment-emergent symptoms and the risk of breast cancer recurrence in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. Cancer Research 69[24 Suppl], 488s, 2009.
  • Strevel EL, Ding K, Seymour L, Tsao MS, Le Maître A, Shepherd FA, Burkes RL. Pathologic determinants of survival for adjuvant treatment of stage IB non-small cell lung cancer: An analysis of the National Cancer Institute of Canada and Intergroup Study JBR.10. J Thoracic Oncol 4[9 suppl 1, abstr B4.6], S333-S334. 2009.
  • Tsao M-S, Sakurada A, Aviel-Ronen S, Ding K, Liu N, Gandara DR, Johnson DH, Rigas JR, Seymour L, Shepherd FA. Impact of EGFR tyrosine kinase domain mutations on adjuvant chemotherapy in early stage non-small cell lung cancer. J Thoracic Oncol 4[9 suppl 1, abstr B9.6], S351-S352. 2009.
  • Twumasi-Ankrah P, Ding K, Seymour L, Shepherd F. Identifying non-responders of vinorelbine plus cisplatin in adjuvant chemotherapy in completely resected non-small cell lung cancer. Clinical Trials 6, 546-7, 2009.
  • Twumasi-Ankrah P, Ding K, Seymour L, Shepherd F. Identifying non-responders of vinorelbine plus cisplatin in adjuvant chemotherapy in completely resected non-small cell lung cancer. Soc Clin Trials, 2009.
  • Vincent MD, Butts C, Seymour L, Ding K, Graham B, Twumasi-Ankrah P, Gandara D, Schiller J, Green M, Shepherd F. Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer. J Clin Oncol 27[15s], 2009.
  • Avall-Lundqvist E, Wimberger P, Gladieff L, Gebski V, Huober J, Floquet A, Fitzharris B, Zeimet A, Heywood M, Schmalfeldt B. Pegylated liposomal doxorubicin-carboplatin vs paclitaxel-carboplatin in relapsing sensitive ovarian cancer: a 500-patient interim safety analysis of the CALYPSO GCIG intergroup phase III study. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 308s, 2008.
  • Bacon M. The evolving role of the nurse in clinical trials: Impact and opportunities. Clinical Trials Seminar for Nurses (Tokyo), 2008.
  • Bacon M, Gotlieb W, May N, Tinker L, Manojlovich M. Clinical trials: X marks the spot. Ovarian Cancer Canada, Voices of Hope Symposium, 2008.
  • Bartlett JMS, Desmedt C, Munro A, O'Malley FP, Larsimont D, di Leo A, Cameron DA, Isola J, Shepherd L, Twelves CJ, Pritchard KI. Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines? Cancer Research 69[Suppl 2], 375s, 2008.
  • Biagi JJ, Oza AM, Grimshaw R, Ellard SL, Lee U, Sederias J, Ivy P, Eisenhauer EA. A phase II study of sunitinib (SU11248) in patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND.185. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 298s, 2008.
  • Booth CM, Le Maître A, Ding K, Farn K, Fralick M, Phillips C, Cescon DW, Meyer RM. Presentation of non-final results of randomized controlled trials at major oncology meetings. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 349s, 2008.
  • Bradbury PA, Tu D, Seymour L, Ng R, Zhu L, Isogai PK, Mittmann N, Evans WK, Shepherd FA, Leighl NB, on behalf of the NCIC CTG Working Group on Economic Analysis. Impact of clinical and molecular predictors of benefit from erlotinib in advanced non-small cell lung cancer on cost-effectiveness. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 344s, 2008.
  • Burnell MJ, O'Connor EM, Chapman JW, Levine MN, Pritchard KI, O'Brien PS, Howarth KJ, Ding Z, Whelan TJ, Shepherd LE. Triple-negative receptor status and prognosis in the NCIC CTG MA.21 adjuvant breast cancer trial. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 18s, 2008.
  • Chapman JW, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer: NCIC CTG MA.17. EHRLICH II - 2nd World Conference on Magic Bullets, A-53, 2008.
  • Chapman J-A, Qu C, Ding Z, Shepherd L, O'Brien P, Burnell M, Levine M, Pritchard K, Matthews D. Estimating efficacy in clinical trials: Case study of NCIC CTG MA.21 adjuvant breast cancer trial. Statistical Society of Canada, 2008.
  • Duran I, Siu LL, Jimeno A, Panisko D, Seymour L. Development of core competencies in drug development in medical oncology: an unexplored field. Association of Medical Education of Europe, 160, 2008.
  • Duran I, Siu LL, Jimeno A, Panisko DM, Seymour L. Development of core competencies in drug development in medical oncology: An unexplored field. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 622s, 2008.
  • Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubenstein L, Shankar L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1. Eur J Can Supplements 6[12], 13, 2008.
  • Hoskins PJ, Vergote I, Stuart G, Cervantes A, Tu D, Carey M, Provencher D, Katsaros D, Ghatage P, Eisenhauer E. A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG and GEICO. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 294s, 2008.
  • Jang RW, Le Maître A, Ding K, Winton TL, Bezjak A, Seymour L, Shepherd FA, Leighl NB. A Q-TWiST analysis of adjuvant chemotherapy in non-small cell lung cancer in the NCIC CTG JBR.10 trial. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 345s, 2008.
  • Jiang S, Wu Y, Tu D. Bandwidth selection for nonparametric confidence intervals of a probability density function. Statistical Society of Canada, 2008.
  • Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Langer C, Moore MJ, Zalcberg JR. KRAS mutation status is a predictive biomarker for cetuximab benefit in the treatment of advanced colorectal cancer - results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care. World Congress on Gastrointestinal Cancer, 2008.
  • Laurie SA, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, Goss G, Ding K, Seymour L. Randomized double-blind phase II trial of carboplatin + paclitaxel with either daily oral cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced non-small cell lung cancer: A study of the NCIC Clinical Trials Group. Annals of Oncology 19[Suppl 8], viii90-viii91, 2008.
  • Le Maître A, Ding K, Shepherd FA, Leighl NB, Arnold A, Seymour L. Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 440s, 2008.
  • Lerner SP, Stein JP, Stadler WM, Groshen S, Tuazon E, Skinner DG, Raghavan D, Esrig D, Steinberg G, Hall C, Cote R. Results of the p53 targeted therapy trial for patients with organ confined node negative bladder cancer treated with radical cystectomy. Society of Urologic Oncology, 2008.
  • Lipton A, Chapman JW, Demers L, Shepherd LE, Han L, Wilson CF, Pritchard KI, Leitzel K, Ali SM, Pollak MN. Use of elevated bone turnover to predicts bone metastasis. Proc.Am.Soc.Clin.Oncol. 26[15S Part 1], 28s, 2008.
  • Lukka H, Whelan T, Blake P, Swart AM, Orton J, Branson A, Parmar M, Murphy C, Qian W, On behalf of investigators of ASTEC EN5 study. Adjuvant external beam radiotherapy in the treatment of endometrial cancer: results of the randomised MRC ASTEC and NCIC CTG EN.5 trials, a systematic review and meta-analysis. International Journal of Radiation Oncology, Biology, Physics 72[1 Suppl 1], S353-S354, 2008.
  • Lukka H, Whelan T, Blake P, Swart AM, Orton J, Branson A, Kitchener H, Eisenhauer E, Parmar M, Murphy C, Amos C, Bacon M, Tu D, Qian W. Adjuvant external beam radiotherapy in the treatment of endometrial cancer: results of the randomised MRC ASTEC and NCIC CTG EN.5 trials, a systematic review and meta-analysis. Canadian Association of Radiation Oncology 2008.
  • Mackay H, Tinker A, Winquist E, Thomas G, Sederias J, Ivy P, Eisenhauer EA. A phase II study of sunitinib, an oral multi-targeted tyrosine kinase inhibitor, in patients with unresectable, locally advanced or metastatic cervical carcinoma: IND184. Eur J Can Supplements 6[12], 66, 2008.
  • Messerschmidt T, Koski B, Johnson D. Critical components of preparing for a compliance assessment by an industry partner. Clinical Trials 5[4], 419, 2008.
  • Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Karapetis CS, Moore MJ, Zalcberg J, Simes J, Evans WK, Jonker DJ. A prospective economic analysis of cost-effectiveness of cetuximab for metastatic colorectal cancer patients from the NCIC CTG and AGITG CO.17 trial. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 344s, 2008.
  • Moy B, Tu D, Shepherd LE, Palmer MJ, Ingle JN, Goss PE. NCIC CTG MA.17: hormone receptor expression of in-breast recurrences and contralateral primary breast cancers arising on aromatase inhibitors. Cancer Research 69[Suppl 2], 145s, 2008.
  • O'Callaghan CJ, Tu D, Karapetis CS, Au HJ, Moore MJ, Zalcberg JR, Trudeau M, Yip D, Vachan B, Jonker DJ. The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 210s, 2008.
  • Osborne R, Filiaci V, Schink J, Mannel R, Lage J, Alvarez-Secord A, Kelly J, Provencher D, Schilder J, Miller D. A randomized phase III trial comparing weekly parenteral methotrexate and "pulsed" dactinomycin as primary management for low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Society Gynecologic Oncologists, 2008.
  • Oza AM, Elit L, Provencher D, Biagi JJ, Panasci L, Sederias J, Dancey JE, Tsao MS, Eisenhauer EA. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 296s, 2008.
  • Parissenti AM, Chapman J-AW, Kahn HJ, Guo B, Han L, O'Brien P, Clemons MP, Jong R, Dent R, Fitzgerald B, Pritchard KI, Shepherd LE, Trudeau ME. Reductions in tumor RNA integrity associated with clinical response to epirubicin/docetaxel chemotherapy in breast cancer patients. Cancer Research 69[Suppl 2], 378s, 2008.
  • Pollak MN, Chapman JW, Pritchard KI, Krook JE, Dhaliwal HS, Vandenberg TA, Norris BD, Whelan TJ, Wilson CF, Shepherd LE. NCIC-CTG MA14 trial: Tamoxifen (tam) vs. tam + octreotide (oct)for adjuvant treatment of stage I or II postmenopausal breast cancer. Proc.Am.Soc.Clin.Oncol. 26[15S Part 1], 14s, 2008.
  • Reiman T, Seve P, Vataire A, Dunant A, Rosell R, Graziano S, Seymour L, Pirker R, Lai R. Prognostic value of class III b-tubulin in operable non-small cell lung cancer and predictive value for adjuvant cisplatin-based chemotherapy: A validation study on three randomized trials. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 398s, 2008.
  • Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.
  • Sebag-Montefiore D, Quirke P, Steele R, Couture J, Thompson L, Stephens R. The impact of short course pre-operative radiotherapy on patients' quality of life: data from the MRC CR07/NCIC CO16 randomised clinical trial in patients with rectal cancer. Int J Rad Oncol Biol Phys 72[Suppl 1], S28, 2008.
  • Sehn LH, Macdonald DA, Rubin SH, Rubinger M, Imrie KR, Chapman J-AW, Djurfeldt M, Shepherd L, Couban S, Crump M. Tolerability and efficacy of bortezomib added to CVP-R for previously untreated advanced stage follicular lymphoma: Interim analysis of a phase II study by the NCIC Clinical Trials Group. Blood (ASH Annual Meeting Abstracts) 112[11, abstr 1576], 2008.
  • Song H, Peng Y, Tu D, Niu Y. Testing the homogeneity in two-sample censored mixture model when cure proportion may exist in one group. Statistical Society of Canada, 2008.
  • Tan X, Takahara G, Tu D. Two-stage design for phase II cancer clinical trials with responses and early progression as coprimary endpoints. Statistical Society of Canada, 2008.
  • Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, Stupp R, Mirimanoff R, van den Bent MJ, Bottomley A. The EORTC QLQ-BN20 questionnaire for assessing the health-related quality of life in brain cancer patients: A phase IV validation study on behalf of the EORTC QLG, BCG, ROG, NCIC-CTG. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 99s, 2008.
  • Taylor SK, Ding K, Ernst DS, Elliott C, Parulekar WR. Palliative response measurement in a phase III study of patients with prostate cancer and painful bone metastases: Secondary analysis of NCIC-CTG PR6. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 535s, 2008.
  • Trneny M, Rieger M, Osterborg A, Pettengell R, White DJ, Gill D, Walewski J, Kuhnt E, Loeffler M, Pfreundschuh M, Ho AD. The addition of rituximab eliminates the negative prognostic impact of PMBCL compared to DLBCL in young patients with CD20-positive aggressive lymphomas receiving a CHOP-like chemotherapy: Results of a subgroup analysis of the Mabthera International Trial Group (MInT) study. Blood (ASH Annual Meeting Abstracts) 112[11, abstr 839], 2008.
  • Tsao MS, Zhu C, Ding K, Strumpf D, Pintilie M, Meyerson M, Seymour L, Jurisica I, Shepherd FA. A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 399s, 2008.
  • Tu D. Statistical designs for phase II trials of targeted anticancer agents. International Symposium on Biopharmaceutical Statistics, 2008.
  • van Oers MHJ, van Glabbeke M, Baila L, Giurgia L, Klasa R, Marcus RE, Wolf M, Kimby E, Hagenbeek A. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study. Blood (ASH Annual Meeting Abstracts) 112[11 abstr 836], 2008.
  • Vergote I, Tropé CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Benedetti Panici P, Kenter GG, Casado A, Mendiola C, Coens C, Stuart G, Pecorelli S, Reed NS. EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA). Int Gyn Cancer Soc, 2008.
  • Verleye L, Coens C, Amant F, van der Burg MEL, Johnson N, Verheijen R, Coronado P, Reed NS, Parker RJ, Vergote I. Predictive value of C-ERB2 for response to first-line chemotherapy in 206 advanced-stage ovarian cancer patients: An EORTC-GCG/NCIC-CTG study. Int Gyn Cancer Soc, 2008.
  • Verleye L, Ottevanger PB, Coens C, Amant F, Kristensen G, Tropé C, Johnson N, van der Burg MEL, Reed NS, Verheijen R, Hoskins P, Trimbos B, Mosgaard B, Mendiola C, van der Velden J, Stuart G, Vergote I. Quality of histopathology in advanced ovarian cancer: Audit of original pathology reports of 466 patients from the EORTC-GCG/NCIC-CTG neoadjuvant trial. Int Gyn Cancer Soc, 2008.
  • Verleye L, Ottevanger PB, Coens C, Amant F, Kristensen G, Tropé C, Johnson N, van Doorn HC, Reed NS, Verheijen R, Hoskins P, Trimbos B, Mosgaard B, Mendiola C, van der Velden J, Eisenhauer E, Vergote I. Quality of surgery in advanced ovarian cancer: Audit of original surgery reports of 442 patients from the EORTC-GCG/NCIC-CTG neoadjuvant trial. Int Gyn Cancer Soc, 2008.
  • Wheatley-Price P, Le Maître A, Ding K, Leighl N, Hirsh V, Seymour L, Shepherd FA. The influence of sex on efficacy, toxicity and delivery of treatment in NCIC Clinical Trials Group non-small cell lung cancer chemotherapy trials. Proc.Am.Soc.Clin.Oncol. 26[15S Part I], 437s, 2008.
  • Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small cell lung cancer in the elderly. Canadian Association of Medical Oncologists, 2008.
  • White DJ, Bahlis NJ, Marcellus D, Belch A, Stewart AK, Chen C, Kovacs MJ, Macdonald DA, Reece DE, Harnett E, Chapman J-AW, Meyer RM. Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: The NCIC CTG MY.11 trial. Blood (ASH Annual Meeting Abstracts) 112[11, abstr 2767], 2008.
  • Zhu L, Tan X, Tu D. Testing the homogeneity of two survival functions against a mixture alternative based on censored data. Statistical Society of Canada, 2008.
  • Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I, Ravdin P, Yoshizawa C, Baehner F, Davidson N, Sledge G, Winer E, Hudis C, Ingle J, Perez E, Pritchard K, Shepherd L, Allred C, Osborne K, Hayes D. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). Breast Cancer Research and Treatment 106[Suppl 1], 2007.
  • Arnold AM, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Seymour L, Langmuir P, Shepherd F. Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer patients who have a complete or partial response to induction therapy: NCIC CTG BR.20. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Au H-J, Brundage M, Ringash J, Bezjak A, Palmer M, Richardson H, Lee CW, Maunsell E, Brotto L, Sussman J, Davis A, Osoba D. Added value of health-related quality of life outcomes in NCIC CTG clinical trials: results from QOL committee workshop. Quality of Life Research Suppl, A-71, 2007.
  • Au H, Karapetis C, Jonker D, O'Callaghan C, Kennecke H, Shapiro J, Tu D, Wierzbicki R, Zalcberg J, Moore M. Quality of life in patients with advanced colorectal cancer treated with cetuximab: results of the NCIC CTG and AGITG CO.17 trial. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Bezjak A, Ung Y, Seymour L, Pater JL, Ding K, Whitehead M, Magoski N, Shepherd FA. Progress in lung cancer radiotherapy - the impact of NCIC CTG clinical trials. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC's 60th Anniversary, 140, 5007.
  • Bezjak A, Lee C, Ding K, Winton T, Brundage M, Graham B, Whitehead M, Seymour L, Shepherd FA. Quality of life impact of adjuvant chemotherapy for early stage non-small cell lung cancer: final analysis of JBR.10 randomized trial. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Bradbury PA, Seymour L, Ng R, Mittmann N, Cote I, Shepherd FA, Leighl NB, Canadian BR.21 Investigators. An economic analysis of the NCIC Clinical Trials Group BR.21, a randomized trial of erlotinib versus best supportive care after cisplatin based chemotherapy in advanced non-small-cell lung cancer. J Thoracic Oncol 2[8 Suppl 4], S707. 2007.
  • Bramwell VHC, Pritchard KI, Tu D, Tonkin K, Vachhrajani H, Robert J, Arnold A, Vandenberg TA, O'Reilly SE, Graham B, Shepherd LE. How compliant are patients with oral hormonal therapies? Data from a randomized, placebo controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (NCIC CTG MA.12). Breast Cancer Research and Treatment 106[Suppl 1], 2007.
  • Bramwell VH, Pritchard KI, Tu D, Tonkin K, Vachhrajani H, Robert J, Arnold A, Vandenberg T, Graham B, Shepherd L. Tamoxifen compared to placebo, after adjuvant chemotherapy, in premenopausal women with early breast cancer: interim results of NCIC-CTG MA.12. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Burnell M, Levine M, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal HI, Albain K, Perez E, Rugo H, Pritchard KI, Ding Z, O'Brien P, Shepherd L. A phase III adjuvant trial of sequenced EC + filgrastim + epoetin alfa followed by paclitaxel versus sequenced AC followed by paclitaxel versus CEF in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC's 60th Anniversary, 197-198, 2007.
  • Burnell MJ, Levine MN, Chapman JA, Bramwell V, Vandenberg T, Chalchal HI, Albain K, Perez E, Rugo H, Pritchard K. A phase III adjuvant trial of sequenced EC + filgrastim + epoetin alfa followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node positive or high-risk node-negative breast cancer (NCIC CTG MA.21). Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 15s, 2007.
  • Catton C, Saad F, Sydes M, Parulekar W, Savage C, Kynaston H, Logue J, Murphy C, Payne H, Clarke N, Parker C. NCIC PR.13 (RADICALS) - An Intergroup randomized controlled trial in prostate cancer of optimal timing of radiotherapy and duration of hormone therapy after radical prostatectomy (MRC PR10, ISRCTN40814031). Canadian Association of Radiation Oncology, 2007.
  • Chapman J-A, Meng D, Shepherd L, Parulekar W, Ingle J, Muss H, Palmer M, Yu C, Goss P. Competing causes of death in breast cancer extended adjuvant endocrine therapy: NCIC CTG MA.17. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC's 60th Anniversary, 46-47, 2007.
  • Chapman JW, Meng D, Shepherd L, Parulekar W, Ingle J, Muss H, Palmer M, Yu C, Goss P. Competing causes of death in breast cancer extended adjuvant endocrine therapy: NCIC CTG MA.17. ASCO Breast Cancer Symposium, 2007.
  • Chapman J, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE. Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 12s, 2007.
  • Chapman J-AW. SSC accreditation - the Canadian model. Joint Statistical Meetings, 2007.
  • Chen E, Jonker D, Gauthier I, MacLean M, Wells J, Powers J, Robertson J, Seymour L. Phase I study of AZD2171 in combination with oxaliplatin and infusional 5-FU (mFOLFOX6) in patients with advanced colorectal cancer. Eur J Can Supplements 5[4], 113, 2007.
  • Chi KN, Hotte SJ, Yu E, Eigl B, Tannock I, Saad F, North S, Powers J, Eisenhauer EA. A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer: NCIC CTG IND.165. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC's 60th Anniversary, 52, 2007.
  • Chi KN, Hotte SJ, Yu E, Eigl BJ, Tannock I, Saad F, North S, Powers J, Eisenhauer E. A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Chia S, Dent S, Ellard SL, Ellis P, Vandenberg T, Gelmon K, Powers J, Seymour L, Eisenhauer EA. A phase II trial of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel in metastatic breast cancer: NCIC CTG IND 164 trial. Proc Am Assoc Cancer Res 48, 836, 2007.
  • Cigler T, Fabian CF, Yaffe MJ, Johnston D, Ingle JN, Nassif E, Brunner R, Wadden N, Pater JL, Richardson H, Tu D, Shangle Q, Goss PE. Effects of the steroidal aromatase inhibitor exemestane on mammographic breast density and other end-organ functions. Breast Cancer Research and Treatment 106[Suppl 1], 2007.
  • Cigler T, Yaffe MJ, Johnston D, Verma S, Findlay B, Wadden N, Pater JL, Richardson H, Tu D, Shangle Q, Goss PE. A placebo-controlled trial examining the effects of letrozole on mammographic breast density and bone and lipid metabolism. Breast Cancer Research and Treatment 106[Suppl 1], 2007.
  • DeAngelo DJ, Dahlberg S, Silverman LB, Couban S, Amrein PC, Seftel MD, Turner AR, Leber B, Howson-Jan K, Wadleigh M, Sirulnik LA, Supko J, Galinsky I, Sallan SE, Stone RM. A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) 110[11, abstr 587], 181a, 2007.
  • Ding K. Determining the cutoff points for a predictive continuous biomarker with time to event outcome. Proc Joint Statistical Meetings, 2007.
  • Ellard S, Gelmon KA, Chia S, Clemons M, Kennecke H, Norris B, McIntosh L, Seymour L. A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Fruh M, Tribodet H, Pignon J, Winton T, LeChevalier T, Scagliotti GV, Douillard JY, Seymour L, Spiro S, Shepherd FA. A pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Goffin J, Tu D. Phase II stopping rules employing response rates and early progression. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Goss GD, Laurie S, Shepherd F, Leighl N, Chen E, Gauthier I, Reaume N, Feld R, Powers J, Seymour L. IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor, in combination with gemcitabine and cisplatin in patients with advanced non-small cell lung cancer: a study of the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Graham B, Tu D, Whitehead M, Voskoglou-Nomikos D, Parulekar W, Pater J. Assessing the reliability of reporting adverse event attribution: a NCIC Clinical Trials Group evaluation of a phase I/III placebo controlled trial (NCIC CTG PA.3). Clinical Trials 4, 2007.
  • Hicks L, Cheung M, Hasan B, Ding K, Seymour L, Leighl NB, Winton TL, Shepherd FA. Venous thromboembolism and non-small cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group. Blood (ASH Annual Meeting Abstracts) 110[11, abstr 3995], 2007.
  • Johnston D, Richardson H, Moase S. Recruitment strategies for a large international breast cancer prevention trial. Clinical Trials 4, 2007.
  • Jonker DJ, Karapetis CS, Moore M, Zalcberg JR, Tu D, Berry S, Koski S, Krahn M, Simes J, Tebbutt N, Van Hazel G, O'Callaghan CJ. Randomized phase III trial of cetuximab monotherapy plus best supportive care [BSC] versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor-positive colorectal carcinoma. A trial of the NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group. Proc Am Assoc Cancer Res 48, 2007.
  • Koski B, Messerschmidt T, Pho L, Sadura A, Voskoglou-Nomikos D, Powers J, Vandersluis B. Impact of changing from paper based data collection to electronic data capture on the activities of the coordinating centre of the NCIC CTG. Clinical Trials 4, 2007.
  • Koski B, Wu Q, Pho L, Sadura A, Voskoglou-Nomikos D, Powers J. Planning the change from paper based to electronic data capture. Clinical Trials 4, 2007.
  • Kristensen GB, Vergote I, Stuart G, del Campo JM, Kaern J, Baekelandt M, Lopez AB, Hirte H, Aavall-Lundquist E, Lorenz E, Cerar O. First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on overall survival. Eur Soc Gyn Oncol, 2007.
  • Laurie SA, Crabb S, Arnold A, Goss G, Shepherd FA, Seymour L. Implications of tumour cavitation on response assessment in trials of vascular endothelial growth factor receptor inhibitors in combination with platinum-based chemotherapy for advanced non-small cell lung cancer: an analysis of trials conducted by the NCIC Clinical Trials Group. J Thoracic Oncol 2[8 Suppl 4], S465. 2007.
  • Lee CW, Pater J, Martin J, MacRae R, Laurie SA, Ung Y, Willman C, Soroka D, Shepherd FA. A survey of Canadian practice in management of malignant pleural mesothelioma. J Thoracic Oncol 2[8 Suppl 4], S606, 2007.
  • Li X, Wu Y, Tu D. Correction for Wald test in Cox regression model. Interdisciplinary Mathematical & Statistical Techniques, 2007.
  • Markovich Y, Virk S, Tsao M, Shepherd L. The NCIC CTG tumour/tissue/data repository, a Canadian resource: How have we been doing? Making Connections: A Canadian Cancer Research Conference Celebrating NCIC's 60th Anniversary, 84, 2007.
  • McGill SR, Koski B, Whelan T, Parulekar WR. Participation of subjects on multiple clinical trials: the NCIC Clinical Trials Group MA.20 experience. Clinical Trials 4, 2007.
  • Mirimanoff R, Mason W, van den Bent M, Kortmann R, Taphoorn M, Brandes AA, Villa S, Cairncross G, Gorlia T, Stupp R. Is long-term survival in glioblastoma possible? Updated results of the EORTC/NCIC Phase III randomized trial on radiotherapy (RT) and concomitant and adjuvant temozolomide versus RT alone. Int.J.Rad.Oncol.Biol.Phys. 69[3 Suppl 1], S2, 2007.
  • Moase S, Johnston D, Richardson H. Efforts don't end with recruitment: retention strategies for a large international breast cancer prevention trial. Clinical Trials 4, 2007.
  • Moore MJ, Ding K, Parulekar W, Kotecha J, Whitehead M, Goldstein D, Hamm J, Das-Gupta A. Erlotinib improves clinical outcomes when added to gemcitabine in pancreatic cancer; prolonged survival among patients with metastatic disease. An exploratory sub-analysis of the NCIC CTG study PA.3. Annals of Oncology 18[Suppl 7], vii14, 2007.
  • Moore MJ, da Cunha Santos G, Kamel-Reid S, Chin K, Tu D, Parulekar W, Ludkovski O, Squire J, Richardson F, Tsao M. The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with erlotinib on NCIC Clinical Trials Group trial study PA.3. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Moy B, Richardson H, Johnston D, Pater JL, Chlebowski R, Alès-Martinez JE, Ingle J, Goss PE. NCIC CTG MAP.3: enrollment and study drug adherence of ethnic minority women in a breast cancer prevention trial. Breast Cancer Research and Treatment 106[Suppl 1], 2007.
  • Moy B, Elliott CR, Chapman JW, Pater JL, Ding Z, Goss PE. NCIC CTG MA.27: Menopausal symptoms of ethnic minority women. ASCO Breast Cancer Symposium, 2007.
  • Niazi MT, Cakir B, Brundage M, Parulekar W, Parliament M. A review of quality assurance including real time review in trials involving radiotherapy. Clinical Trials 4, 2007.
  • O'Brien P, Willman C, Hiltz A, Pater J. Variations in activation times over time and according to trial type: the NCIC Clinical Trials Group experience. Clinical Trials 4, 2007.
  • Orton J, Blake P, on behalf of ASTEC/EN.5 collaborators. . Adjuvant external beam radiotherapy in the treatment of endometrial cancer: results of the randomised MRC ASTEC and NCIC CTG EN.5 trial. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 275s, 2007.
  • Palmer MJ, Lee CW, Miller E, Richardson H, Bezjak A, Ringash J, Brundage M. NCIC CTG experience in collecting quality of life data in phase I and phase II clinical trials. Quality of Life Research Suppl, A-101, 2007.
  • Palmer M, Paramore J, Broxterman J, Goss P, Parulekar W. Efforts to increase activation of sites in a clinical trial involving re-randomization. Clinical Trials 4: 407-8, 2007.
  • Palmer M, Parulekar W, Broxterman J, Goss P, Pater J. Reasons for non-participation in a clinical trial involving re-randomization. Clinical Trials 4, 2007.
  • Parissenti AM, Chapman JW, Kahn HJ, Guo B, O'Brien P, Han L, Clemons M, Jong R, Pritchard KI, Shepherd L, Trudeau ME. Relationship of tumour RNA integrity to clinicopathologic parameters associated with epirubicin/docetaxel chemotherapy. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC's 60th Anniversary, 203-204, 2007.
  • Parissenti AM, Chapman JW, Kahn H, Guo B, Han L, Clemons M, Jong RA, Pritchard KI, Shepherd LE, Trudeau ME. Relationship of tumor RNA integrity to clinicopathologic parameters associated with epirubicin/docetaxel chemotherapy. ASCO Breast Cancer Symposium, 2007.
  • Parker C, Sydes MR, Catton C, Kynaston H, Logue J, Morash C, Payne H, Murphy C, Parulekar W, Savage C, Clarke NW. RADICALS - an Intergroup randomised controlled trial in prostate cancer of radiotherapy timing and hormone therapy duration after radical prostatectomy (MRC PR10, NCIC PR13, ISRCTN40814031). NCRI United Kingdom, 2007.
  • Philip PA, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz H, O'Reilly E, Wong R, Atkins J, Abruzzese J, Blanke C. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Powell BL, Moser B, Stock W, Gallagher RE, Willman C, Coutre S, Feusner JH, Appelbaum FR, Tallman MS, Larson RA. Effect of consolidation with arsenic trioxide (As2O3 ) on event-free survival and overall survival among patients with newly diagnosed acute promyelocytic leukemia: North American Intergroup Protocol C9710. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Richardson H, Johnston D, Goss PE. Participant characteristics on an international NCIC CTG breast cancer prevention trial. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Richardson H, Johnston D, Pater J. Challenges of conducting cancer prevention trials. Clinical Trials 4, 2007.
  • Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. N9741: Survival update and prognostic factor analysis of oxaliplatin(Ox) and irinotecan (Iri) combinations for metastatic colorectalcancer (MCRC). J Clin Oncol 25[18s Part 1, abstr 4067], 2007.
  • Schacter B, Geary P, Ling V, Mes-Masson A-M, Sawyer M, Shepherd L, Watson P, Zanke B. Canadian tumour repository network facilitating translational cancer research through a national tumour bank network. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC's 60th Anniversary, 79-80, 2007.
  • Shepherd FA, Seymour L, Tsao MS, Ding K, Magoski N, Eisenhauer E, Pater J. From Nihilism To Hope - The impact of NCIC Clinical Trials Group trials of systemic therapy for lung cancer. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC's 60th Anniversary, 54, 2007.
  • Shepherd FA, Ding K, Sakurada A, da Cunha Santos G, Zhu C, Seymour L, Whitehead M, Kamel-Reid S, Squire J, Tsao MS. Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor gene and codons 12 and 13 of the KRAS gene in non-small cell lung cancer patients treated with erlotinib in NCIC Clinical Trials Group BR.21. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Shepherd F, Hasan B, Hicks L, Cheung M, Ding K, Leighl N, Winton T, Seymour L. Venous thromboembolism and non-small cell lung cancer: a pooled analysis of NCIC Clinical Trials Group trials. Eur J Can Supplements 5[4], 361, 2007.
  • Stock W, Moser B, Powell BL, Appelbaum FR, Tallman MS, Larson RA, Feusner JH, Bloomfield CD, Willman C, Gallagher RE. Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia: results from the North American Intergroup trial, C9710. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P, McIntosh L, Eisenhauer E. NCIC CTG phase I/II trial of GW572016 (Lapatinib) in patients with recurrent glioblastoma multiforme: Clinical outcome, pharmacokinetic studies and molecular correlation. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC's 60th Anniversary, 205, 2007.
  • Tsao M. Predictors of benefit from targeted therapy: lessons learned from the EGFR inhibitor story. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC's 60th Anniversary, 17, 2007.
  • Tsao MS, Lau S, Boutros P, Pintilie M, Zhu C-Q, Strumpf D, Penn L, Jurisica I, Shepherd FA. Gene expression prognostic classifiers for early stage non-small cell lung cancer. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC's 60th Anniversary , 98, 2007.
  • Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Whitehead M, Seymour L, Winton T, Shepherd FA. P53 protein over-expression but not p53 gene mutation is a poor prognostic marker and a predictive marker for survival benefit from adjuvant chemotherapy in non-small cell lung cancer in the JBR.10 trial. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.
  • Tu D, Cheng M-Y, Qiu P, Tan X. Nonparametric confidence interval for the cross point of two hazard functions. Interdisciplinary Mathematical & Statistical Techniques, 2007.
  • Tuazon ED, Groshen SG, Lerner SP, Stadler W, Stein JP, Cote RJ. Patient randomization factors in the P53 targeted therapy trial in bladder cancer (SWOG 4B951). American Urological Association, 2007.
  • van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley J. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients. Proc.Am.Soc.Clin.Oncol. 25[18s Part 1], 2007.
  • White D, Kovacs M, Belch A, Stewart K, Chen C, Rubin S, Macdonald D, Harnett E, Chapman J, Shepherd L, Meyer R. Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: Toxicity data from the NCIC CTG MY.11 trial. Blood (ASH Annual Meeting Abstracts) 110[11, abstr 189], 2007.
  • Asmis TR, Ding K, Whitehead M, Seymour L, Shepherd FA, Winton T, Leighl N, Goss G. Are age and comorbidity independent prognostic factors in the treatment of metastatic NSCLC? A review of prospectively randomized NCIC Clinical Trials Group trials. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 393, 2006.
  • Burnell M, Levine M, Chapman J-A, Bramwell V, Gelmon K, Walley B, Whelan T, Albain K, Perez E, Rugo H, Ding K, O'Brien P, Shepherd L, Pritchard K. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of an interim analysis. Breast Cancer Research and Treatment 100[Suppl 1], 2006.
  • Carey MS, Bacon M, Tu D, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 272, 2006.
  • Chapman JW. Clinical implications of tumour heterogeneity demonstrated pathologically and with image analysis. Statistical Society of Canada, 2006.
  • Chen CI, Kouroukis T, White D, Voralia M, Stadtmauer E, Wright J, Powers J, Eisenhauer E. Bortezomib is active in Waldenström's Macroglobulinemia (WM) - Results of a NCIC Clinical Trials Group phase II study in previously untreated or treated WM. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 432, 2006.
  • Chen E, Zhang W, Laurie S, Arnold A, Gauthier I, Goss G, Ellis P, Shepherd F, Matthews S, Seymour L. Effects of AZD2171 on pharmacokinetics of carboplatin and paclitaxel in patients with advanced non-small cell lung cancer: a study of the NCIC Clinical Trials Group. Eur J Can Supplements 4[12], 32, 2006.
  • Chen E, Jonker D, Gauthier I, MacLean M, Wells J, Matthews S, Robertson J, Seymour L. Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors, in combination with oxaliplatin and infusional 5FU (mFOLFOX6) in patients with advanced colorectal cancer: a study of the NCIC Clinical Trials Group. Eur J Can Supplements 4[12], 32, 2006.
  • Chi KN, Ellard S, Hotte SJ, Czaykwski P, Moore M, Ruether JD, Hansen C, Seymour L. Phase II study of BAY 43-9006 (sorafenib) in patients with chemo-naive hormone refractory prostate cancer. Annals of Oncology 17[Suppl 9], 152, 2006.
  • DeAngelo DJ, Silverman LB, Couban S, Dahlberg S, Amrein P, Seftel MD, Turner AR, Wadleigh M, Sirulnik A, Galinsky I, Sallan SE, Stone RM. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 108[11, abstr 1858], 2006.
  • Dos Santos N, Chapman J, Andrews H, Meng D, Shepherd L, Pollak M, Li D, Wilson C, Dunn S. Urokinase plasminogen activator is a serum marker for breast cancer recurrence: a nested case-control pilot study by the NCIC Clinical Trials Group. Breast Cancer Research and Treatment 100[Suppl 1], 2006.
  • Douillard JY, Tribodet H, His P, Shepherd F, Ding K, Winton T, LeChevalier T, Spiro S, Stephens R, Pignon J-P. Lung adjuvant cisplatin evaluation (LACE vinorelbine project): Pooled analysis of adjuvant vinorelbine-cisplatin trials for completely resected non-small cell lung cancer. Annals of Oncology 17[Suppl 9], 213, 2006.
  • Eisenhauer E. Rational drug development in oncology: setting the scene for use of biomarkers. Eur J Can Supplements 4[12], 7, 2006.
  • Ellard SL, Gelmon KA, Clemons M, Norris BD, Kennecke H, Chia S, McIntosh L, Seymour L. A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer. Eur J Can Supplements 4[12], 164, 2006.
  • El-Maraghi RH, Ellard S, Gelmon K, McIntosh L, Seymour L. Pulmonary changes in a randomized phase II study of the mTOR inhibitor RAD001C (Everolimus): NCIC CTG IND.163. Eur J Can Supplements 4[12], 164, 2006.
  • Florescu M, Hasan B, Shepherd FA, Seymour L, Ding K, Pater J. Identifying patients with non-small cell lung cancer unlikely to benefit from erlotinib: An exploratory analysis of National Cancer of Institute of Canada Clinical Trials Group BR.21. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 404, 2006.
  • Fuchs C, Tepper JE, Niedzwiecki D, Hollis D, Haller DG, Dragovich T, Alberts SR, Bjarnason G, Mayer RJ. Postoperative adjuvant chemoradiation for gastric or gastroesophageal adenocarcinoma using epirubicin, cisplatin, and infusional 5-FU before and after CI 5-FU and radiotherapy: Interim toxicity results from Intergroup trial CALGB 80101. ASCO Gastrointestinal Cancers Symposium [Abstr 61], 2006.
  • Gauthier I, Laurie SA, Arnold A, Goss G, Ellis P, Chen E, Shepherd F, Matthews S, Walsh W, Robertson J, Seymour L. Hypertension: Experience in IND.171, a phase I dose-seeking trial combining AZD2171 with standard chemotherapy in patients with advanced incurable non-small cell lung cancer. Presented: 8th International Symposium on Anti-Agiogenic Agents, 2006.
  • Goldberg RM, McLeod HL, Sargent DJ, Morton RF, Green EM, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. Genetic polymorphisms, toxicity, and response rate in African Americans (AA) with metastatic colorectal cancer (MCRC) compared to Caucasians (C) when treated with IFL, FOLFOX or IROX in Intergroup N9741. J Clin Oncol 24[18S Part 1, abstr 3503]. 2006.
  • Ingle J, Tu D, Shepherd L, Palmer M, Pater J, Goss P. NCIC CTG MA.17: Intent to treat analysis of randomized patients after a median follow-up of 54 months. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 15, 2006.
  • Jonker D, Cripps C, Gauthier I, Maroun J, Moore M, Matthews S, Seymour L. Phase I study of AZD2171 in combination with capecitabine in patients with advanced colorectal cancer. Annals of Oncology 17[Suppl 9], 122, 2006.
  • Laurie SA, Arnold A, Gauthier I, Chen E, Goss G, Ellis P, Shepherd F, Matthews S, Robertson J, Seymour L. Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors, in combination with carboplatin + paclitaxel in patients with advanced non-small cell lung cancer: a study of the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 134, 2006.
  • El-Maraghi RH, Ellard S, Gelmon K, McIntosh L, Seymour L. Pulmonary changes in a randomized phase II study of the mTOR inhibitor RAD001C (Everolimus): NCIC CTG IND.163. Presented: American Association for Cancer Research, 2006.
  • Meng D, Chapman J-A, Shepherd L, Parulekar W, Ingle J, Goss P, Li D. Competing causes of death in MA.17, a placebo controlled trial of letrozole as extended adjuvant therapy for breast cancer patients. ENAR Int Biometric Soc, 2006.
  • Mitry E, Fields A, Bleiberg H, Labianca R, Portier G, Tu D, Torri V, Lazorthes F, Van Cutsem E, O'Callaghan CJ, Rougier P. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomzied trials. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 152, 2006.
  • Moy B, Tu D, Shepherd LE, Pater JL, Whelan TJ, Ingle JN, Goss PE. NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 305, 2006.
  • Moy B, Elliott CR, Chapman J-AW, Pater JL, Ding Z, Goss PE. NCIC CTG MA.27: menopausal symptoms of ethnic minority women. Breast Cancer Research and Treatment 100[Suppl 1], 2006.
  • Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan T, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Treatment and Research 100[Suppl 1], S23, 2006.
  • Ng R, Mittmann N, Florescu M, Shepherd FA, Salvarrey A, Seymour L, Winton T, Evans B, Leighl N, Canadian JBR.10 Investigators. An economic analysis of NCIC Clinical Trials Group JBR.10, a randomized trial of adjuvant vinorelbine plus cisplatin versus observation in early stage non-small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 402, 2006.
  • O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KI. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1],S18, 2006.
  • O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis IL, Pritchard KI. Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 11, 2006.
  • Oza AM, Elit L, Biagi J, Chapman W, Tsao M, Hedley D, Hansen C, Dancey J, Eisenhauer E. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer -- NCIC IND 160. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 121, 2006.
  • Palmer M, Parulekar W, Bertrim C, Flindall S, Pritchard K, Martino S, Robert N, Muss H, Ingle J, Goss P. Challenges in implementing a study involving re-randomization to an ongoing multinational, intergroup phase III trial. Clinical Trials 3[Suppl 1], 195, 2006.
  • Parulekar W, Pater JL. Early closure of clinical trials: The experience of the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 314, 2006.
  • Pater JL, Tu D, Ingle JN, Shepherd LE, Goss PE. An evaluation of the early termination of MA.17 extended adjuvant therapy trial. Breast Cancer Treatment and Research 100[Suppl 1], S107, 2006.
  • Pater JL, Parulekar W. Use of placebo in cancer medicine: The experience of a National Clinical Trials organization. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 326, 2006.
  • Pepe C, Hasan B, Winton T, Seymour L, Pater J, Livingston R, Johnson D, Rigas J, Ding K, Shepherd F. Adjuvant chemotherapy in elderly patients: An analysis of NCIC Clinical Trials Group and Intergroup BR.10. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 366, 2006.
  • Pollak M, Chapman JW, Shepherd L, Meng D, Richardson P, Wilson C, Orme B, Pritchard KI. Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for post menopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 9, 2006.
  • Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Preliminary results from the North American acute promyelocytic leukemia study C9710. Blood (ASH Annual Meeting Abstracts) 108 [11, abstr 566], 2006.
  • Quirke P, Sebag-Montefiore D, Steele R, Khanna S, Monson J, Holliday A, Thompson L, Griffiths G, Stephens R. Local recurrence after rectal cancer resection is strongly related to the plane of surgical dissection and is further reduced by pre-operative short course radiotherapy. Preliminary results of the Medical Research Council (MRC) CR07 trial. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 149, 2006.
  • Reiman T, Lai R, Ding K, Winton T, Butts C, Mackey J, Dabbagh L, Seymour L, Tsao M, Shepherd F, Seve P. Class III beta tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of the NCIC Clinical Trials Group study JBR.10. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 376, 2006.
  • Robert NJ, Goss PE, Ingle JN, Tu D, Shepherd L, Palmer M, Pater J. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 15, 2006.
  • Sebag-Montefiore D, Steele R, Quirke P, Grieve R, Khanna S, Monson J, Holliday A, Thompson L, Griffiths G, Stephens R. Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 148, 2006.
  • Shepherd LE, Parulekar W, Pritchard KI, Trudeau M, Paul N, Tu D, Levine M. Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 8, 2006.
  • Thomas GM, Ali S, Patel M, Abulafie O, Lucci JA, III. A GOG phase III trial to evaluate maintaining hemoglobin = 120 G/L with erythropoietin during chemoradiation for cervical cancer. Int J Gynecol Cancer 16[3], 603-604, 2006.
  • Tsao M, Zhu C, Sakurada A, Zhang T, Whitehead M, Kamel-Reid S, Ding K, Seymour L, Shepherd F. An analysis of the prognostic and predictive importance of K-ras mutation status in the NCIC Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 24[18S Part 1], 365, 2006.
  • Wagner LI, Wang M, Miller K, Davidson NE, Gralow J, Dickler M, Cobleigh M, Perez E, Shenkier T, Cella D. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the eastern cooperative oncology group (ECOG) study E2100. Breast Cancer Res Treat 100[Suppl 1, abstr 5078], S239, 2006.
  • Wang M, Tu D, Feldman-Stewart D. Analysis of quality of life data from cancer clinical trials based on item response theory. Statistical Society of Canada, 2006.
  • Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, Gandara DR, Johnson DH, Green MR, Miller RC. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer: outcomes update of North American Intergroup 0139 (RTOG 9309). Proc.Am.Soc.Clin.Oncol. 23 [16S Part 1], 624s, 2005.
  • Asmis T, Ding K, Shepherd F, Leighl N, Seymour L. Are age and co morbidity independent prognostic factors in the treatment of metastatic non-small cell lung cancer. A review of a NCIC Clinical Trials Group randomized trial. Lung Cancer 49[Suppl 2], S85, 2005.
  • Au H, Goldstein D, Ding K, Parulekar W, Gallinger S, Moore M. Does epidermal growth factor receptor inhibitor skin toxicity affect QOL? Results from a NCIC Clinical Trials Group. Quality of Life Research 14[9], 2135, 2005.
  • Bezjak A, Shepherd F, Tu D, Clark G, Santabarbara P, Pater J, Seymour L. Symptom response in non-small cell lung cancer patients treated with erolotinib: quality of life analysis of the NCIC CTG BR.21 trial. Proc.Am.Soc.Clin.Oncol. 23[16S Part 1], 625s, 2005.
  • Bjarnason G, MacKenzie R, Hodson I, Nabid A, Grimard LJ, Jordan RC, El-Sayed S, Hay JH, Tu D, Parulekar WR. A randomized prospective phase-III study comparing the acute oral mucositis of morning vs. afternoon radiotherapy in patients with squamous cell carcinoma of the head and neck: NCIC CTG HN.3. Proc.Am.Soc.Clin.Oncol. 23 [16S Part 2], 1093s, 2005.
  • Blackstein ME, Rankin C, Fletcher C, Heinrich M, Benjamin R, Von Mehren M, Blanke C, Fletcher JA, Borden E, Demetri G. Clinical benefit of imatinib in patients with metastatic gastrointestinal stromal tumors negative for the expression of CD117 in the S0033 trial. Proc.Am.Soc.Clin.Oncol. 23[16S Part 1], 818s, 2005.
  • Bottomley A, Taphoorn M, Coens C, Osoba D, Van Steen K, Efficace F, van den Bent M, Baumert B, Mason W, Stupp R. Predicting survival using health related quality of life scores in glioblastoma cancers: findings from an international phase III randomised controlled trial. Proc.Am.Soc.Clin.Oncol. 23 [16S Part I], 861s, 2005.
  • Chapman JW, Jasani B, Ibrahim M, Miller K, Murray D, Hewlett B, Daidone MG, Allred C, Hammond E, Li D, Sweep F, O'Malley FP, Kelly J, Goss P. Standardization of estrogen and progesterone receptor assay values. Breast Cancer Research and Treatment 94[Suppl 1], 2005.
  • Chapman J, Yu E, Royce M, Tai P. Effects of statistical method of assessment on prognosis of limited-stage small-cell lung cancer. Statistical Society of Canada, 2005.
  • Chapman J. The Canadian experience with accreditation of professional statisticians. ENAR Int Biometric Soc, 2005.
  • Chapman J. The Canadian model for accreditation of professional statisticians. Proc Joint Statistical Meetings, 2005.
  • Chapman JW, Yu E, Royce M, Tai P. Prognosis of limited-stage small-cell lung cancer affected by statistical method of assessement. Proc Am Assoc Cancer Res 46, 111, 2005.
  • Chi KN, Ellard S, Hotte SJ, Kollmannsberger C, Czaykwski P, Moore M, Winquist E, Ruether JD, Fisher B, Seymour L. Phase II study of BAY 43-9006 (sorafenib) in patients with chemo-naive hormone refractory prostate cancer. Eur J Can Supplements 3[2], 248, 2005.
  • Chi KN, Eisenhauer E, Siu L, Hirte H, Hotte SJ, Chia S, Knox J, Guns E, Powers J, Gleave ME. A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154. Proc.Am.Soc.Clin.Oncol. 23[16S Part I], 213s, 2005.
  • Clark G, Zborowski D, Santabarbara P, Ding K, Whitehead M, Seymour L, Shepherd F. Smoking history is more predictive of survival benefit from erlotinib for patients with non-small cell lung cancer than EGFR expression. Proc.Am.Soc.Clin.Oncol. 23[16S Part 1], 628s, 2005.
  • Dileo P, Rankin CJ, Benjamin RS, Von Mehren M, Blanke C, Bramwell V, Maki R, Fletcher C, Borden EC, Demetri GD. Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate in the phase III intergroup study S0033 of patients with unresectable or metastatic gastrointestinal stromal tumor. Proc.Am.Soc.Clin.Oncol. 23[16S Part 1]. 2005.
  • Eisenhauer EA. Combinations of agents for clinical development: which ones? How and when to develop these? Annals of Oncology 16[Suppl 3], 26, 2005.
  • Gauthier I, Seymour L. Target effect and predictors of efficacy using laboratory correlative studies in early clinical trials: The Investigational New Drug Program at the NCIC Clinical Trials Group perspective. CIHR/NCIC National Meeting for Trainees, 2005.
  • Gauthier I, Ding K, Winton T, Shepherd F, Livingston R, Johnson DH, Rigas JR, Whitehead M, Graham B, Seymour L. Impact of hemoglobin on outcomes of adjuvant chemotherapy with cisplatin/vinorelbine in patients with completely resected non small cell lung cancer in JBR.10. Proc.Am.Soc.Clin.Oncol. 23 [16S Part 1], 670s, 2005.
  • Gauthier I, Ding K, Winton T, Shepherd F, Livingston R, Johnson D, Rigas J, Whitehead M, Graham B, Seymour L. Do hemoglobin levels influence outcomes of adjuvant chemotherapy with cisplatin/vinorelbine in patients with completely resected non small cell lung cancer? The JBR.10 trial experience. Lung Cancer 49[Suppl 2], S280, 2005.
  • Goss PE, Ingle JN, Palmer MJ, Shepherd LE, Tu D. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. Breast Cancer Treatment and Research 94[Suppl 1] S10, 2005.
  • Goss PE, Ingle J, Tu D, Shepherd L, Pater J. NCIC CTG MA17: Disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor. Breast Cancer Treatment and Research 94[Suppl 1] S98, 2005.
  • Green JA, Duffaud F, Coens C, Laframboise S, Vergote I, Eisenhauer E, Bacon M, Chapman W, van der Burg ME, Oza A. Prognostic value of clinical and molecular markers in advanced ovarian cancer: importance of residual disease. Translational study using tumor specimens from EORTC 55931/NCIC OV10 phase III randomized clinical trial. Proc.Am.Soc.Clin.Oncol. 23[16S Part], 456s, 2005.
  • Hamilton M, Wolf J, Zborowski D, Lu J, Lum BL, Ding K, Clark G, Rakhit A, Seymour L, Ptaszynski M, Rusk J, Shepherd F. TarcevaTM (erlotinib) exposure/effects analysis from a phase III study in advanced NSCLC: Effect of smoking on the PK of erlotinib. Proc Am Assoc Cancer Res 46: 1451, 2005.
  • Heinrich MC, Shoemaker JS, Corless CL, Hollis D, Demetri GD, Bertagnolli MM, Fletcher JA. Correlation of target kinase genotype with clinical activity of imatinib mesylate in patients with metastatic GI stromal tumors expressing KIT (KIT+). Proc.Am.Soc.Clin.Oncol. 23[16S Part 1]. 2005.
  • Ingle JN, Goss PE, Tu D. Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17. Breast Cancer Treatment and Research 94[Suppl 1] S11, 2005.
  • Karp D, Lee S, Keller S, Johnson D, Kucuk O, Clamon G, Marks R, Johnston M, Okawara G, Ruckdeschel J. Interim report: A phase III randomized double blind chemoprevention trial of selenium supplementation in persons with resected stage I non small cell lung cancer. Lung Cancer 49 [Suppl 2], S181, 2005.
  • Kelly K, Gaspar LE, Chansky K, Albain KS, Crowley J, Gandara DR. Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 23 [16S Part 1], 634s, 2006.
  • Koski B, Messerschmidt T, Wu Q, Kotecha J, Wainman N. Training at the coordinating centre for multicentre trials. Clinical Trials 2[Suppl 1], S74, 2005.
  • Koski B, Wu Q, Messerschmidt T, Parulekar W. Monitoring the activities of a coordinating centre for multicentre trials. Clinical Trials 2[Suppl 1], S71, 2005.
  • Kotecha J, Spirovski B, Hopkins S, DeAngelis C. The NCIC CTG Pharmacist Network: The role of pharmacists in clinical trials. Clinical Trials 2[Suppl 1], S68, 2005.
  • Kovacs M, Chapman J-A.W, Shepherd L, Meyer R, Keeney M, MacKinnon K, Stewart K, Paul N. Maintenance therapy with thalidomide/prednisone post autologous stem-cell transplant for patients with multiple myeloma elevates d-dimer and possibly factor VIII levels. Blood (ASH Annual Meeting Abstracts) 106[11, abstr 2561], 720a, 2005.
  • Laurie SA, Ding K, Whitehead M, Feld R, Murray N, Seymour L, Shepherd FA. Impact of anemia on outcomes of therapy in limited small cell lung cancer: an analysis of studies performed by the NCIC Clinical Trials Group. Lung Cancer 49[Suppl 3], S323-S324, 2005.
  • Laurie SA, Arnold A, Gauthier I, Ellis P, Goss G, Chen E, Shepherd F, Fisher B, Robertson J, Seymour L. Phase I study of daily oral ADZ 2171, an inhibitor of the vascular endothelial growth factor receptor, in combination with carboplatin / paclitaxel in patients with advanced non-small cell lung cancer: a study of the NCIC CTG. Clinical Cancer Research 11[24 (part 2)], 8970s, 2005.
  • Lee S-J, Royce ME, Wallace AM, Chapman JW, Tai P. Improvements of breast cancer cure fractions in surveillance, epidemiology, and end results (SEER) estimated using CanSurv software. Breast Cancer Research and Treatment 94[Suppl 1], 2005.
  • Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.
  • Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.
  • Luk C, Ding K, Belch AR, Browman GP, Shustik C, Djurfeldt M, Johnston D, Shepherd LE, Meyer RM. Outcomes of previously untreated older patients with multiple myeloma over time: An analysis of 3 consecutive trials conducted by the NCIC CTG, 1983-2003. Blood (ASH Annual Meeting Abstracts) 106[11, abstr 2568], 2005.
  • Luk C, Goss P, Pritchard K, Whelan TJ, Liu S, Shepherd L, Pater J. Determinants of preferences for starting extended adjuvant letrozole in postmenopausal women following five years of tamoxifen. Proc.Am.Soc.Clin.Oncol. 23[16S Part 1], 39s, 2005.
  • Macdonald DA, Gospodarowicz MK, Wells WA, Pearcey RG, Connors JR, Winter JN, Horning SJ, Djurfeldt MS, Ding K, Shepherd LE, Meyer RM. Relapse patterns and subsequent outcomes of patients treated on the NCIC CTG HD.6 (ECOG JHD06) randomized trial evaluating ABVD alone in patients with limited stage Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 106[11, abstr 817], 2005.
  • Maunsell E, Au H, Palmer M, Tu D, Whelan TJ, Goss PE, Davis A. Health-related quality of life in breast cancer survivors after 5 years of adjuvant tamoxifen. Quality of Life Research 14[9], 2092, 2005.
  • Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.
  • Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkier TN, Davidson NE. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 94[Suppl 1, abstr 3], S6, 2005.
  • Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, Au H, Ding K, Christy-Bittel J, Parulekar W. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 23 [16S Part 1], 1s, 2005.
  • Oza A, Elit L, Biagi J, Panasci L, Tonkin K, Tsao MN, Dore N, Dancey J, Eisenhauer E, Seymour L. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or recurrent endometrial cancer - NCIC CTG IND.160. Eur J Can Supplements 3[2], 261, 2005.
  • Oza A, Elit L, Biagi J, Gotlieb W, Tonkin KS, Tsao MN, Hedley D, Hanson C, Dancey J, Eisenhauer E, Seymour L. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally recurrent endometrial cancer - NCIC CTG IND.160. Clinical Cancer Research 11[24 (part 2)], 9099s, 2005.
  • Paul N, Wong R, Whitehead M, Pater J. Daily diary reporting of symptoms in SC19: a NCIC Clinical Trials Group study of prophylaxis against radiation-induced emesis. Support Care Cancer 13[6], 419, 2005.
  • Paul N, Wong R, Brundage M, Ding K, Whitehead M, Pater J. Symptom assessment in SC19: ondansetron plus dexamethasone as prophylaxis against radiation-induced emesis - a NCIC Clinical Trials Group study. Support Care Cancer 13[6], 419, 2005.
  • Rowe J, Xiachum L, Cassileth P, Appelbaum F, Schiffer CA, Wiernik P, Litzow MR, Cripe LD, Lazarus HM, Paietta E, Dewald GW, Weinstein H, Ogden A, Woods W, Shepherd L, Feusner J, Bloomfield C, Tallman M. Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative Oncology Group experience. Blood (ASH Annual Meeting Abstracts) 106[11, abstr 546], 2005.
  • Seymour L, Goss G. Epidermal growth factor receptor tyrosine kinase inhibitors: is dose relevant? Annals of Oncology 16[Suppl 3], 40, 2005.
  • Shustik C, Turner R, Desjardins P, Fernandez L, Rubin S, Larratt L, Duncan A, Rizi D, Sadura A, Shepherd L, Li D, Rassenti L, Kipps T. A NCIC Clinical Trials Group phase II study of oral fludarabine in untreated B-cell chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 106[11, abstr 2977], 2005.
  • Sloan JA, McLeod H, Sargent D, Zhao X, Fuchs C, Ramanathan R, Williamson S, Findlay B, Morton R, Goldberg RM. Preliminary Evidence of Relationship between Genetic Markers and Oncology Patient Quality of Life (QOL) Prior to Treatment. Psycho-Oncology 14[Suppl 1, abstr VII-1], S19, 2005.
  • Tsao MS, Zhu C-Q, Livingston R, Johnson DH, Gandara D, Viallet J, Ding K, Seymour L, Winton T, Shepherd F. The significance of K-ras mutations in the intergroup JBR.10 trial on adjuvant chemotherapy in completely resected early stage non-small cell lung cancer patients. Lung Cancer 49[Suppl 2], S41, 2005.
  • Tsao MS, Sakurada A, Lorimer I, Cutz J, Kamel-Reid S, Squire J, Ding K, Frank R, Seymour L, Shepherd F. Molecular analysis of the epidermal growth factor receptor gene and protein expression in patients treated with erlotinib in NCIC Clinical Trials Group trial BR.21. Proc.Am.Soc.Clin.Oncol. 23[16S Part 1], 622s, 2005.
  • Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.
  • Wong R, Paul N, Ding K, Brundage M, Fyles A, Pater J. Optimizing prophylaxis of radiation induced emesis: a phase III double blind randomized study comparing ondansetron plus dexamethasone vs ondansetron alone. Support Care Cancer 13[6], 423, 2005.
  • Assouline S, Eisenhauer E. RECIST (Response Evaluation Criteria in Solid Tumors) applied to response in lymphoma. Proc.Am.Soc.Clin.Oncol. 23, 582, 2004.
  • Belch A, Kouroukis T, Crump M, Sehn L, Gascoyne R, Klasa R, Powers J, Eisenhauer E. Phase II trial of bortezomib in mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 104[11, abstr 608]. 2004.
  • Cairncross G, Seiferheld W, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Curran W. An intergroup randomized controlled clinical trial of chemotherapy plus radiation versus radiation alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02. Proc.Am.Soc.Clin.Oncol. 23, 107, 2004.
  • Chen C, White D, Kouroukis T, Stewart KA, Howson-Jan K, Larratt L, Powers J, Eisenhauer E. Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's Macroglobulinemia. Blood (ASH Annual Meeting Abstracts) 104[11, abstr 3278], 2004.
  • Chi K, Eisenhauer E, Fazli L, Jones EC, Powers J, Hurtado-Coll A, Goldenberg L, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. Eur.J.Can.Supplements 2(8), 13, 2004.
  • Chi K, Eisenhauer E, Fazli L, Jones EC, Powers J, Ayers D, Goldenberg SL, Gleave ME. A phase I pharmacokineic and pharmacodynamic study of OXG-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. Proc.Am.Soc.Clin.Oncol. 23, 203, 2004.
  • Chi K.N., Eisenhauer E, Fazli L, Jones T, Powers J, Ayers D, Goldenberg L, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. Presented: Canadian Urological Assoc Mtg, 2004.
  • Ciuleanu TE, Shepherd F, Pereira J, Tan EH, Hirsh V, Thongprasert S, Bezjak A, Ding K, Ptaszynski M, Seymour L. NCIC Clinical Trials Group trial BR.21. A placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer. NCIC Clinical Trials Group trial BR.21. Annals of Oncology 15[Suppl 3], iii14, 2004.
  • Colacchio TA, Niedzwiecki D, Compton CC, Warren RS, Benson AIB, Goldberg RM, Kerr D, Fields A, Hollis D, Mayer RJ. Phase III study of adjuvant immunotherapy with MoAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). Proc.Am.Soc.Clin. Oncol. 23, 251, 2004.
  • Crump M, Leber B, Kassis J, Hedley D, Minden M, Buckstein R, McIntosh L, Eisenhauer E, Seymour L. A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC Clinical Trials Group study. Proc.Am.Soc.Clin.Oncol. 23, 583, 2004.
  • Delaunoit TP, Krook J, Sargent DJ, Green E, Alberts SR, Fuchs C, Ramanathan R, Williamson S, Findlay B, Morton R, Goldberg RM. Chemotherapy-allowed resection of metastatic colorectal cancer: A cooperative group experience. ASCO Gastrointestinal Cancers Symposium [abstr 196], 2004.
  • Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.
  • Efficace F, Therasse P, Piccart M, Coens C, Van Steen K, Welnicka-Jaskiewicz M, Cufer T, Lichinitser M, Shepherd L, Bottomley A. Predicting survival with health-related quality of life scores in locally advanced breast cancer: Results from an international randomized controlled trial. Proc.Am.Soc.Clin.Oncol. 23, 31, 2004.
  • Fuchs C, Pollak M, Sargent DJ, Meyerhardt JA, Ramanathan RK, Williamson S, Findlay B, Green E, Goldberg RM. Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): Results from Intergroup Trial N9741. Proc Am Soc Clin Oncol 22 (July 15 Suppl)[Post Meeting Ed. No 14S (abstr 3521)], 2004.
  • Gauthier I, Seymour L. The Investigational New Drug Program at the NCIC Clinical Trials Group: Current activity and access to novel cancer therapeutics. International Workshop on the Design & Management of Clinical Trials, 2004.
  • Goldberg RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP. N9741: Oxaliplatin (Oxal) + CPT-11 or 5-fluorouracil (5FU)/leucovorin (LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study. ASCO Gastrointestinal Cancers Symposium [abstr 215], 2004.
  • Goldberg RM, Sargent DJ, Morton R, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study. Proc Am Soc Clin Oncol 22 (July 15 Suppl)[Post Meeting Ed. No 14S (abstr 3621)], 2004.
  • Gorlia T, Stupp R, Eisenhauer EA, Mirimanoff RO, van den Bent MJ, Belanger K, Lacombe D, Allgeier A. Clinical prognostic factors affecting survival in patients with newly diagnosed glioblastoma multiforme. Proc.Am.Soc.Clin.Oncol. 23, 855, 2004.
  • Goss P, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione MM, Tu D, Shepherd LE, Pater JL. Updated analysis of the NCIC CTG MA.17 randomized placebo controlled trial of letrozole after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc.Am.Soc.Clin.Oncol. 23, 87, 2004.
  • Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pater JL. Randomized placebo-controlled trial of letrozole in postmenopausal women with early breast cancer completing 5 years of tamoxifen. Breast Cancer Research and Treatment 85[2], 180. 2004.
  • Hegi ME, Diserens A-C, Hamou M-F, Gorlia T, Weller M, Kros JM, Hainfeller J, Bogdahn U, Cairncross G, Stupp R. Temozolomide targets only glioblastoma with a silenced MGMT-gene. Results of a translational companion study to EORTC 26981/NCIC CE.3 of Radiotherapy ± TMZ. Eur J Can Supplements 2[8], 14, 2004.
  • Jasas K, Fyles A, Elit L, Hoskins PJ, Biagi J, Dubuc-Lissoir J, Matthews S, Dancey J, Eisenhauer E, Oza AM. Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND.148. Proc.Am.Soc.Clin.Oncol. 23, 452, 2004.
  • Kovacs M, Marcellus D, Meyer R, Matthews S, Dong R-P, Eisenhauer E. A phase II study of ZD6474, a vascular endothelial growth factor receptor and epidermal growth factor receptor tyrosine kinase inhibitor in patients with relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 104[11, abstr 3464], 2004.
  • Kristensen GB, Vergote I, Eisenhauer E, Baekelandt M, Stuart G, Aavall-Lundquist E, del Campo J, Lopez AB, Mirza M, Lorenz E. First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival. Proc.Am.Soc.Clin.Oncol. 23, 448, 2004.
  • Leighl NB, Shepherd F, Paz-Ares L, Douillard J, Peschel C, Arnold A, Tu D, Galbraith S, Hann K, Seymour L. Randomized phase II-III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: NCIC CTG BR.18. Proc.Am.Soc.Clin.Oncol. 23, 623, 2004.
  • Li D. Directly Using The Lab Ranges Data into SAS Program of Determining Lab Normality. International SAS User's Group Conference (SUGI 29), 2004.
  • Lukka H, Hayter C, Jones T, Srigley J, Daya D, Warde P, Morris J, Julian J, Gospodarowicz M, Levine M. Post radiotherapy biopsy correlation with PSA failure: results from a randomized hypofractionated study in localized prostate cancer. Int.J.Rad.Oncol.Biol.Phys. 60[suppl 1], S171, 2004.
  • Marks LB, Cirrincione C, Peterson B, Fitzgerald TJ, Laurie F, Rosner F, Vredenburgh J, Shpall EJ, Crump M, Hurd D, Norton L, Peters WP. The impact of local/regional radiotherapy (RT), and its timing, on survival following lumpectomy/mastectomy and systemic chemotherapy in patients with 10 positive axillary nodes: Analysis of CALGB 9082. Int J Radiat Oncol Biol Phys 60[1 Suppl], S136, 2004.
  • O'Sullivan B, Davis A, Turcotte R, Bell R, Wunder J, Catton C, Kandel R, Sadura A, Tu D, Pater J. Five year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma. Proc.Am.Soc.Clin.Oncol. 23, 815, 2004.
  • O'Sullivan B, Davis A, Turcotte R, Bell R, Wunder J, Catton C, Hammond A, Freeman C, Marc I, Chabot P, Kandel R, Tu D. Local control with pre-operative vs post-operative external beam radiotherapy in extremity soft-tissue sarcoma: 5 year results of a randomized phase III trial. Canadian Association of Radiation Oncology, 2004.
  • Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, Cufer T, Roozendaal K, Nooij M, Mattiacci M-R. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 22 (July 15 Suppl)[Post Meeting Ed. No 14S (abstr 515)]. 2004.
  • Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women completing > 5 years of adjuvant tamoxifen: NCIC CTG MA.17b. Breast Cancer Treatment and Research 88[Suppl 1] S36, 2004.
  • Pfisterer J, Plante M, Vergote I, du Bois A, Wagner U, Hirte H, Lacave AJ, Stähle A, Kimmig R, Eisenhauer E. Gemcitabine/carboplatin vs. carboplatin in platinum sensitive recurrent ovarian cancer. Results of a gynecologic cancer intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Proc.Am.Soc.Clin.Oncol. 23, 449, 2004.
  • Pfreundschuh MG, Trümper T, Ma D, Österborg A, Pettengell R, Trneny M, Shepherd L, Waleswski J, Zinzani P-L, Loeffler M. Randomized intergroup trial of first line treatment for patients < 60 years with diffuse large B-cell non-Hodgkin's lymphoma with a CHOP-like regimen with or without the anti-CD20 antibody rituximab - early stopping after the first interim analysis. Proc.Am.Soc.Clin.Oncol. 23, 556, 2004.
  • Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields ALA, Carver G, Mayer RJ. Irinotecan plus fluorouracil/leucovorin versus fluorouracil/leucovorin alone in stage III colon cancer (intergroup trial CALGB C89803). Proc.Am.Soc.Clin.Oncol. 23, 246, 2004.
  • Shepherd F, Winton T, Livingston R, Johnson D, Rigas J, Cormier Y, Bezjak A, Ding K, Graham B, Seymour L. The impact of adjuvant vinorelbine and cisplatin on quality of life: Results from the NCIC Clinical Trials Group Trial BR.10 Randomised trial of VIN/CIS versus observation in stage IB and II non-small cell lung cancer. Annals of Oncology 15[Suppl 3], iii165, 2004.
  • Shepherd FA, Pereira J, Tudor-Eliade C, Tan EH, Hirsh V, Thongprasert S, Bezjak A, Tu D, Santabarbara P, Seymour L. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group trial. Proc Am Soc Clin Oncol 22 (July 15 Suppl), [Post Meeting Ed. No 14S (abstr 7022)], 2004.
  • Shustik C, Belch A, Robinson S, Rubin S, Dolan S, Kovacs M, Djurfeldt M, Shepherd L, Ding K, Meyer RM. Dexamethasone maintenance versus observation in patients with previously untreated multipe myeloma: a NCIC Clinical Trials Group study: MY.7. Proc.Am.Soc.Clin.Oncol. 23, 558, 2004.
  • Singh S, Parulekar W, Murray N, Feld R, Evans B, Tu D, Pater J, Shepherd FA. Influence of gender on treatment outcome and toxicity in small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 23, 623, 2004.
  • Sloan JA, McLeod H, Sargent D, Zhao X, Fuchs C, Ramanathan RK, Williamson S, Findlay B, Morton R, Goldberg RM. Preliminary evidence of relationship between genetic markers and oncology patient quality of life. Proc.Am.Soc.Clin.Oncol. 23, 2, 2004.
  • Sloan JA, McLeod H, Sargent DJ, Zhao X, Fuchs CS, Ramanathan RK, Williamson SK, Findlay B, Morton RF, Goldberg RM. Preliminary Evidence of Relationship Between Genetic Markers and Oncology Patient Quality of Life (QoL). International Society for Quality of Life Research [abstr 146], 2004.
  • Stewart AK, Chen C, Howson-Jan K, White D, Roy J, Kovacs M, Shustik C, Sadura A, Shepherd L, Ding K, Meyer RM, Belch A. Results of a multi-center randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma following autologous stem cell transplant. Blood (ASH Annual Meeting Abstracts) 104[11, abstr 335], 2004.
  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn M, Brandes AA, Cairncross G, Lacombe D, Mirimanoff RO. Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme. Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 23, 1, 2004.
  • Tallman M, Kim HT, Schiffer C, Appelbaum F, Feusner J, Ogden A, Shepherd L, Willman CL, Bloomfield C, Rowe J, Larson RA, Wiernik P, Martin G, Rayon C, de la Serna J, Rivas C, Gonzalez-San Miguel JD, Deben G, Sanz MA. Microgranular variant of acute promyelocytic leukemia (APL) does not have a worse prognosis than classical APL in the atra era: a report of 153 patients treated on intergroup 0129 and pethema LPA96 and LPA99. Blood (ASH Annual Meeting Abstracts) 104[11, abstr 394], 2004.
  • Taphoorn M, Stupp R, Osoba D, Curschmann J, Kortmann R, van den Bent M, Mason W, Coens C, Eisenhauer E, Bottomley A. Joint EORTC brain tumour group/radiotherapy group and NCIC CTG phase III randomized controlled trial evaluating health-related quality of life in glioblastoma patients. Annals of Oncology 15[Suppl 3], iii206, 2004
  • Taphoorn M, Stupp R, Osoba D, Curschmann J, Kortmann R, van den Bent M, Mason W, Coens C, Eisenhauer E, Bottomley A. An international phase III randomised controlled trial evaluating health-related quality of life in glioblastoma patients. Soc Neuro Oncol, 2004.
  • Tu D, Gou S. A comparison of statistical tests for the interaction of treatment and biomarker in tumour correlative studies. International Biometric Conference in parallel with Australia Statistical Conference, 2004.
  • van Meerbeeck JP, Manegold C, Gaafar R, Van Klaveren RJ, Vincent M, Legrand C, Debruyne C, Giaccone G. A randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the EORTC Lung Cancer Group and NCIC. Proc Am Soc Clin Oncol 22 (July 15 Suppl), [Post Meeting Ed. No 14S (abstr 7021)], 2004.
  • Whelan T, Goss P, Ingle J, Pater J, Shepherd L, Palmer M, Tu D, Robert NJ, Martino S, Muss H. Assessment of quality of life in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. Proc.Am.Soc.Clin.Oncol. 23, 6, 2004.
  • Winton T, Livingston R, Johnson D, Rigas J, Cormier Y, Butts C, Ding K, Seymour L, Magoski N, Shepherd F. A prospective randomised trial of adjuvant vinorelbine and cisplatin in completely resected stage 1B and II non-small cell lung cancer. Intergroup JBR.10. Proc Am Soc Clin Oncol 22 (July 15 Suppl), [Post Meeting Ed. No 14S (abstr 7018)], 2004.
  • Wong R, Paul N, Ding K, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Pater J. A phase III double blind randomized trial comparing ondansetron plus dexamethasone vs. ondansetron alone in the prophylaxis against radiation-induced emesis. A NCIC Clinical Trials Group study. European Society for Therapeutic Radiation and Oncology S387, 2004.
  • Alam N, Shepherd F, Winton T, Graham B, Johnson D, Livingston R, Rigas J, Whitehead M, Ding K, Seymour L. Compliance with adjuvant chemotherapy in non-small cell lung cancer: NCIC-CTG BR.10/JBR.10.Proc.Am.Soc.Clin.Oncol. 22, 633, 2003.
  • Albain KS, Scott CB, Rusch VR, Turrisi AT, Shepherd FA, Smith C, Gandara DR, Johnson DH, Green MR, Miller RC. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer: Initial results from intergroup trial 0139 (RTOG 93-09). Proc.Am.Soc.Clin.Oncol. 22, 621, 2003.
  • Albain KS, Scott C, Rusch V, Turrisi AT, Shepherd F, Smith C, Gandara D, Johnson D, Green M, Miller R. Phase III study of concurrent chemotherapy and full course radiotherapy (CT/RT) versus CT/RT induction followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer: First outcome analysis of North American Intergroup trial 0139. World Conference on Lung Cancer, 14, 2003.
  • Assouline S, Belch A, Sehn L, Kouroukis T, Gascoyne R, Meyer R, Powers J, Eisenhauer E. A phase II study of bortezomib in patients with mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 102(11, abstr 3358), 2003. (Abst # 3358)
  • Baetz T, Moore M, Eisenhauer E, Siu L, MacLean M, Doppler K, Walsh W, Fisher B, de Alwis D, Weitzman A. Phase I and pharmacokinetic study of LY293111 in combination with irinotecan. Clinical Cancer Research 9(suppl), 2003.
  • Benjamin RS, Rankin C, Fletcher C, Blanke C, Von Mehren M, Maki R,Bramwell V, Baker L, Borden E, Demetri GD. Phase III dose-randomized study of imatinib mesylate (ST1571) for GIST: Intergroup S0033 earlyresults. Proc.Am.Soc.Clin.Oncol. 22, 814, 2003.
  • Bezjak A, Winton T, Ding K, Graham B, Seymour L, Ayoub J, Livingston R, Vallieres E, Rigas J, Demmy T, Devore R, Kessler K, Shepherd F. Quality of life in a trial of adjuvant chemotherapy for early stage completely resected non-small cell lung cancer (NCIC CTG BR.10). Lung Cancer 41(2): a0-58, 2003.
  • Bezjak A, Winton T, Ding K, Graham B, Seymour L, Ayoub J, Livingston R, Vallieres E, Rigas J, Demmy T, Devore R, Kessler K. Does adjuvant chemotherapy impair quality of life? Results of the NCIC CTG BR.10 trial of adjuvant navelbine/cisplatinum for early stage completely resected non-small cell lung cancer. International Society for Quality of Life Research, 2003.
  • Brundage MD, Feldman-Stewart D, Bezjak A, Leis A, Zetes-Zanatta L, Degner L, Velji K, Tu D, Ritvo P, Pater J. Communicating quality of life information to cancer patients: An evaluation of six presentation formats. Proc.Am.Soc.Clin.Oncol. 22, 537, 2003.
  • Brundage M, Bezjak A, Tu D, Palmer M, Dixon P, Pater J. How should palliation be measured - Illustrative examples from the NCIC CTG palliative thoracic radiation trial. Lung Cancer 41(2), ao248, 2003.
  • Dancey J, Crump M, Gluck S, Tu D, Marlin S, Shepherd L. Quality of life analysis of a randomized trial of high-dose chemotherapy with peripheral stem cell transplant versus standard chemotherapy in women with metastatic breast cancer: NCIC Clinical Trials Group study (NCIC CTG) MA.16. Proc.Am.Soc.Clin.Oncol. 22, 749, 2003.
  • Ding K, Hall WJ. Sequential test and estimates after overrunning based on p-value combination. Statistical Society of Canada, 2003.
  • Ehrenberger H, Bacon M, Burkes K, Lillington L, Ward K, Zimmerman J. The development of a virtual work group of the ONS Clinical Trials Nurses Special Interest Group: Keys to productivity. Oncology Nursing Society, 2003.
  • Friedenberg WR, Rue M, Dalton W, Schiffer CA, Shustik C, Cella D, Sonneveld P, Greipp PR, Kyle R. Phase 3 study of the multi-drug resistant modulator PSC-833 in relapsing or refractory multiple myeloma: An integroup study led by ECOG (E1A95). Blood (ASH Annual Meeting Abstracts) 102(11, abstr 2559), 2003.
  • Gill S, Loprinzi CL, Sargent DJ, Haller DG, Benedetti J, Francini G, Shepherd LE, Seitz JF, Labianca R, Goldberg RM. Using a pooled analysis to improve the understanding of adjuvant therapy benefit for colon cancer. Proc.Am.Soc.Clin.Oncol. 22, 253, 2003.
  • Goldberg RM, Morton RF, Sargent DJ, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP. N9741: oxaliplatin or CP-11 + 5-fluorouracil/leucovorin or oxal + CPT-11 in advanced colorectal cancer. Update efficacy and quality of life data from an intergroup study. Proc.Am.Soc.Clin.Oncol. 22, 252, 2003 (abst # 1009).
  • Hirte H, Oza A, Hoskins,P, Ellard S, Grimshaw R, Dubuc-Lissoir J, Kerr I, Fisher B, Seymour L. Phase II study of OSI-774 given in combination with carboplatin in patients with recurrent epithelial ovarian cancer: NCIC CTG IND.149. Eur.J.Can.Supplements 1(5): S51, 2003
  • Jatoi A, Rowland KM, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Malliard JA, Krook JE. An eicosapentainoic acid-enriched supplement versus megestrol acetate versus both for patients with cancer-associated wasting. A collaborative effort from the North Central Cancer Treatment Group and the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 22, 2003 (abst # 2987).
  • Li D. A SAS macro to automate the covariance structure determination in repeated measures data analysis with mixed procedure. Pharmaceutical Industry SAS Users Group, 2003.
  • Li D.Tired of defining axis scale for SAS graphs? A solution with an automaticoptimizing approach. Pharmaceutical Industry SAS Users Group, 2003.
  • Lukka H, Hayter C, Warde P, Morris J, Julian J, Gospodarowicz M, Levine M. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Int.J.Rad.Oncol.Biol.Phys. 57[2 (suppl 1)], S126, 2003
  • Mangioni C, Malmstrom H, Reed N, Scarfone G, Poveda A, Tateo S, Pecorelli S, Vergote I, Giurgea L, Coens C, Teodorovic I. First results of a randomised trial comparing radiotherapy - versus - observation post operatively in patients with uterine sarcomas. An EORTC-GCG study. Revised Abstract. Int J Gynecol Cancer 13(Suppl 1), 2003.
  • Mazumdar M, Tu D. Efficiency of STRTA matched case-control studies with multiple controls per case in survival data setting. Controlled Clin Trials 24(3S), 112S, 2003.
  • McLeod HL, Sargent DJ, Marsh S, Fuchs C, Ramanathan RK, Williamson S, Findlay B, Thibodeau S, Petersen G, Goldberg R. Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)CPT-11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer (CRC): Results from an intergroup trial. Proc Am Soc Clin Oncol 22[abstr 1013], 2003.
  • Meyer R, Gospodarowicz M, Connors J, Pearcey R, Bezjak A, Wells W, Burns B, Winter J, Horning S, Dar R, Djurfeldt M, Shepherd L, Ding K. A randomized phase III comparison of single - modality ABVD with a strategy that includes radiation therapy in patients with early-stage Hodgkin's disease: The HD-6 Trial of the NCIC Clinical Trials Group (Eastern Cooperative Group Oncology Group Trial JHD06) Trial JHD06). Blood (ASH Annual Meeting Abstracts) 102[11, Part 1, abstr 81], 26a, 2003.
  • Oza A, Elit L, Eisenhauer E, Hoskins P, Biagi J, Carey M, Dubuc-Lissoir J, Dundas G, Stuart G, Matthews S, Tsao MS, Dancey J, Fyles A. Phase II study of erlotinib (Tarceva, OSI 774) in women with recurrent or metastatic endometrial cancer -- NCIC IND.148. Clin Cancer Res 9(suppl), 6094s, 2003.
  • Palmer M, Broekhoven M, Pater J. Drug supply issues in a multinational, intergroup phase III trial. Controlled Clin.Trials 24(3S), 67S, 2003.
  • Paul N, Pater J, Wainman N, Marlin S, Sadura A. Description of adverse effects in consent forms for oncology clinical trials. Controlled Clin.Trials 24(3S), 234S, 2003.
  • Shepherd L, Sadura A, Pritchard K, Feener T. A tumour/tissue/data bank for the Breast Disease Site Committee of the NCIC Clinical Trials Group. How have we been doing? Reasons for Hope Conference, 2003.
  • Shustik C, Duncan A, Ben Amor H, Turner R, Desjardins P, Ding K, Shepherd L, Sadura A. Cytogenetic abnormalities in untreated CLL. Blood (ASH Annual Meeting Abstracts) 102[11, abstr 4496], 2003.
  • Shepherd L, Sadura A, Feener T. Compliance with central pathology review and tumour block submission in a national cooperative clinical trials group: The NCIC CTG experience. Controlled Clin.Trials 24(3S), 230S, 2003.
  • Smalley SR, Benedetti J, Williamson S, Robertson J, Fisher B, Martenson JA, Benson AB, Robert M, Cripps C, Macdonald J. Intergroup 0144 - phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV. Proc.Am.Soc.Clin.Oncol. 22, 251. 2003.
  • Stuart G on behalf of the NSGO-EORTC-GCG-NCIC CTG Intergroup Investigators. First line treatment of ovarian cancer FIGO stage IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Interim results of an NSGO-EORTC-GCG--NCIC CTG Gynaecological Cancer Intergroup phase III trial. Eur Soc Gyn Oncol, 2003.
  • Siu LL, Goss GD, Powers J, Waterfield B, MacLean M, Adams LM, Drolet D, Rusk J, Seymour L. A phase I trial of the novel nucleoside analog OSI-7836 given on days 1 and 8 every 3 weeks: NCIC CTG IND.147. Eur.J.Can.Supplements 1(5):S165, 2003
  • Tu D, Liu J, Pater J. Analysis of ordinal quality of life response data: whither simple chi-square tests? Controlled Clin.Trials 24(3S), 229S, 2003.
  • Turrisi AT, Scott C, Rusch V, Albain KS, Shepherd F, Smith C, Chen Y, Livingston R, Gandara D, Darling G, Johnson D, Green M. Randomized trial of chemoradiotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy [S] followed by surgery using cisplatin etoposide in stage IIIa non-small cell lung cancer: Intergroup trial 0139, RTOG (9309). Int.J.Rad.Oncol.Biol.Phys. 57(2), S125-S126, 2003.
  • Albain K, Green S, Ravdin P, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, Abeloff M, Norton L, Henderson I, Lew D, Livingston R, Martino S, Osborne C. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc.Am.Soc.Clin.Oncol. 21(part a), 37a, 2002.
  • Bezjak A, Perrone F, Gallo C, Hirsh V, Seymour L, Piantedosi F, Shepherd F, Robbiati S, Barbera S, Frontini L, Gridelli C. Quality of life as the primary endpoint in a lung cancer study: A successful international collaborative effort. Quality of Life Research 11(7), 643, 2002.
  • Bezjak A, Dancey J, Tu D, Pater JL, Seymour L, Moore M. Clinical benefit in patients with cancer of the pancreas: How does it compare with clinically significant changes in quality of life scores? Clinical Therapeutics 24(Suppl.2), 12-14, 2002.
  • Brundage M. Communicating quality of life (HRQL) information to cancer patients: A quantitative evaluation of six presentation formats. Quality of Life Research 11(7), 2002.
  • Brundage MD, Pater JL, Tu D, Palmer M, Bezjak A, Dixon P. Assessment of palliation in patients with lung cancer: Comparisons between patient symptom diary scores and "minimum clinical change" in qualityof life scores. Clinical Therapeutics 24(Suppl.2), 23-24, 2002.
  • Burdette-Radoux S, Tozer R, Lohmann R, Quirt I, Ernst S, Walsh W, Wainman N, Colevas D, Eisenhauer E. NCIC CTG phase II study of flavopiridol in patients with previously untreated metastatic malignant melanoma (IND.137). Proc.Am.Soc.Clin.Oncol. 21(part 1), 346a, 2002.
  • Calvert A, Grimshaw R, Poole C, Dark G, Swenerton K, Gore M, Kaye S, Coleman R, Trudeau M, Jayson G, Ellard S, Le T, Vasey P, Cameron T, Barrett E,Ptaszynski M, McIntosh L, Eisenhauer E. Randomized phase II trial of two intravenous schedules of the liposomal topoisomerase I inhibitor, NX211, in women with relapsed epithelial ovarian cancer. An NCIC CTG study. Proc.Am.Soc.Clin.Oncol. 21(part 1), 208a, 2002.
  • Cassidy J, Vergote I, Bertelsen K, Stuart G, Baron B, Piccart M. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Gyn Cancer Soc, 2002.
  • Crump M, Baetz T, Belch A, Couban S, Meyer R, Imrie K, Yau J, Myers R, Paul N, Turner R, Shepherd L, Iglesias J. Gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy for relapsed or refractory Hodgkin's disease (HD): A NCIC Clinical Trials Group Study. Blood (ASH Annual Meeting Abstracts) 100[11 Part 1, abstr 2240], 570a, 2002.
  • Crump M, Baetz T, Belch A, Couban S, Meyer R, Imrie K, Howson-Jan K, Myers R, Adams G, Turner R, Paul N, Shepherd L, Iglesias J. Gemcitabine, dexamethasone, cisplatin for relapsed or refractory non-Hodgkin's lymphoma (NHL): A NCIC Clinical Trials Group Study. Blood (ASH Annual Meeting Abstracts) 100[11 Part 1, abstr 3077], 778a, 2002.
  • Crump M, Leber B, Buckstein R, Kassis J, Matthews JH, Robinson S, Turner R, Hedley D, Petrenciuc O, McIntosh L, Seymour L. A randomized phase I clinical and biologic study of two schedules of the raf-kinase inhibitor BAY 43-9006 in patients with myelodsplastic syndrome or acute myeloid leukemia: a NCI Canada Clinical Trials Group Study. Blood (ASH Annual Meeting Abstracts) 100(11, abstr 4597), 267b, 2002.
  • Ernst S, Tannock I, Venner P, Winquist E, Reyno L, Walker H, Ding K, Elliott C, Parulekar W. Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer and pain: NCIC Clinical Trials Group study. Proc.Am.Soc.Clin.Oncol. 21(part 1), 177a, 2002.
  • Goldberg RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP. N9741: oxaliplatin or CP-11 + 5-fluorouracil/leucovorin or oxal + CPT-11 in advanced colorectal cancer. Initial toxicity and response data from a GI intergroup study. Proc.Am.Soc.Clin.Oncol. 21(part 1), 128a, 2002.
  • Goss G, Stewart D, Hirte H, Miller W, Major P, Batist G, Matthews S, Douglas L, Lorimer I, Seymour L. Initial results of part 2 of a phase I/II pharmacokinetics, pharmacodynamic and biological activity study of ZD1839 (Iressa): NCIC CTG IND.122. Proc.Am.Soc.Clin.Oncol. 21(part 1), 16a, 2002.
  • Goss G, Siu L, Powers J, Adams L, Trader K, Seymour L. NCIC CTG IND.147: A first in man dose escalation and pharmacokinetic study of the novel nucleoside analog OSI-7836 given in a day 1 and 8 schedule. Eur.J.Can. 38(Suppl 7), 25, 2002.
  • Gridelli C, Shepherd F, Perrone F, Illiano A, Piantedosi F, Robbiati S, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Findlay B, Hirsh V, Seymour L, Bezjak A, Gallo C. GEMVIN III: A phaseIII study of gemcitabine plus vinorelbine compared to cisplatin plus vinorelbine or gemcitabine chemotherapy for stage IIIB or IV non-small cell lung cancer: an Italo-Canadian study. Proc.Am.Soc.Clin.Oncol. 21(part 1), 292a, 2002.
  • Hamilton M, Wolf J, Demetri G, Seiden M, de Vries E, Eisenhauer E, Gelmon K, Hammond A, Rowinsky E, Hirte H, Rothenberg M, Verweij J, Sparreboom A, Versluis J, Culbertson J, Roberts L, Ptaszynski M, Santabarbara P. Phase I pharmacokinetics of NX211 (liposomal lurtotecan) in patients with solid tumors. Proc.Am.Soc.Clin.Oncol. 21(part 1), 90a, 2002.
  • Hayter C, Lukka H. Process and outcome of real-time radiotherapy review in a national study of prostate cancer radiotherapy. Int.J.Rad.Oncol.Biol.Phys. 54[2(suppl 1)], 276, 2002.
  • Hirte H, Siu L, Gelmon K, Britten C, Eisenhauer E, Fisher B, Ptaszynski M, Onetto N. Phase I study of NX211/cisplatin given as an intravenous infusion on days 1, 2 & 3 every 3 weeks in patients with solid cancer - an NCIC Clinical Trials Group study. Proc.Am.Soc.Clin.Oncol. 21(part 1), 98a, 2002.
  • Kirby S, Gertler S, Mason W, Watling C, Forsyth P, Aniagolu J, Stagg R, Powers J, Eisenhauer E. A phase II study of T138067-sodium in patients with malignant glioma. A trial of the NCI Canada Clinical Trials Group. Society for Neuro-Oncology, 2002.
  • Kristensen G, Vergote I, Stuart G, Izquierdo Delso M, Mirza MR, Aavall-Lundquist E, Lopez AB, Ridderheim M, Havesten H, Scheistroen M, Eisenhauer E. First line treatment of ovarian cancer FIGO stage IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Interim results of an NSGO-EORTC-NCIC CTG Gynaecological Cancer Intergroup phase III trial. Proc.Am.Soc.Clin.Oncol. 21(part 1), 202a, 2002.
  • Kwok A, Zee B. Group sequential design for a global tests statistic with mixed endpoints. Controlled Clin.Trials 23(2S), 94s, 2002.
  • Langer B, Bleiberg H, Labianca R, Shepherd L, Nitti D, Marsoni S, Tu D, Sargeant A, Fields A. Fluorouracil plus l-leucovorin versus observation after potentially curative resection of liver or lung metastases from colorectal cancer: results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc.Am.Soc.Clin.Oncol. 21(part 1), 149a, 2002.
  • Liu J, Tu D, Pater J. A comparative analysis of quality of life data from a clinical trial in patients with advanced breast cancer. Statistical Society of Canada, 2002.
  • MacDonald S, Dudgeon DJ, Bruera E, Gagnon B, Watanabe S, Allan S, Warr D, Savage C, Pater J. A phase III double-blind equivalence study of two different formulations of slow-release morphine followed by a randomization between dextromethorphan or placebo plus statex SR for chronic cancer pain relief in terminally ill patients. Proc.Am.Soc.Clin.Oncol. 21(part 1), 381a, 2002.
  • Madarnas Y, Fine S, Sawka C, Shepherd L, Tannock I, Tu D, Levine M. Body size, received dose-intensity and myelotoxicity of adjuvant chemotherapy in relation to outcome of premenopausal women with N1 breast cancer: results from a NCIC Clinical Trials Group randomized controlled trial. Eur.J.Can. 38(Suppl 3), S94, 2002.
  • Maroun J, Jonker D, Seymour L, Goel R, Kocha W, Cripps C, Dent S, Fisher B. Phase I/II study of triple drug combination of CPT-11, oxaliplatin and Tomudex in previously untreated patients with metastatic colorectal cancer. Eur.Soc.Med.Oncol., 2002.
  • Maroun J, Jonker D, Goel R, Cripps C, Dent S, Kocha W, Seymour L, Fisher B. A phase I/II study of triple drug combination of CPT-11, oxaliplatin and Tomudex in previously untreated patients with metastatic colorectal cancer: Final results. NCIC Clinical Trials Group, IND.135. Ann.Oncol. 13(Suppl. 5), 76, 2002.
  • Maroun J, Jonker D, Goel R, Cripps C, Dent S, Fisher B, Seymour L, Kocha W. Phase I study of triple drug combination of CPT-11, oxaliplatin and tomudex in previously untreated patients with metastatic colorectal cancer: NCIC Clinical Trials Group IND.135. Proc.Am.Soc.Clin.Oncol. 21(part 1), 143a, 2002.
  • Moore M, Winquist E, Pollak M, Chi K, Berry S, Ernst S, Douglas L, Baetz T, Fisher B, Seymour L. A randomized phase II study of two doses of ZD1839 in patients with hormone refractory prostate cancer: A NCI Canada Clinical Trials Group Study. Ann.Oncol. 13(Suppl. 5), 90, 2002.
  • Osoba D, Bezjak A, Zee B, Whitehead M, Pater JL. Correlation between target scores and anchor ratings on a health transition questionnaire. Clin Therapeutics 24(suppl 2): 26-27, 2002.
  • Piccart M, Bertelsen K, Stuart G, Cassidy J, Vergote I, Simonsen E, Swenerton K, Kaye S, Roy J, Baron B. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Ann.Oncol. 13(Suppl.5), 109, 2002.
  • Pollak M, Pritchard K, Whelan T, Bowman D, O'Reilly S, Burnell M, Shepherd L, Richardson P, Tu D. The NCIC CTG MA.14 experience with the gallbladder toxicity of octreotide pamoate (Oncolar) in a postmenopausal patient population undergoing adjuvant treatment for stage 1-3 breast cancer. Eur.J.Can. 38(Suppl 3), S93, 2002.
  • Pritchard K, O'Malley F, Andrulis I, Shepherd L, Tu D, Levine M, Bramwell V. Prognostic and predictive value of HER2/neu in a randomized trial comparing CMF to CEF in premenopausal women with axillary lymph node postive breast cancer (NCIC CTG MA.5). Proc.Am.Soc.Clin.Oncol. 21(part 1), 42a, 2002.
  • Pritchard K, Levine M, Bramwell V, Shepherd LE, Tu D, Paul N. A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA5. Breast Cancer Research and Treatment 76[Suppl 1], 2002.
  • Ribic C, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton P, Laurent-Puig P, Shepherd L, Tu D, Redston M, Gallinger S. Tumor microsatellite instability and the benefit of 5-FU based chemotherapy in stage II & III colon cancer: a pooled molecular reanalysis of randomized chemotherapy trials. Proc.Am.Soc.Clin.Oncol. 21(part 1), 128a, 2002.
  • Rothenberg M, Liu PY, Wilczynski S, Braly PS, Wadler S, Stuart G, Hannigan EV, Bonebrake AJ, Alberts DS, Markman M. Excellent 2-year survival in women with optimally-debulked ovarian cancer treated with intraperitoneal and intravenous chemotherapy: A SWOG-ECOG-NCIC study (S9619). Proc.Am.Soc.Clin.Oncol. 21(part 1), 203a, 2002.
  • Savage C, Pater J, Tu D, Norris B. He said/she said: how much agreement is there on symptoms between common toxicity criteria and quality of life? Proc.Am.Soc.Clin.Oncol. 21 (part 1), 386a, 2002.
  • Seymour L, Goss G, Stewart D, Hirte H, Miller W, Major P, Batist G, Matthews S, Lorimer I, Douglas L. A translational research study of ZD1839 at a dose of 750mg in patients with pretreated advanced or metastatic colorectal cancer: NCIC CTG IND.122. Ann.Oncol. 13 (Suppl. 5), 73, 2002.
  • Siu L, Batist G, Bangash N, MacLean M, McIntosh L, Miller WH, Oza A, Petrenciuc O, Seymour L. A phase I and pharmacokinetic study of BAY 38-3441 in a daily times five schedule. Ann.Oncol. 13 (Suppl. 5), 26, 2002.
  • Siu L, Batist G, Bangash N, MacLean M, McIntosh L, Miller WH, Oza A, Petrenciuc O, Seymour L. A phase I study of BAY 38-3441 given as a short infusion daily for five days every 3 weeks: a NCIC Clinical Trials Group study. Proc.Am.Soc.Clin.Oncol. 21(part 1), 99a, 2002.
  • Stewart DJ, Gelmon K, Chi K, Cripps C, Ayers D, Fry D, Douglas L, McIntosh L, Seymour L. Phase I/pharmacokinetic study of ZD0473 and docetaxel. Proc.Am.Soc.Clin.Oncol. 21(part 1), 106a, 2002.
  • Stewart KA, Chen C, Howson-Jan K, White D, Roy J, Kovacs M, Shustik C, Sadura A, Shepherd L, Ding K, Meyer RM, Belch A. A randomized phase II dose-finding trial of thalidomide and prednisone as maintenance therapy for myeloma following autologous stem cell transplant. Proc.Am.Soc.Clin.Oncol. 21(part 1), 269a, 2002.
  • Trudeau M, Walley B, Yelle L, Crump M, Pritchard K, Eisenhauer E, Matthews S. Temozolomide in metastatic breast cancer. A phase II trial of the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 21(part 2), 55b, 2002.
  • Tu D, Liu Y. A comparison of some statistical procedures for therapeutic equivalence clinical trials with survival endpoints. Joint ASA and Biometrics Meeting, 2002.
  • Tu D, Liu Y. A comparison of some statistical procedures for therapeutic equivalence clinical trials with survival endpoints. Proc Biopharmaceutical Statistics Section of the American Statistical Assoc, 3529-3534, 2002.
  • Vergote I, Kristensen G, Stuart G, Aavall-Lundquist E, Kaern J, Eisenhauer E on behalf of the NSGO-EORTC-GCG-NCIC CTG Intergroup Invesitgators. First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin vs. paclitaxel/carboplatin. Interim results of an NSGO-EORTC-GCG-NCIC CTG Gynaecological Cancer Intergroup phase III trial. Int Gyn Cancer Soc, 2002.
  • Voskoglou-Nomikos T, Pater J, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft and mouse allograft pre-clinical cancer models. Proc.Am.Soc.Clin.Oncol. 21(part 1), 91a, 2002.
  • E. Winquist, J. Knox, J.-P. Ayoub, L. Wood, N. Wainman, L. Pearce, A. Shah, E. Eisenhauer. Phase II study of the DNA Methyltransferase I (DNMT1) inhibitor MG98 in patients with renal cell carcinoma. A trial of the NCIC Clinical Trials Group. E J Can 38(Suppl 7), 141,2002.
  • Wolf J, Hamilton M, Eisenhauer E, Calvert A, Grimshaw R, Murtomaki E, Rusk J, Ptaszynski M, Onetto N. Pharmacokinetics of NX211 (liposomal lurtotecan) using a limited sampling model in a phase II trial of patients with ovarian cancer. Proc.Am.Soc.Clin.Oncol. 21(part 1), 122a, 2002.
  • Ackland S, Moore M, Jones M, Tu D, Simes RJ, Yuen J, Sargeant A, Dhillon H, Goldberg RM, Abdi E, Shepherd L. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Proc.Am.Soc.Clin.Oncol. 20, 132a, 2001.
  • Albain K, Green S, Ravdin P, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, Abeloff M, Norton L, Norton L, Lew D, Martino S, Osborne C. Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen is superior to T alone in postmenopausal, receptor(+), node(+) breast cancer: new findings from phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100). Proc.Am.Soc.Clin.Oncol. 20(part 1), 24a, 2001.
  • Barrett E, Verweij J, Gelmon K, Hirte H, Eisenhauer E, Rothenberg M, Demetri G, Seiden M, Hammond A, Rowinsky E, Hao D, Roberts L, Ptaszynski M. Phase I evaluation of NX211, a liposomal lurtotecan (topoisomerase I inhibitor), administered by four schedules: activity in patients with advanced epithelial ovarian cancer. International Conference on Ovarian Cancer, 2001.
  • Batist G, Siu L, MacLean M, Cammisana J, McIntosh L, Schwartz B, Seymour L. NCIC CTG IND.134: A phase I study of a novel glycoconjugated camptothecin (BAY 38-3441) given as a short infusion daily for five days every 3 weeks. Proc Am Assoc Cancer Res 42, 538, 2001.
  • Bezjak A, Shepherd FA, Seymour L, Sadura A, Tu D, Pater J, Giaccone G, Debruyne C, Ahmedzai S. Usefulness of quality of life information in a trial of a matrix metalloproteinase inhibitor marimastat. Quality of Life Research 10(3), 270, 2001.
  • Bezjak A, Heath C, Adam J, Payne D, Tsuji D, Dixon P, Palmer M, Pater J. How to interpret survival data from palliative studies in non-small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 20, 260b, 2001.
  • Bezjak A, Dixon P, Brundage M, Tu D, Pater J, Palmer M, Leong C, Mulroy L, Wright J, Grafton C, Blood P, Lochrin C. Randomized study of single versus fractionated radiotherapy in the palliation of non-small cell lung cancer: NCIC CTG SC.15. International Journal of Radiation Oncology, Biology, Physics 51[3], 20, 2001.
  • Bezjak A, Brundage M, Dixon PF, Palmer M, Pater J, Tu D, Grafton C,Blood P, Leong C, Mulroy LA, Wright J. Is more better? Quality of life results of a Canadian palliative radiotherapy trial in patients with unresectable lung cancer (NCIC CTG SC.15). Quality of Life Research 10(3), 211, 2001.
  • Brundage M, Leis A, Bezjak A, Feldman-Stewart D, Degner L, Velji K, Zetes-Zanatta L, Tu D, Ritvo P, Pater J. Cancer patients' preferences for communicating quality of life information: a qualitative study. International Society for Quality of Life Research, 2001.
  • Brundage M, Bezjak A, Degner L, Feldman-Stewart D, Leis A, Pater J, Ritvo P, Tu D, Velji K. Cancer patients' preferences for communicating quality of life information: results of focus group discussions. Presented: Canadian Association Radiation Oncology, 2001.
  • Connors J, Klimo P, Adams G, Burns B, Cooper I, Meyer R, O'Reilly S, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B. Comparison of hybrid MOPP/ABV vs alternating MOPP/ABVD chemotherapy for advanced Hodgkin's lymphoma: long-term outcomes, late toxicity and implications of complete vs incomplete response. International Syposium on Hodgkin's Lymphoma, 2001.
  • Connors J, Kouroukis T, Belch A, Crump M, Imrie K, Klasa R, Lohmann R, Powers J, Eisenhauer E. Flavopiridol for mantle cell lymphoma: moderate activity and frequent disease stabilization. Blood (ASH Annual Meeting Abstracts), 2001.
  • Crump M, Tu D, Shepherd L, Levine E, Bramwell V, Pritchard K. Risk of acute leukemia following adjuvant epirubicin-based adjuvant chemotherapy for breast cancer. San Antonio Breast Cancer Symposium, 2001.
  • Crump M, Gluck S, Stewart D, Levine M, Pritchard K, Kirkbride P, Dancey J, O'Reilly S, Shore T, Couban S, Girouard C, Abu-Zahra H, Tu D, Marlin S, Shepherd L. A randomized trial of high-dose chemotherapy with autologous peripheral blood stem cell support compared to standard therapy in women with metastatic breast cancer: a NCIC Clinical Trials Group study. Proc.Am.Soc.Clin.Oncol. 20, 21a, 2001.
  • Dent S, Arnold A, Stewart D, Gertler S, Ayoub J, Batist G, Goss G, Neville A, Soulieres D, Jolivet J, McIntosh L, Seymour L. NCIC CTG IND 120: phase II study of Troxacitabine (BCH-4556) in patients with advanced non-small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 20, 259b, 2001.
  • Dixon P, Bezjak A, Brundage M, Tu D, Palmer M, Pater J, Lochrin C, Leong C, Mulroy L, Wright J, Blood P, Grafton C. NCIC CTG phase III trial of single versus 5 fraction radiotherapy in the palliation of non-small cell lung cancer. Canadian Association Radiation Oncology, 2001.
  • Donehower RC, Stewart D, Eisenhauer E, Wainman N, Moore M, Bonfils C, Reid G. A phase I and pharmacokinetic study of MG98, a human DNA methyltransferase mRNA inhibitor, given as a 2-hour twice weekly infusion 3 out of every 4 weeks. Clinical Cancer Research 7(Suppl), 3680s, 2001.
  • Douillard J, Petersen V, Shepherd F, Paz-Ares L, Arnold A, Tonato M, Ottaway J, Davis M, Van Vreckem A, Humphrey J, Seymour L. Randomised phase II study of BMS-275291 versus placebo in patients with stage IIIb or IV non small cell lung cancer receiving paclitaxel + carboplatin: NCIC Clinical Trials Group BR.18. Eur.J.Can. 37(suppl 6), S19, 2001.
  • Eisenhauer E, Verweij J, Rothenberg M, Demetri G, de Vries E, Gelmon K, Hirte H, Loos W, Seiden M, Sparreboom A, Cameron T, Hamilton M, Ptaszynski M, Onetto N. Phase I evaluation of liposomal topoisomerase I inhibitor, NX211, administered by three schedules to patients with advanced solid tumors. Proc.Am.Soc.Clin.Oncol. 20, 103a, 2001.
  • Gelmon K, Belanger K, Britten C, Soulieres D, Janke S, Dionne J, Powers J, Seymour L, McNally J. A phase I study of T900607 given once every three weeks to patients with advanced refractory cancer. A NCIC Clinical Trials Group Study (NCIC CTG-IND.130). Eur.J.Can. 37(suppl 6), S30, 2001.
  • Gelmon K, Rothenberg M, Verweij J, Hirte H, Demetri G, Sparreboom A, Eisenhauer E, de Vries E, Warren S, Hamilton M, Ptaszynski M, Onetto N. NX 211, a liposomal camptothecin: phase I and pharmacokinetic results. Cancer Investigation 19(Suppl 1), 61-63, 2001.
  • Gelmon K, Stewart D, Ayers D, Fry D, Douglas L, McIntosh L, Seymour L. A phase I study of ZD0473 and docetaxel given once every three weeks in patients with advanced refractory cancer. A NCIC Clinical Trials Group study (NCIC CTG-IND.131). Eur.J.Can. 37(Suppl 6), S72, 2001.
  • Gluck S, Crump M, Stewart D, Levine M, Pritchard K, Kirkbride P, Dancey J, O'Reilly S, Shore T, Couban S, Girouard C, Abuzara H, Tu D, Marlin S, Shepherd L. A randomized trial of high-dose chemotherapy with autologous peripheral blood stem cell support compared to standard chemo therapy in women with metastatic breast cancer: a NCIC Clinical Trials Group study. Eur.J.Can. 37(6), S285, 2001.
  • Goss G, Hirte H, Batist G, Miller W, Stewart D, Matthews S, Seymour L. NCIC CTG IND.122: a phase I/II pharmacokinetics and pharmacodynamic study of ZD1839 (Iressa'TM'). Final phase I results and preliminary phase II results of ZD1839 (750 mg/day) in patients with colorectal cancer. Eur.J.Can. 37(suppl 6), S289, 2001.
  • Goss G, Hirte H, Lorimer I, Miller W, Stewart DJ, Batist G, Matthews S, Douglas L, Seymour L. Final results of the dose escalation phase of a phase I pharmacokinetics, pharmacodynamic and biological activity study of ZD1839: NCIC CTG IND 122. Proc.Am.Soc.Clin.Oncol. 20, 85a, 2001.
  • Hirte HW, Vergote IB, Jeffrey JR, Grimshaw RN, Stuart GC, Mendiola C, Vorobiof DA, Carey MS, Coppieters S, Schwartz B, Tu D, Sadura A, Seymour L. An international multicentre phase III study of BAY 12-9566 versus placebo in patients with advanced ovarian cancer responsive to primary surgery/paclitaxel + platinum containing chemotherapy. South African Society of Medical Oncology & South African Society of Radiation Oncology Congress, 2001.
  • Hirte H, Vergote I, Jeffrey J, Grimshaw R, Stuart G, Mendiola C, Vorobiof D, Carey M, Coppieters S, Schwartz B, Tu,D, Sadura A, Seymour L. An international multicentre phase III study of BAY 12-9566 versus placebo in patients with advanced ovarian cancer responsive to primary surgery/paclitaxel + platinum containing chemotherapy. Proc.Am.Soc.Clin.Oncol. 20, 211a, 2001.
  • Hirte H, Miller W, Major P, Goss G, Stewart D, Batist G, Douglas L, Matthews S, Lorimer I, Seymour L. Initial results of part 2 of a phase I/II pharmacokinetics pharmacodynamic, and biological activity study of ZD1839 (Iressa 'TM'): NCIC CTG IND.122. Clinical Cancer Research 7(suppl), 3761s, 2001.
  • Lorimer I, Parolin D, Robinson S, Goss G, Hirte H, Miller W, Stewart D, Batist G, Douglas L, Matthews S, Seymour L. NCIC CTG IND.122: Immunohistochemical analysis of tumor biopsy specimens from patients undergoing treatment with ZD1839. Clinical Cancer Research 7(suppl), 3708s, 2001.
  • Madarnas Y, Fine S, Sawka C, Shepherd L, Tannock I, Tu D, Levine M.Body size, received dose-intensity and myelotoxicity of adjuvant chemotherapy in relation to outcome of premenopausal women with N1 breast cancer: results from a NCIC Clinical Trials Group randomized controlled trial. North American Association for the Study of Obesity 9, 151S, 2001.
  • Madarnas Y, Fine S, Sawka C, Shepherd L, Tannock I, Tu D, Levine M. Body size, received dose-intensity and myelotoxicity of adjuvant chemotherapy in relation to outcome of premenopausal women with N1 breast cancer: results from a NCIC Clinical Trials Group randomized controlled trial. Breast Cancer Research and Treatment 69, 319, 2001.
  • Maroun J, Jonker D, Seymour L, Goel R, Kocha W, Fisher B. Phase I study of triple drug combination of CPT-11, oxaliplatin and tomudex in previously untreated metastatic colorectal cancer: NCIC Clinical Trials Group, IND.135. Eur.J.Can. 37(suppl 6), S295, 2001.
  • Maroun J, Goel R, Stewart DJ, Tomiak E, Belanger K, Soulieres D, Charpentier D, Seymour L, Matthews S, Jimeno J, Guzman C. Phase I study of aplidine in a 5 day bolus q 3 weeks in patients with solid tumors and lymphomas. Proc.Am.Soc.Clin.Oncol. 20, 83b, 2001.
  • Moore M, Chi K, Ernst S, Belanger K, Tannock I, Bjarnason G, Stewart D, Goel R, Ruether JD, Jolivet J, McIntosh L, Seymour L. A phase II study of troxacitabine in patients with advanced and/or metastatic renal cell carcinoma. NCIC CTG IND.119. Proc.Am.Soc.Clin.Oncol. 20, 193a, 2001.
  • O'Connell M, Skillings J, Windschitl H, Shepherd L, Sargent D, Krook J, Tria Tirona M, Morton R, Rowland K, Rubin J, Kugler J. Phase III trial of high dose levamisole + 5-fluorouracil + leucovorin as adjuvant treatment for high risk colon cancer: an NCCTG/NCIC study. Proc.Am.Soc.Clin.Oncol. 20, 132a, 2001.
  • Parulekar W, Trudeau M, Shepherd L, Ottaway J, Day A, Franssen E, Bramwell V, Levine M, Pritchard K. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high risk premenopausal breast cancer patients: analysis of a NCIC Clinical Trials Group phase III study. Proc.Am.Soc.Clin.Oncol. 20, 25a, 2001.
  • Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Marks L, Cirrincione C, Hurd D, Norton L. Updated results of a prospective, randomized comparison of two doses of combination alkyating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: CALGB 9082/SWOG 9114/NCIC MA-13. Proc.Am.Soc.Clin.Oncol. 20, 21a, 2001.
  • Raymond E, Paz-Ares L, Izquierdo M, Belanger K, Maroun J, Bowman A, Anthoney A, Jodrell D, Armand J-P, Cortes-Funes H, Germa-Lluch J, Twelves C, Celli N, Guzman C, Jimeno J. Phase I trials with aplidine, a new marine derived anticancer compound. Eur.J.Can. 37(Suppl 6), S32, 2001.
  • Reyno L, Seymour L, Tu D, Pearce L, Dent S, Gelmon K, Walley B, Pritchard K, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Lebwohl D. Phase III study of DPPE (BMS217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: a NCIC Clinical Trials Group study. Proc.Am.Soc.Clin.Oncol. 20, 30a, 2001.
  • Seymour L, Siu L, Batist G, Cammisana J, MacLean M, McIntosh L, Petrenciuc O. A phase I study of BAY 38-3441 given as a short infusion daily for five days every 3 weeks. A NCIC Clinical Trials Group Study. Eur.J.Can. 37(suppl 6), S73, 2001.
  • Shepherd F, Giaccone G, Debruyne C, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Zee B, Sadura A, Seymour L. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer following response to first-line chemotherapy: an NCIC CTG and EORTC study. Proc.Am.Soc.Clin.Oncol. 20, 4a, 2001.
  • Shepherd L. The role of neu/erb B-2 as a predictive factor for differential response to adjuvant chemotherapy and tamoxifen: The NCIC Clinical Trials Group experience in retrospective paraffin embedded tissue collection. Reasons for Hope Scientific Conference, 2001.
  • Shepherd L, Parulekar W, Day A, Ottaway J, Bramwell V, Levine M, Pritchard K. Weight gain during adjuvant therapy in high risk pre/perimenopausal breast cancer patients: analysis of a NCIC Clinical Trials Group phase III study. Proc.Am.Soc.Clin.Oncol. 20, 36a, 2001.
  • Shustik C, Belch A, Meyer R, Robinson S, Rubin S, Barr R, Kovacs M, Wilson J, Shepherd L, Djurfeldt M, Zee B. Melphalan-dexamethasone is not superior to melphalan-prednisone as induction therapy in multiple myeloma. Proc.Am.Soc.Clin.Oncol. 20, 298a, 2001.
  • Sidhu K, Fyles A, Eisenhauer E, Shelley W, Stanimir G, Wallwiener D, Ghatage P, Elit L, Bastert G, Powers J, Pouliot J, Oza A. Phase II study of the aromatase inhibitor letrozole in endometrial carcinoma - NCIC CTG IND 126. Proc.Am.Soc.Clin.Oncol. 20, 192b, 2001.
  • Stewart D, Gelmon K, Ayers D, Fry D, Douglas L, McIntosh L, Seymour L. A phase I study of ZD0473 and docetaxel given once every three weeks in patients with advanced refractory cancer. A NCIC Clinical Trials Group study (NCIC CTG-IND.131). Clinical Cancer Research 7(suppl), 3751s, 2001.
  • Tu D, Liu Y. Statistical procedures for the equivalence of two survival rates based on the censored data. Proceedings of the International Statistical Institute 3, 221-222, 2001.
  • Tu D, Zee B, Lam D. Treatment comparisons in stratified clinical trials with survival endpoints. Controlled Clin.Trials 22(2S), 96S, 2001.
  • Vandenberg T, Gelmon K, Panasci L, Crump M, Norris B, Tomiak A, Shenkier T, Lee C, Martin L, Matthews S, Seymour L, Douglas L. A phase II trial of ZD0473 in patients with metastatic breast cancer a NCIC Clinical Trials Group Study (NCIC CTG-IND 129). Proc.Am.Soc.Clin.Oncol. 20, 58b, 2001.
  • Vandenberg T, Gelmon K, Panasci L, Crump M, Norris B, Tomiak A, Shenkier T, Douglas L, Matthews S, Seymour L. A phase II trial of ZD0473 in patients with metastatic breast cancer. A NCIC Clinical Trials Group study (NCIC CTG-IND.129). Eur.J.Can. 37(suppl 6), S194, 2001.
  • Winquist E, Moore M, Chi K, Ernst S, Hirte H, Iscoe N, Venner P, Huan S, Powers J, Seymour L, Boucher T. NCIC CTG IND.128. A phase II study of a farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract failing prior chemotherapy. Proc.Am.Soc.Clin.Oncol. 20, 197a, 2001.
  • Yee K, Pater J, Pho L, Zee B. Enrollment of elderly patients in cancer treatment trials in Canada. Proc.Am.Soc.Clin.Oncol. 20, 392a, 2001.
  • Bakal J, Tu D. Nonparametric regression analyses to identify prognostic factors for women with early breast cancer. Statistical Society of Canada, 2000.
  • Dixon P, Brundage M, Palmer M, Zee B, Pater J, Leong C, Mulroy L, Wright J, Grafton C, Blood P, Lochrin C. Characteristics of lung cancer patients entered on a Canadian palliative radiotherapy study (NCIC Clinical Trials Group SC.15 study). Lung Cancer 29 (Suppl 1), 171, 2000.
  • Brundage M, Zee B, Palmer M, Bezjak A, Dixon P, Pater J. The use of a patient symptom diary to assess palliation in lung cancer patients: agreement with physician assessment and EORTC QLQ scores. Quality of Life Research 9(3), 274, 2000.
  • Butler L, Bezjak A, Carey M, Bacon M, Zee B, Stewart D, Brundage M. Determining the relationship between toxicity and quality of life using OV10, an international ovarian cancer chemotherapy trial. Quality of Life Research 9(3), 287, 2000.
  • Davis A, Moore M, Gelmon K, Siu L, Brittain M, Beaulieu N, Bonfils C, Firby P, Klamut H, Eisenhauer E. Phase 1 and pharmacodynamic study of human DNA methyltransferase (MeTase) antisense oligodeoxynucleotide (ODN), MG98, administrered as 21-day infusion q4 weekly. Clinical Cancer Research 6(Suppl), 4517, 2000.
  • Eisenhauer E, Gelmon K, Hirte H, Fisher B, Walsh W, Ptaszynski M, Onetto N, Zee B. Predictors of inter-patient toxicity in a phase I trial of NX211 given in a daily x 3 intravenous infusion schedule every 3 weeks. Clinical Cancer Research 6(Suppl), 4514, 2000.
  • El-Sayed S, Nabid A, MacKenzie R, Gelinas M, Hay J, Shelley W, Berthelet E, Lau H, Duncan G, Epstein J, James K, Tu D, Burns P, Ottaway J. Prophylaxis of radiation associated mucositis in patients with head and neck cancer: results of a double blind phase III trial evaluating the clinical efficacy of an antimicrobial lozenge and utilizing the newly validated mucositis scoring system. Int.J.Rad.Oncol.Biol.Phys. 48, 321, 2000.
  • Gelmon K, Eisenhauer E, Reyno L, Hirte H, Britten C, Lee U, Fisher B, Ayers D, D'Aloisio S, Stafford S, Hamilton M, Ptaszynski M, Onetto N. Phase I study of NX211 (liposomal lurtotecan) given as an intravenous infusion on days 1, 2, & 3 every 3 weeks in patients with solid tumours -- an NCIC Clinical Trials Group study. Proc Am Assoc Cancer Res, 2000.
  • Goel R, Chouinard E, Stewart D, Huan S, Hirte H, Stafford S, Walsh W, Waterfield B, Roach J, Schwartz B, Matthews S, Seymour L. Phase I/pharmacokinetic study of the metalloproteinase and angiogenesis inhibitor Bayer 12-9566 in conjunction with 5-fluorouracil/folinic acid. Proc.Am.Soc.Clin.Oncol. 19, 232a, 2000.
  • Goss G, Lorimer I, Miller W, Hirte H, Stewart D, Batist G, Matthews S, Averbuch S, Seymour L. A phase I, dose escalation, pharmacokinetics and pharmacodynamic study of ZD1839: NCIC CTG IND.122. Clinical Cancer Research 6(Suppl), 4543, 2000.
  • Goss G, Hirte H, Batist G, Stewart D, Miller W, Lorimer I, Abugaber A, Matthews S, Seymour L. NCIC CTG IND.122: A two-part phase I pharmacokinetic and pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Proc.Am.Soc.Clin.Oncol. 19, 225a, 2000.
  • Hamilton M, Sparreboom A, Loos W, Verweij J, Demetri G, Gelmon K, Eisenhauer E, Warren S, Ptaszynski M. Pharmacokinetics of NX 211 (liposomal lurtotecan) in phase I patients with solid tumours. Clinical Cancer Research 6(Suppl), 4513, 2000.
  • Hirte H, Vergote I, Jeffrey J, Grimshaw R, Stuart G, Mendiola C, Vorobiof D, Carey M, Coppieters S, Tu D, Sadura A, Seymour L. An international multicentre phase III study of BAY 12-9566 versus placebo in patients with advanced ovarian cancer responsive to primary surgery/ paclitaxel + platinum containing chemotherapy. Ann.Oncol. 11, 714, 2000.
  • Kraut M, Rusch V, Crowley J, Gandara D. Induction chemoradiation plus surgical resection is feasible and highly effective treatment for pancoast tumors: initial results of SWOG 9416 (intergroup 0160) trial. Proc.Am.Soc.Clin.Oncol. 19, 487a, 2000.
  • Marlin S, Fourt M, Koski T, Sinnott C, Degendorfer P, Green D. The assessment of educational needs and design of educational programs for ethics and regulatory aspects of NCIC Clinical Trials Group (NCIC CTG) Trials. Controlled Clin.Trials 21(2S), 131s, 2000.
  • Maroun J, Belanger K, Seymour L, Soulieres D, Charpentier D, Goel R, Stewart D, Tomiak E, Jimeno J, Matthews S. Phase I study of aplidine in a 1 hour daily infusion x 5 q 3 weeks in patients with solid tumors and low and intermediate grade Non Hodgkin's Lymphomas. A NCIC Clinical Trials Group study. Ann.Oncol. 11(Suppl 4), 2000.
  • Maroun J, Belanger K, Seymour L, Soulieres D, Charpentier D, Goel R, Stewart D, Tomiak E, Jimeno J, Matthews S. Phase I study of aplidine in a 5 day bolus q 3 weeks in patients with solid tumors and lymphomas. Clinical Cancer Research 6(Suppl), 4509, 2000.
  • Moore M, Siu L, Oza A, MacLean M, Fisher B, Jordan C, Slapak C, Seymour L. A phase I study of vinorelbine plus multidrug resistance inhibitor LY 335979 in patients with advanced solid tumors. Clinical Cancer Research 6(Suppl), 4504, 2000.
  • Moore M, Hamm J, Eisenberg P, Dagenais M, Hagan K, Fields A, Greenberg B, Schwartz B, Ottaway J, Zee B, Seymour L. A comparison between gemcitabine and the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced pancreatic cancer. Proc.Am.Soc.Clin.Oncol. 19, 240a, 2000.
  • Ottaway J, Fischer P, Seymour L, Correa R, Day A. Data collection using remote data entry in the cooperative group setting: NCIC CTG experience. Controlled Clin.Trials 21(2S), 114s, 2000.
  • Oza A, Eisenhauer E, Swenerton K, Elit L, Ghatage P, Carey M, Faught W, McIntosh L, Dorr A, Holmlund J. Phase II study of c-raf kinase antisense oligonucleotide ISIS 5132 in patients with recurrent ovarian cancer (NCIC IND.116). Clinical Cancer Research 6(Suppl), 4572, 2000.
  • Palmer M, Broekhoven M, Garrah A, Tu D. CTASSIST: A computer program for patient randomization and tracking of drug distribution. Controlled Clin.Trials 21(2S), 110s, 2000.
  • Palmer M, Zee B, Bezjak A, Pater J. The timing of baseline quality of life in clinical trials. Quality of Life Research 9(3), 337, 2000.
  • Paul N, Roche K. Screening patients for clinical trials: factors affecting the ratio of time spent to accrual. Controlled Clin.Trials 21(2S), 95s, 2000.
  • Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami RL, Stuart G, Tu D. A clinical trial comparing concurrent cisplatin and radiation therapy versus radiation alone for locally advanced squamous cell carcinoma of the cervix carried out by the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 19, 378a, 2000.
  • Roche K, Paul N, Whitehead M, Walker H, Pater J, Zee B. Predicting trial complexity and time consumption: further results of the workload measurement study of the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 19, 449a, 2000.
  • Rothenberg M, Gelmon K, Eisenhauer E, Hirte H, Vermeulen W, Naujoks R, Hamilton M, Warren S, Onetto N, Demetri G. Phase I evaluation of liposomal topoisomerase I inhibitor, NX 211, given on days 1, 2, 3 or days 1, 8 every 3 weeks to patients with advanced solid tumors. Proc.Am.Soc.Clin.Oncol. 19, 198a, 2000.
  • Sargent D, Goldberg RM, Macdonald J, Labianca R, Haller D, Shepherd L, Seitz J, Francini G. Adjuvant chemotherapy for colon cancer is beneficial without significantly increased toxicity in elderly patients: results from a 3351 patient meta-analysis. Proc.Am.Soc.Clin.Oncol. 19, 241a, 2000.
  • Seymour L, Hirte H, Stafford S, Goss G, Miller W, Belfer H, Batist G, Hanna P, Matthews S, Averbuch S. NCIC CTG IND.122: A multicentre phase I dose-escalation study of ZD1839 with pharmacodynamic endpoints -- feasibility of serial tumour sampling. Ann.Oncol. 11(Suppl 4), 2000.
  • Shepherd FA, Arnold A, Neville A, Cormier Y, Davis M, Wierzbicki R, Dancey J, Rusthoven J, Fisher B, Eisenhauer E. Phase II study of MTA (Alimata) and cisplatin in patients with advanced non-small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 19, 507a, 2000.
  • Siu L, Gelmon K, Moore M, Britten C, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman J, Reid G, Eisenhauer E. A phase I and pharmacokinetic study of the human DNA methyltransferase (MeTase) antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Proc.Am.Soc.Clin.Oncol. 19, 189a, 2000.
  • Stewart D, Donehower RC, Eisenhauer E, Wainman N, Moore M, Bonfils C, Reid G. A phase I and pharmacokinetic study of MG98, a human DNA methyltransferase (MeTasse) antisense oligonucleotide, given as a 2-hour twice weekly infusion 3 out of every 4 weeks. Clinical Cancer Research 6(Suppl), 4571, 2000.
  • Trudeau M, Crump M, Latreille J, Pritchard K, Palmer M, Tu D, Shepherd L, Shear N, Shapiro L, Oldfield S, Burnell M, Vandenberg T, Gelmon K, Blackstein M, Noel D. Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer. A phase I/II study of the NCIC Clinical Trials Group. Presented: 23rd Annual Breast Cancer Symposium, 2000.
  • Walker H, Stuart G, Bacon M, Eisenhauer E, Bacon E, Tu D, Zee B. Comparative cost-effectiveness of paclitaxel-cisplatin vs cyclophosphamide-cisplatin in women with advanced epithelial ovarian cancer: results from a randomized trial. Proc.Am.Soc.Clin.Oncol. 19, 379a, 2000.
  • Williams T, Pentz L, Bacon M, Mak M, Cleary J, Bishop C, Pieters-Mohammed B, Sears C, Pho L, Pater J. Evaluating the effectiveness of a "no exceptions" policy in eligibility checklist screening. Controlled Clin.Trials 21(2S), 109s, 2000.
  • Zee B. Design issues of a phase III randomized trial incorporating a phase II portion. Statistical Society of Canada, 2000.
  • Zee B, Dancey J, Bezjak A, Seymour L, Moore M, Ottaway J. Pain score from visual-analogue scale versus quality of life questionnaire in pancreatic cancer trials. International Society for Quality of Life Research, 2000.
  • Zee B, Mak R, Tu D. Multiple imputation method for EORTC QLQ-C30 with missing data in cancer clinical trials. Quality of Life Research 9(3), 247, 2000.
  • Bacon M, Zee B, James K, Stuart G, Soroka D, Walsh W, Bacon E. A comparison of the neurological toxicities of cisplatin-paclitaxel and cisplatin-cyclophosphamide. Proc.Am.Soc.Clin.Oncol. 18, 369a,1999.
  • Baker S, Stephenson J, Goetz A, Belanger K, Moore M, Seymour L, Yee L, Chu E, Hunt W, Jolivet J, Rowinsky E. Determinants affecting B-L-dioxolane-cytidine (BCH-4556) exposure and relationship with toxicity in phase I trials. Proc.Am.Soc.Clin.Oncol. 18, 197a, 1999.
  • Belanger K, Tozer R, Burdette-Radoux S, Davis M, Lohmann R, Zee B, Wainman N, Seymour L. Results of a randomized phase II study of two schedules of bryostatin-1 in patients with malignant melanoma: Experience with the multivariate stopping rule. Eur.J.Can. 35(Suppl 4), S374, 1999.
  • Belanger K, Moore M, Siu L, Dionne J, McLean M, Hunt W, Jolivet J, Wainman N, Seymour L. A phase I study of the l-nucleoside analogue B-L-dioxolane-cytidine (BCH-4556) given as a 30 minute infusion every 21 days. Proc.Am.Soc.Clin.Oncol. 18, 197a, 1999.
  • Bjarnason G, Charpentier D, Wong R, Goel R, Smith M, Abugaber A, Matthews S, Seymour L. NCIC CTG IND.98: A phase I dose escalation study of raltitrexed (Tomudex) plus doxorubicin in patients with advanced cancer. Eur.J.Can. 35(Suppl 4), S290, 1999.
  • Chouinard E, Goel R, Hirte H, Stewart D, Hurak S, Waterfield B, Matthews S, Elias I, Seymour L. A phase I interaction study between BAY 12-9566 and doxorubicin in cancer patients. Proc Am Assoc Cancer Res, 1999.
  • Crump M, Meyer R, Couban S, Rudinskas L, Matthews S, Eisenhauer E. A phase II study of topotecan + etoposide in patients with intermediate grade non-Hodgkin's lymphoma. International Conference on Malignant Lymphoma, 1999.
  • Crump M, Meyer R, Couban S, Rudinskas L, Hoskins P, Zanke B, Gluck S, Maksymiuk A, Matthews S, Eisenhauer E. Phase II study of topotecan + etoposide in patients with aggressive histology non-hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 94[10 Suppl 1, abstr 2353] 526a, 1999.
  • Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. The palliative effect of chemotherapy in metastatic breast cancer: Objective tumour response is associated with symptom improvement. Eur.J.Can. 35(Suppl 4), S314, 1999.
  • Gelmon K, Eisenhauer E, Reyno L, Fisher B, Ayers D, Lee U, Hirte H, D'Aloisio S, Hurak S, Hamilton M, Ptaszynski M, Onetto N. Phase I study of NX211 given as an intravenous infusion on days 1, 2 & 3 every 3 weeks in patients with solid tumors -- an NCIC Clinical Trials Group study. Clinical Cancer Research 5(11) Suppl, 3794, 1999.
  • Goel R, Hirte H, Chouinard E, Moore M, Ottaway J, Sadura A, Coppieters S, Elias I, Schwartz B, Seymour L. BAY 129566 - A selective matrix metalloproteinase inhibitor with distinct pharmacologic and toxicity profiles: update on NCIC CTG experience in 5 phase I and III trials. Clinical Cancer Research 5(11)Suppl, 3740, 1999.
  • Goel R, Hirte H, Major P, Waterfield B, Holohan S, Bennett K, Elias I, Seymour L. Clinical pharmacology of the metalloproteinase and angiogenesis inhibitor Bayer 12-9566 in cancer patients. Proc.Am.Soc.Clin.Oncol. 18, 160a, 1999.
  • Goss G, Hirte H, Stewart D, Batist G, Miller WH, Lorimer I, Averbuch S, Ochs J, Blackledge G, Feld A, Matthews S, Seymour L. A novel two-part phase I, dose seeking pharmacokinetic and pharmacodynamic study of ZD1839, a potent and specific inhibitor of epidermal growth factor receptor tyrosine kinase. Clinical Cancer Research 5(11) Suppl, 3841, 1999.
  • Hirte H, Stewart D, Goel R, Chouinard E, Huan S, Elias I, Matthews S, Seymour L. NCIC CTG IND 113: Two phase I dose escalation pharmacokinetic studies of BAY 12-9566 in combination with either doxorubicin or modulated 5-fluorouracil. Eur.J.Can. 35(Suppl 4), S283, 1999.
  • Hoskins P, Eisenhauer E, Fisher B, Vergote I, Dubuc J, Stuart G, Grimshaw R, Plante M, Vermorken J, Oza A. Sequential couplets of cisplatin/topotecan and cisplatin/paclitaxel as first-line therapy for advanced epithelial ovarian cancer: an NCIC Clinical Trials Group phase II study. Proc.Am.Soc.Clin.Oncol. 18, 357a, 1999.
  • Knowling M, Browman G, Cooke A, Siu L, Seymour L, Cripps C, Matthews S, Rodgers A. Phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer. Proc.Am.Soc.Clin.Oncol. 18, 396a, 1999.
  • Kwok A. Bivariate endpoint design in clinical trials. Controlled Clin.Trials 20(2S), 59s, 1999.
  • Lathia C, Seymour L, Grochow L, Eckhardt G, Erlichman C, Hirte H, Goel R, Elias I, Humphrey R. BAY 12-9566, a selective, non-peptidic biphenyl inhibitor of matrix metalloproteases: summary of phase I clinical and pharmacokinetic results. Clinical Cancer Research 5(11) Suppl, 3731, 1999.
  • Marks LB, Fitzgerald TJ, Laurie F, Glicksman AS, Rosner GL, Vredenburgh J, Shpall EJ, Crump M, Norton L, Peters W. Preliminary analysis of radiotherapy data from CALGB 9082: variability of treatment fields for local/regional breast cancer and the impact of high dose chemotherapy on the ability to deliver radiation therapy. Int J Radiat Oncol Biol Phys 45[3 Suppl,abstr 94], 195-196, 1999.
  • Moore M, Belanger K, Dionne J, McLean M, Jolivet J, Proulx L, Baker S, Wainman N, Seymour L. Troxacitabine (BCH-4556) a nucleoside analog with distinct stereochemical, pharmacologic and pharmacokinetic characteristics is tolerable and active in phase I studies: the NCIC CTG experience. Clinical Cancer Research 5(11) Suppl, 3729, 1999.
  • Moore M, Belanger K, Jolivet J, Baker S, Wainman N, Seymour L. NCIC CTG IND 103: A phase I and pharmacokinetic study of the novel L-nucleoside analogue troxacitabine (BCH-4556) given every 21 days. Eur.J.Can. 35(Suppl 4), S284, 1999.
  • Morrison VA, Rai K, Peterson B, Kolitz J, Elias I, Hines J, Shepherd L, Larson R, Schiffer C. Therapy-related myelodysplastic syndrome or acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with chlorambucil, fludarabine, or fludarabine + chlorambucil: an intergroup study (cancer and Leukemia Group B (CALGB) 9011). Proc.Am.Soc.Clin.Oncol. 18, 9a, 1999.
  • O'Sullivan B, Davis A, Canadian Sarcoma Group, Sadura A, James K, Zee B. Effect on radiotherapy field sizes in a recently completed Canadian Sarcoma Group and NCI Canada Clinical Trials Group randomized trial comparing pre-operative and post-operative radiotherapy in extremity soft tissue sarcoma. Am Soc Therapeutic Rad Oncol, 1999.
  • O'Sullivan B, Davis A, Bell R, Catton C, Turcotte R, Wunder J, Chabot P, Hammond A, Benk V, Isler M, Freeman C, Goddard K, Kandel R, Sadura A, James K, Zee B. Phase III randomized trial of preoperative versus postoperative radiotherapy in the curative management of extremity soft tissue sarcoma. A Canadian Sarcoma Group and NCI Canada Clinical Trials Group study. Proc.Am.Soc.Clin.Oncol. 18, 535a, 1999.
  • Paul N, Roche K, Smuck B, Walker H, Zee B, Whitehead M. Lessons learned from conducting a study to measure workload of cancer clinical trials. Controlled Clin.Trials 20(2S), 57s, 1999.
  • Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, Marks L, Cirrincione C, Wood W, Henderson I, Hurd D, Norton L. A prospective, randomized comparison of two doses of combination alkyating agents as consolidation after CAF in high-risk primary breast cancer involving 10 or more axillary lymph nodes: preliminary results of CALGB 9082/ SWOG 9114/ NCIC MA.13. Proc.Am.Soc.Clin.Oncol. 18, 1a,1999.
  • Seymour L. Phase I studies with antimetabolites: Should dose escalation be driven by considerations other than body surface area? Eur.J.Can. 35(Suppl 4), S284, 1999.
  • Tozer RG, Burdette-Radoux S, Belanger K, Davis M, Lohmann R, Rusthoven J, Wainman N, Seymour L. NCIC CTG randomized phase II study of two schedules of bryostatin 1 (NSC339555) in patients with advanced malignant melanoma. Proc.Am.Soc.Clin.Oncol. 18, 532a, 1999.
  • Trudeau M, Stuart G, Hirte H, Drouin P, Charpentier D, Plante M, Bessette P, Lebwohl D, Fisher B, Seymour L. NCIC CTG IND.102: A phase II study of the oral platinum compound BMS-182751 in patients with advanced and or recurrrent squamous cell carcinoma of the cervix. Eur.J.Can. 35(Suppl 4), S235, 1999.
  • Trudeau M, Crump M, Latreille J, Pritchard K, Palmer M, Tu D, Shepherd L, Shear N, Shapiro L, Oldfield S, Burnell M, Vandenberg T, Gelmon K, Blackstein M, Delorme F. Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer. A phase I/II study of the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 18, 117a, 1999.
  • Tu D, Pater J. Some issues related to applications of Cox's models in cancer clinical trials. Controlled Clin.Trials 20(2S), 84s, 1999.
  • Tu D, Chen J, Shi P. A Bartlett type correction for Rao's score test in Cox proportional hazards model. Proc Joint Statistical Meetings, 1999.
  • Wong R, Bjarnason G, Charpentier D, Winquist E, Abugaber A, Matthews S. Raltitrexed (TomudexTM) plus doxorubicin in patients with advanced cancer: results of a phase I dose escalation study. Proc.Am.Soc.Clin.Oncol. 18, 232a, 1999.
  • Zee B. Quality of life analysis in clinical trials. Proc Soc Clin Trials, 1999.
  • Arbuck SG, Ivy P, Setser AN, Eisenhauer E, Wanders J. Common Toxicity Criteria Version 2.0: Highlights and Tools. Ann.Oncol. 9(2), 12, 1998.
  • Belanger K, Moore M, Dionne J, McLean M, Proulx L, Hunt W, Marsolais C, Baker S, Wainman N, Seymour L. A phase I study of the novel L-nucleoside analogue BCH-4556 given every 21 days. Ann.Oncol. 9(2), 157, 1998.
  • Bjarnason G, Charpentier D, Winquist E, Wong R, Matthews S, Seymour L. Raltitrexed (TomudexTM) plus doxorubicin in patients with advanced gastric cancer: interim results of a phase I dose escalation study. Ann.Oncol. 9(2), 120, 1998.
  • Bonnefoi H, Diebold-Berger S, Hamilton A, van de Vijver M, MacGrogan G, Shepherd L, Amaral N, Raoust I, Drijkoningen M, Therasse P, Piccart M. A study of molecular markers with potential prognostic and predictive value (C-ERB B-2, P53, CYCLIN D1, MIB1, ER and PGR) in locally advanced breast cancer treated with neo-adjuvant dose intensive chemotherapy in an EORTC-NCIC-SAKK randomized phase III study. European Breast Cancer Conference, 1998.
  • Charpentier D, Bjarnason G, Belanger K, Winquist E, Wong R, Matthews S, Seymour L. Phase I study of doxorubicin and raltitrexed (Tomudex) in patients with advanced gastric cancer: a study of the Investigational New Drug Program of the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 17, 238, 1998.
  • Connors J, Belch A, Benger A, Burns B, Gluck S, Klasa R, Meyer R, Sadura A, Sawka C, Schacter L, Shepherd L, Smith A, Zee B. Brief VACOP-B followed by high dose EC+A + GM-CSF for patients with poor prognosis aggressive lymphoma. Proc.Am.Soc.Clin.Oncol. 17, 12, 1998.
  • Crump M, Lipton J, Bow E, Kovacs M, Laneuville P, Williams P, Hedley D, Matthews S, Eisenhauer E. Phase II evaluation of topotecan and etoposide in relapsed or refractory acute myeloid leukemia - a NCIC Clinical Trials Group study. Ann.Oncol. 9(2), 173, 1998.
  • Eisenhauer E. Cytoprotection. Eur Soc Med Oncol Education Book, 109-113, 1998.
  • Eisenhauer E. Phase II and beyond: assessment of efficacy. Ann.Oncol. 9(2), 5, 1998.
  • Eisenhauer E, Latreille J, Gelmon K, Fisher B, Daigneault L, Hostetler-Yanowitz C, Lebecq A, Besenval M. Phase I trial of the new taxoid RPR 109881A in a day 1 and 8 intravenous schedule every 3 weeks. An NCI Canada Clinical Trials Group study. Proc.Am.Soc.Clin.Oncol. 17, 194, 1998.
  • Eisenhauer E. Phase I and II trials of novel anticancer agents: endpoints, efficacy and existentialism. Ann.Oncol. 9(2), 9, 1998.
  • Eisenhauer E, MacNeil M. Is there a role of high dose chemotherapy in the standard management of common solid tumors? International Congress on Anti-Cancer Treatment, 1998.
  • Gelmon K, Tomiak E, Tolcher A, Blackstein M, Zee B, Batist G, Iglesias J, Fisher B, Eisenhauer E. Randomized trial of high dose paclitaxel (Taxol,T.) plus/minus amifostine in recurrent breast cancer. Proc.Am.Soc.Clin.Oncol. 17, 143, 1998.
  • Gelmon K, Tomiak E, Tolcher A, Blackstein M, Zee B, Batist G, Iglesias J, Fisher B, Eisenhauer E. Randomized trial of high dose paclitaxel plus/minus amifostine in metastatic breast cancer: a study of the NCIC Clinical Trials Group. Ann.Oncol. 9(2), 97, 1998.
  • Gertler SZ, Macdonald D, Goodyear M, Forsyth P, Stewart,DJ, Seymour L, Wainman N. NCIC CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Proc.Am.Soc.Clin.Oncol. 17, 387, 1998.
  • Goel R, Hirte H, Shah A, Major P, Waterfield B, Holohan S, Bennett K, Elias I, Seymour L. Phase I study of the metalloproteinase inhibitor BAYER 12-9566. Proc.Am.Soc.Clin.Oncol. 17, 217, 1998.
  • Hirte H, Goel R, Bennett K, Elias I, Shah A, Seymour L. Phase I study of the matrix metalloprotease inhibitor BAY 12-9566 in patients with advanced cancer. Ann.Oncol. 9(2), 75, 1998.
  • Hirte H, Goel R, Major P, Waterfield B, Holohan S, Bennett K, Shah A, Elias I, Seymour L. Pharmacokinetics of BAY 12-9566: early results of a Canadian phase I dose escalation study in cancer patients. Proc Am Assoc Cancer Res 39, 364, 1998.
  • Khoo K, Brandes L, Reyno L, Dent S, Vandenberg T, Lebwohl D, Fisher B, Eisenhauer E. Phase II trial of DPPE and doxorubicin chemotherapy in patients with metastatic breast cancer: a National Cancer Institute of Canada study. Proc.Am.Soc.Clin.Oncol. 17, 152, 1998.
  • Khoo K, Brandes L, Reyno L, Dent S, Vandenberg T, Lebwohl D, Fisher B, Eisenhauer E. Phase II trial of DPPE and doxorubicin chemotherapy in patients with metastatic breast cancer: a NCIC Clinical Trials Group study. Ann.Oncol. 9(2), 171, 1998.
  • Kirkbride P, Pater J, Zee B, Palmer M, Sun A, Wong R, Cross P, Dundas G, Ganguly P, Lim J, Chowdhury A, Gulavita S, Kumar E, Dar R, Blood P. A phase III study of the efficacy of dexamethasone in the prophylaxis of radiation induced emesis. Proc.Am.Soc.Clin.Oncol. 17, 51, 1998.
  • Latreille J, Gelmon K, Eisenhauer E, Tolcher A, Fisher B, Vernillet L, Daigneault L, Hostetler-Yanowitz C, Lebecq A, Besenval M. Phase I trial of the new taxoid RPR 109881A in a day 1 and 8 intravenous schedule every 3 weeks. An NCI Canada Clinical Trials Group study. Ann.Oncol. 9(2), 100, 1998.
  • Lebecq A, Dieras V, Marty M, Sessa C, Pazdur R, Gelmon K, Latreille J, Eisenhauer E, Besenval M, Riva A, Durrleman S. Preliminary evaluation of the modified continual reassessment method in four phase I studies with RPR 109881A. Ann.Oncol. 9(2), 127,1998.
  • Li T, Zee B, James K, Brundage M. Determination of toxicity health states for multiple myeloma patients - a comparison between correspondence analysis and clinicians' survey. Statistical Society of Canada, 1998.
  • Li T, Zee B, James K, Brundage M. Sensitivity analyses of q-twist model for interferon maintenance therapy in multiple myeloma. Controlled Clin.Trials 19(3S), 59, 1998.
  • Moore M, Tannock I, Winquist E, Tolcher A, Bennett K, Seymour L. Gemcitabine + cisplatin: An active regimen in advanced cell carcinoma: An NCIC study. Ann.Oncol. 9(Suppl 4), 57, 1998.
  • Moore M, Tannock I, Winquist E, Tolcher A, Bennett K, Seymour L. Gemcitabine + cisplatin: an active regimen in advanced transitional cell carcinoma. Proc.Am.Soc.Clin.Oncol. 17, 320, 1998.
  • Moore M, Tannock I, Winquist E, Tolcher A, Bennett K, Seymour L. Gemcitabine and cisplatin is an active regimen for advanced transitional cell carcinoma: results of a phase II study. Ann.Oncol. 9(2), 169, 1998.
  • O'Sullivan B, Davis A, Bell R, SR2 Trial Committee of the NCIC CTG and the Canadian Sarcoma Group. Description of a phase III trial of pre-op versus post-op radiotherapy in extremity soft tissue sarcoma. Connective Tissue Oncology Society, 1998.
  • Pater J, Bezjak A, Osoba D, Zee B, Palmer M. Quality of life as an endpoint in NCIC Clinical Trials Group studies: Have we learned anything new? Ann.Oncol. 9(suppl 4), 142, 1998.
  • Ravdin P, Green S, Albain K, Boucher V, Ingle J, Pritchard K, Shepherd L, Davidson N, Hayes D, Clark G, Martino S, Osborne C, Allred D. Initial report of the SWOG biological correlative study of C-ERBB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone. Proc.Am.Soc.Clin.Oncol. 17, 97, 1998.
  • Rusthoven J, Clarke S, Eisenhauer E, Abratts R, Thornton D. Phase II studies of multi-targeted antifolate (LY231514) in advanced non-small cell lung cancer. International Congress on Anti-Cancer Treatment, 1998.
  • Sears C, Mak M, Bacon M, Soroka D, Dickson M, Clark A, Williams T, Classen V, Fletcher J, Pieters-Mohammed B, Singers L, Baran J, Pho L, Pater J. What is the utility of eligibility checklist screening? Controlled Clin.Trials 19(3S), 96, 1998.
  • Seymour L, Grochow L, Eckhardt G, Erlichman C, Hirte H, Goel R, Humphrey R, Elias I. Clinical and pharmacokinetic results of 4 phase I studies of the second generation matrix metalloprotease inhibitor bay 12-9566, a non-peptidic biphenyl inhibitor of MMPs 2, 3 & 9. Ann.Oncol. 9(suppl 4), 125, 1998.
  • Seymour L, Hirte H, Goel R, Moore M, Elias I, Humphrey R. Planned and completed NCIC CTG trials with BAY 12-9566, a novel metalloprotease inhibitor. Ann.Oncol. 9(2), 76, 1998.
  • Stuart G, Bertelsen K, Mangioni C, Trope C, James K, Cassidy J, Kaye S, Timmers P, Roy JA, Piccart M. Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial. Proc.Am.Soc.Clin.Oncol. 17, 361, 1998.
  • Therasse P, Mauriac L, Welnicka M, Bruning P, Cufer T, Bonnefoi H, Tomiak E, Hamilton A, Piccart M. Neo-adjuvant dose intensive chemotherapy in locally advanced breast cancer: an EORTC-NCIC-SAKK randomized phase III study comparing FEC (5FU, epirubicin, cyclophosphamide) versus high dose intensity EC + G-CSF (filgrastim). Proc.Am.Soc.Clin.Oncol. 17, 124, 1998.
  • Therasse P, Mauriac L, Welnicka M, Bruning P, Cufer T, Tomiak E, Curran D, Ramirez A, Koopmanschap M, Piccart M. An EORTC-NCIC-SAKK neoadjuvant randomized phase III study comparing CEF (5FU, epirubicin, cyclophosphamide) vs dose intensified EC+G-CSF (filgrastim) in locally advanced breast cancer. Updated results including quality of life. Ann.Oncol. 9 (Supp 4), 13, 1998.
  • Therasse P, Eisenhauer E, Wanders J, Verweij J, van Glabbeke M, van Oosterom AT, Kaplan RS, Christian MC, Gwyther S, Arbuck SG. Evaluation of response to treatment in solid tumors. Can the methodology be harmonized and simplified? Ann.Oncol. 9(2), 25, 1998.
  • Trudeau M, Crump M, Latreille J, Pritchard K, Palmer M, Tu D, Shepherd L, Shear N, Shapiro L, Delorme F. Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer. A phase I study of the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 17, 178, 1998.
  • Tu D, Zee B, Pater J. Duration projection for equivalence clinical trials with survival endpoints. Controlled Clin.Trials 19(3S), 78, 1998.
  • Walker H, Roche K, Zee B, Smuck B, Paul N, Hiatt M, Webster S. Measuring workload of cancer clinical trials: a NCIC Clinical Trials Group study. Proc.Am.Soc.Clin.Oncol. 17, 414, 1998.
  • Zee B, Eisenhauer E. Design issues of phase II cancer clinicaltrials with multiple endpoints. Statistical Society of Canada, 1998.
  • Zhao F, Tu D, Pater J. Bootstrap variable selection and model validation for a Cox's regression model. Statistical Society of Canada, 1998.
  • Albain K, Green S, Osborne K, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, O'Sullivan J, Hess E, Martino S. for SWOG, ECOG, CALGB, NCCTG, and NCI-Canada. Tamoxifen (T) versus cyclophosphamide, adriamycin and 5-FU plus either concurrent or sequential T in postmenopausal receptor (+), or node (+) breast cancer: a Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100). Proc.Am.Soc.Clin.Oncol. 16, 128a, 1997.
  • Belch A, Bergsagel D, Wilson K, Klimo P, White D, Zee B, Johnston D. Is melphalan therapy of multiple myeloma linked to the development of acute leukemia? Blood (ASH Annual Meeting Abstracts) 90[10 Suppl, abstr 1584], 1997.
  • Bennett K, Bacon M. Revisions to the NCIC CTG Expanded Common Toxicity Criteria - do these revisions facilitate collection of more meaningful toxicity data for cancer clinical trials. Controlled Clin.Trials 18(3S), 164, 1997.
  • Bertelsen K, Kaern J, Simonsen E, Piccart M, Hoctin Boes G, Timmers P, Roy JA, Pecorelli S, Stuart G, James K, Cassidy J, Kaye S. Is cisplatin-taxol the standard treatment in advanced ovarian cancer. (NOCOVA, EORTC-GCCG, NCIC CTG, and Scottish Intergroup). Eur.J.Can. 33(8), S138, 1997.
  • Bodurtha A, Eisenhauer E, Steward W, Rusthoven J, Quirt I, Lohmann R, Wainman N, Rugg T. Phase I-II study of marimastat (BB2516) in patients with metastatic melanoma. Proc.Am.Soc.Clin.Oncol. 16, 493, 1997.
  • Cripps C, Burnell M, Jolivet J, Lofters C, Fisher B, Panasci L, Iglesias J, Eisenhauer E. Phase II study of multi-targeted antifolate (LY231514) as first line therapy in patients with locally advanced or metastatic colorectal cancer. Eur.J.Can. 33(S8), 1997.
  • Cripps C, Burnell M, Jolivet J, Lofters C, Fisher B, Panasci L, Iglesias J, Eisenhauer E. Phase II study of multi-targeted antifolate (LY231514) as first line therapy in patients with locally advanced or metastatic colorectal cancer. Proc.Am.Soc.Clin.Oncol. 16, 267, 1997.
  • Daeninck PJ, Johnston JB, Eisenhauer E, Wainman N, Corbett WC, Zaentz S. Treatment of hairy cell leukemia with low dose 2'-deoxycoformycin: results of long-term follow-up. Proc.Am.Soc.Clin.Oncol. 16, 17, 1997.
  • Dancey J, Zee B, Osoba D, Whitehead M, Palmer M, Shepherd F, Pater J. Gender specific differences on baseline quality of life assessments in lung cancer patients: results from four NCIC Clinical Trials Group studies. Lung Cancer 18 (suppl 1), 203, 1997.
  • Dancey J, Zee B, Whitehead M, Palmer M, Osoba D, Pater J. Gender and age influence baseline quality of life assessments in cancer patients. Eur.J.Can. 33 (suppl 8), S59, 1997.
  • Day A, Zee B. The Clinical Trials Group's computerized data checking system. Controlled Clin.Trials 18(3S), 144, 1997.
  • Dent S, Klaassen D, Pater J, Zee B, Whitehead M. Update of second primary malignancies and treatment results in women with early stage ovarian cancer. Proc.Am.Soc.Clin.Oncol. 16, 353, 1997.
  • Eisenhauer E, Bacon M, Walsh W, McDaniel C, Canetta R, Onetto N, Zee B. Long term survivors from a European-Canadian Trial of paclitaxel in platinum-pretreated ovarian cancer. Eur.J.Can. 33(S8), 1997.
  • Eisenhauer E, Hoskins P, Beare S, Roy M, Drouin P, Stuart G, Bryson P, Grimshaw R, Capstick V. Randomized phase II study of two schedules of topotecan in previously treated epithelial ovarian cancer. Proc.Am.Soc.Clin.Oncol. 16, 349, 1997.
  • Erlichman C, Marsoni S, Seitz J, Skillings J, Shepherd L, Zee B, Milan C, Bedenne L, Giovanni M, LE Truet YP, Torri V, Tardio B, Zaniboni A, Pancera G, Martignoni G, O'Connell MJ, Kahn M, Francini G. Event free and overall survival is increased by FUFA in resected B colon cancer: a pooled analysis of 5 randomized trials. Proc.Am.Soc.Clin.Oncol. 16, 280, 1997.
  • Flinn I, Kopecky K, Foucar K, Head D, Bennett J, Hutchison R, Corbett WEN, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever M. Long-term results in hairy cell leukemia treated with pentostatin. Blood (ASH Annual Meeting Abstracts) 90[10 Suppl, abstr 2575], 1997.
  • Hoskins P, Eisenhauer E, Beare S. Randomized phase II study of two schedules of topotecan in previously treated patients with epithelial ovarian cancer. European Society of Gynecologic Oncology, 1997.
  • James K, Eisenhauer E, Terenziani M, Muldal A, Bennett K. Measuring only one dimension is sufficient to determine response in solid tumors. Proc.Am.Soc.Clin.Oncol. 16, 415, 1997.
  • Johnston D, Pater J, Zee B, Whitehead M, Bezjak A. Fatigue: what is being overlooked? Supportive Care in Cancer 5(2), 181, 1997.
  • Kirkbride P, Eisenhauer E, Gelmon K, Fisher B, Dulude H. Phase I/II trial of paclitaxel (Taxol) and radical radiotherapy in patients with stage III non-small cell lung cancer. World Conference on Lung Cancer, 1997.
  • Kirkbride P, Blood P, Cross P, Gulavita S, Wong R, Pater J, Zee B, Palmer M. The effect of dexamethasone on radiation-induced-emesis: a NCIC Clinical Trials Group multicentre randomised controlled trial. Royal College Meeting, 1997.
  • Miller WHJr, Reyno L, Beare S, Loewen G, Jaunakais D, Parker BA, Pitt E, Truglia J, Eisenhauer E. Phase I and pharmacokinetic study of 9-cis-retinoic acid and interferon-alpha 2b in advanced renal cell carcinoma. Proc Am Assoc Cancer Res 38, 86, 1997.
  • Moore MJ, Siu LL, Oza A, Michael M, Thiessen JJ, Firby P, Wainman N, Eisenhauer E. 9-aminocamptothecin given by 24-hour infusion once weekly. A phase I pharmacokinetic and pharmacodynamic study. Proc.Am.Soc.Clin.Oncol. 16, 200, 1997.
  • Murray N, Livingston R, Shepherd F, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin J, Grafton C, Turrisi A, Walde D, Croft H, Ottaway J. A randomized study of CODE plus thoracic irradiation versus alternating CAV/EP for extensive stage small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 16, 456, 1997.
  • Murray N, Livingston R, Shepherd F, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin J, Grafton C, Turrisi A, Walde D, Croft H, Ottaway J. A randomized study of CODE plus thoracic irradiation versus alternating CAV/EP for extensive stage small cell lung cancer: an intergroup study of the NCIC Clinical Trials Group and the Southwest Oncology Group. World Conference on Lung Cancer, 1997.
  • Murray N, Zee B, Pater J, Coy P, Hodson I, Arnold A, Payne D, Kostashuk E, Evans W, Dixon P, Sadura A, Feld R, Levitt M, Wierzbicki R, Ayoub J, Maroun J, Wilson K. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer: an update of the NCIC Clinical Trials Group BR.6 study. World Conference on Lung Cancer, 1997.
  • Palmer M, Pater J, James K, Zee B, Whitehead M, Findlay B, Levine M, Bezjak A. Factors associated with fatigue in a phase one study of increasing cyclophosphamide dose. Supportive Care in Cancer 5(2), 181, 1997.
  • Payne D, Shepherd F, Johnston M, Burkes R, Murray N, Deslauriers J, Laberge F, Darling G, Feld R, Zee B, James K, Ottaway J. What is standard therapy for stage IIIA non-small cell lung cancer?:a randomized trial of combination chemotherapy and surgery versus radiotherapy alone. World Conference on Lung Cancer, 1997.
  • Payne D, Shepherd F, Johnston M, Burkes R, Murray N, Deslauriers J, Laberge F, Darling G, Feld R, Zee B, James K, Ottaway J. What is standard therapy for stage IIIA non-small cell lung cancer? A randomised trial of combination chemotherapy and surgery versus radiotherapy alone. Proc.Am.Soc.Clin.Oncol. 16, 478, 1997.
  • Piccart M, Bertelsen K, Stuart G, James K, Cassidy S, Kaye S, Hoctin Boes G, Timmers P, Roy JA, Pecorelli S. Is cisplatin-paclitaxel the standard in first-line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCIC-C and Scottish intergroup experience. Proc.Am.Soc.Clin.Oncol. 16, 352, 1997.
  • Piccart MJ, Bertelsen K, James K, Cassidy J, Nardi M, Tumolo S, Simonsen E, Kaern J, Blom R, Grimshaw R, Roy M, Kaye S, Atkinson R, Hoctin Boes G. Cisplatin-paclitaxel versus cisplatin-cyclophosphamide for advanced epithelial ovarian cancer: preliminary results from a large European-Canadian intergroup trial. Brystol-Meyers Symposium (ECCO), 1997.
  • Roche K, Paul N, Walker H, Zee B, Smuck B, Hiatt M, Brittain M. Measuring workload of cancer clinical trials: a multi-centre study by the Clinical Research Associates Committee of the NCIC Clinical Trials Group. Controlled Clin.Trials 18(3S), 43, 1997.
  • Rougier P, Buyse M, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Benedetti J, Leichman C, Macdonald J, Laplanche A, Pignon JP, Lokich J, Fryer J, Isacson R, Brufman G, Piedbois P. For the Meta-Analysis Group in Cancer. Secretariat: Henri Mondor Hospital, Department of Oncology, Creteil, France. Meta-analysis of all trials comparing intravenous bolus administration to continuous infusion of 5-fluorouracil in patients with advanced colorectal cancer. Proc.Am.Soc.Clin.Oncol. 16, 267, 1997.
  • Rusthoven J, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J. Phase II trial of multi-targeted antifolate LY231514 as first-line therapy for patients with advanced non-small cell lung cancer. Eur.J.Can. 33(S8), 1997.
  • Rusthoven J, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J. A phase II study of the multi-targeted antifolate LY231514 in patients with advanced non-small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 16, 480, 1997.
  • Shustik C, Johnston D, James K, Zee B, Meyer R, Belch A, Klasa R, Meharchand J, Pater J. Glucocorticoid dose-related susceptibility to infection in myeloma patients treated with melphalan. Blood (ASH Annual Meeting Abstracts) 90[10 Suppl, abstr 1596], 358a, 1997.
  • Swenerton K, for the European-Canadian Ovarian Cancer Intergroup (EORTC, NCI-C, SGCSG, NOCOVA). Taxol/cisplatin compared to cyclophosphamide/cisplatin in women with advanced ovarian cancer. International Gynecologic Cancer Society, 1997.
  • Tsao MS, Liu N, Nicklee T, Shepherd F, Viallet J. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Clin Cancer Res 3(10): 1807-14, 1997.
  • Tu D, Zee B, James K, Palmer M, Pater J. Numbers of events needed in comparing survival data to a standard population using the subjects-years method. Controlled Clin.Trials 18(3S), 115, 1997.
  • Tu D. Statistical procedures in therapeutic equivalence clinical trials with ordered categorical endpoints. Statistical Society of Canada, 1997.
  • van Glabbeke M, Vermorken J, Eisenhauer E. Predictors of survival and time to progression following second- or third-line treatment in advanced ovarian cancer: an analysis of 744 patients treated with paclitaxel, docetaxel or high dose epirubicin. Proc.Am.Soc.Clin.Oncol. 16, 354, 1997.
  • Zee B, Cole B, Li T, James K, Johnston D, Sugano D, Pater J. A quality of life-adjusted survival analysis of interferon maintenance in multiple myeloma. Proc.Am.Soc.Clin.Oncol. 16, 9, 1997.
  • Zee B. Imputation methods for quality of life data with missing values in cancer clinical trials. ASA 1997 Proc Biopharmaceutical Section , 79-84, 1997.
  • Bacon M, Myles J, Fiander W, Thunberg P, Craig C, Papakonstantinou C, Desjardins L, Dionne J, Cowperthwaite B, Johnston N, Binder H, Laamanen M, Sinnott C, McDonald K, Bartel J, Thain C, Green D, Shepert L. Do pre existing biologic characteristics influence chemotoxicities and thus, nursing intervention plans? International Conference on Cancer Nursing, 1996.
  • Cripps C, Osoba D, Zee B. Gender differences in responses to the EORTC quality of life questionnaire. Proc.Am.Soc.Clin.Oncol. 15, 511, 1996.
  • Cripps C, Osoba D, Zee B. Gender differences in responses to the EORTC quality of life questionnaire (QLQ-C30). Clin.Invest.Med. 19(Suppl) 62, S62, 1996.
  • Crump M, Lipton J, Hedley D, Scott J, Sutton D, Keating A, Minden M, Messner H, Eisenhauer E. A phase I trial of sequential topotecan and etoposide in adult acute myeloid leukemia. Proc.Am.Soc.Clin.Oncol. 15, 357, 1996.
  • Crump M, Lipton J, Hedley D, Eisenhauer E. A phase I trial of sequential topotecan and etoposide in adult acute myeloid leukemia. Ann.Oncol. 7(Suppl 1), 133, 1996.
  • Dent S, Zee B, Dancey J, Melnychuck D, Eisenhauer E, Steward W, Lu F. Design of phase II clinical trials - stopping rule using response and early-progression. Ann.Oncol. 7(Suppl 1), 134, 1996.
  • Eisenhauer E, Blackstein M, Forsyth P, Wainman N, Beare S. Phase II trials of docetaxel in patients with malignant glioma and soft tissue sarcoma. Ann.Oncol. 7(Suppl 1), 96, 1996.
  • Findlay B, Tonkin K, Crump M, Norris B, Trudeau M, Blackstein M, Burnell M, Skillings J, Bowman D, Walde D, Levine M, Palmer M, Myles J, James K. A dose escalation trial of adjuvant CEF chemotherapy with G-CSF for premenopausal women with node-positive breast cancer. Proc.Am.Soc.Clin.Oncol. 15, 99, 1996.
  • Forsyth P, Cairncross G, Stewart D, Goodyear M, Fulton D, Wainman N, Eisenhauer E. A phase II trial of docetaxel in patients with recurrent malignant glioma. Proceedings American Academy of Neurology, 1996.
  • Hall R. for MRC Advanced Bladder Cancer Working Party, EORTC GU Group, NCI Canada, Norwegian Bladder Cancer Group, Australian Bladder Cancer Study Group, Club Urologica Espanol de Tratamlento and FinBladder. Neo-adjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer. First analysis of MRC/EORTC intercontinental trial. Proc.Am.Soc.Clin.Oncol. 15, 244, 1996.
  • Kirkbride P, Eisenhauer E, Gelmon K, Shah A, Fisher B, Dulude H. Phase I trial of paclitaxel and radical radiotherapy in patients with stage III non-small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 15 (revised), 392, 1996.
  • Levine M, Myles J, Shepherd L, El Kum N. Optimal timing of breast cancer surgery within the menstrual cycle: results from a prospective trial. Proc.Am.Soc.Clin.Oncol. 15, 99, 1996.
  • Marlin S, Pater J, Myles J. Characteristics of NCIC Clinical Trials Group participants (1974-1993). Clin.Invest.Med. 19(suppl 4), S8, 1996.
  • Myles J, El Kum N, Levine M. A method for modelling circadian rhythms in failure time data with application to predicting the best time for surgery in pre-menopausal breast cancer. International Biometric Conference, 1996.
  • Norris B, Pritchard K, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Goss P, Latreille J, Lopez P, Osoba D, Rodgers A. A phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in metastatic/ recurrent breast cancer. Clin.Invest.Med. 19(suppl 4), S61, 1996.
  • Norris B, Pritchard K, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Goss P, Latreille J, Lopez P, Osoba D, Rodgers A. A phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer. Proc.Am.Soc.Clin.Oncol. 15, 98, 1996.
  • O'Connell C, Laurie J, Shepherd L, Kahn M, Pazdur R, Fitzgibbons R, Erlichman C, Wieand H. A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 15, 209, 1996.
  • Palmer M, Zee B, Kirkbride P, Pater J. Issues in implementing a multi-centre, placebo controlled sequential design trial of anti-emetic prophylaxis in patients receiving radiotherapy. Controlled Clin.Trials 17(2S), 73S-74S, 1996.
  • Pater J, Zee B, Osoba D. Quality of life as an outcome measure in the assessment of nausea and vomiting. Controlled Clin.Trials 17(2S), 137S, 1996.
  • Pater J, Zee B, Osoba D. Quality of life as an outcome measure in the assessment of nausea and vomiting. Proc.Am.Soc.Clin.Oncol. 15, 529, 1996.
  • Piccart M. Is TP the standard in first-line treatment? The EORTC experience. Gynecolgic Conference, 1996.
  • Rai K, Peterson B, Elias L, Shepherd L, Hines J, Nelson D, Cheson B, Kolitz J, Schiffer C. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C and ECOG Inter-group study. Blood (ASH Annual Meeting Abstracts) 86[10 Suppl 1], 1996.
  • Rai K, Peterson B, Kolitz J, Elias L, Shepherd L, Hines J, Cheson B, Schiffer C. (CALGB, SWOG, CTG/NCIC, ECOG and NCI, Chicago, IL.). Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 86[10 Suppl 1], 1996.
  • Shepherd L, Findlay B, Tonkin K, Crump M, Norris B, Trudeau M, Blackstein M, Burnell M, Skillings J, Bowman D, Walde D, Levine M, Palmer M, Myles J, James K. A dose escalation trial of adjuvant CEF chemotherapy with G-CSF for premenopausal women with node-positive breast cancer. Royal College Meeting, 1996.
  • Tallman M, Andersen J, Schiffer C, Appelbaum F, Feusner J, Woods W, Ogden A, Weinstein H, Shepherd L, Rowe J, Wiernik P. (ECOG, CALGB, SWOG, CCSG, POG and NCIC CTG.) Phase III randomized study of all-trans retinoic acid versus daunorubicin and cytosine arabinoside as induction therapy and all-trans retinoic acid versus observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia. Blood (ASH Annual Meeting Abstracts) 86[10 Suppl 1), 1996.
  • Tepper JE, O'Connell M, Petroni G, Benson A, Macdonald J, Martenson J, Rich TA, Stern H. Toxicity in the adjuvant therapy of rectal cancer: a preliminary report of intergroup 0114 (CALGB 9081). Proc Am Soc Clin Oncol 15[abstr 481], 210, 1996.
  • Trudeau M, Eisenhauer E, Dent S, Pritchard K, Lofters W, Norris B, Muldal A, Letendre F, Vandenberg T, Verma S. Central nervous system relapse following chemotherapy with docetaxel for metastatic breast cancer. Update of a study by the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 15, 101, 1996.
  • Vermorken J, Eisenhauer E, Lu F, Fumoleau P, Canetta R, Walling J, van Glabbeke M. Prognostic features of importance for phase II studies in platinum-pretreated ovarian cancer patients. Proc International Congress on Anti-Cancer Treatment , 1996.
  • Zee B, Pho L. System for monitoring timing of data review and entry: a tool for internal data quality control. Controlled Clin.Trials 17(2S), 114S, 1996.
  • Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.
  • Zee B, Melnychuck D, Dancey J, Eisenhauer E. Design of phase II clinical trials incorporating response and early progression. Controlled Clin.Trials 17(2S), 85S, 1996.
  • Blackstein M, Eisenhauer E, Bramwell V, Belanger K, Verma S, Beare S. Docetaxel (Taxotere) as first line therapy for metastatic or recurrent soft tissue sarcoma: a phase II trial. Eur.J.Can. 31A(suppl.5), 177, 1995.
  • Eisenhauer E. Promising new chemotherapeutic agents for cancer: overview of phase I and II studies. Can.J.Infect.Dis. 6 (suppl C), 204, 1995.
  • Eisenhauer E, Vermorken J, Myles J, van Glabbeke M. Tumour bulk, histology, and baseline hemoglobin may influence response in platinum pretreated ovarian cancer. Eur.J.Can. 31A(suppl.5), 105, 1995.
  • Eisenhauer EA, Pritchard KI, Perrault D, Fisher B, Vandenberg T, Panasci L, Norris B. Phase II study of mifepristone (RU486) in previously untreated patients with metastatic breast cancer. A trial of the NCI Canada Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 14, 114, 1995.
  • Johnston D, Latreille J, Laberge F, Stewart D, Rusthoven J, Findlay B, Ernst S, Williams C, Hoskins P, Yelle L, McMurtrie E, Dhaliwal H, Nishimura L, Pater J, Zee B. Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy. A study by the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 14, 529, 1995.
  • Johnston D, Latreille J, Laberge F, Stewart D, Rusthoven J, Findlay B, Ernst S, Williams C, Hoskins P, Yelle L, McMurtrie E, Dhaliwal H, Nishimura L, Pater J, Zee B. Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy. Eur.J.Can. 31A(suppl.5), 251, 1995.
  • Koski B, Pater J. Survey to evaluate case report forms for national multi-center clinical trials designed using generic forms modules. Controlled Clin.Trials 16(3S), 115S, 1995.
  • Latreille J, Johnston D, Laberge F, Stewart D, Rusthoven J, Nishimura L, Pater J, Zee B. Use of granisetron and dexamethasone on day 2-7 following high dose cisplatin. Supportive Care in Cancer 3(5), 339, 1995.
  • Levine M, Bramwell V, Bowman D, Norris B, Findlay B, Warr D, Pritchard K, MacKenzie R, Robert J, Arnold A, Tonkin K, Shepherd L, Ottaway J, Myles J. A clinical trial of intensive CEF versus CMF in premenopausal women with node positive breast cancer. Proc.Am.Soc.Clin.Oncol. 14, 103, 1995.
  • Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.
  • Lofters W, Zee B. Dolasetron vs ondansetron with and without dexamethasone in the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 252, 1995.
  • Lofters W, Zee B. Dolasetron vs ondansetron with and without dexamethasone in the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 338, 1995.
  • Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.
  • Moore M, Erlichman C, Pillon L, Manzo J, Thiessen J, Eisenhauer E. A phase I study of fostrieicin in a daily x 5 schedule. A phase I study of the NCIC Clinical Trials Group. Proc.Am.Assoc.Cancer Res. 36, 239, 1995.
  • Moore MJ, Erlichman C, Pillon L, Manzo J, Thiessen JJ, Eisenhauer E. A phase I clinical and pharmacokinetic study of fostriecin in a daily x 5 schedule. Proc.Am.Soc.Clin.Oncol. 14, 474, 1995.
  • Muldal A, James K, Wainman N, Eisenhauer E, Bennett K. Response criteria in solid tumours: uni-dimensional versus bi-dimensional measurements. Controlled Clin.Trials 16(3S), 88S, 1995.
  • Myles J, Whitehead M, Ottaway J, Levine M. Subscales for the breast cancer chemotherapy questionnaire. Quality of Life Research 4(5), 465-466, 1995.
  • Osoba D, Pater J, Zee B, Lofters W, Warr D, Palmer M, Chin C, Dempsey E. Effective anti-emetic therapy improves quality of life after moderately emetogenic chemotherapy. Quality of Life Research 4(5), 467-468, 1995.
  • Osoba D, Rodrigues G, Myles J, Pater J. Significance of changes in health-related quality of life scores in women receiving chemotherapy for recurrent or metastatic breast cancer. Quality of Life Research 4(5), 468-469, 1995.
  • Osoba D, Warr D, Zee B, Kaizer L, Latreille J, Pater J. Pretreatment health-related quality-of-life status predicts chemotherapy-induced emesis. Proc.Am.Soc.Clin.Oncol. 14, 497, 1995.
  • Osoba D, Aaronson N, Zee B, teVelde A, Sprangers M. Modification of the EORTC QLQ-C30 based on reliability testing in large samples of patients with cancer. Quality of Life Research 4(5), 468, 1995.
  • Palmer M, Zee B, Osoba D, Pater J, Lofters W, Chin C, Dempsey E. Day of assessment and question time frame affect reported quality of life after moderately emetogenic chemotherapy. Quality of Life Research 4(5), 470-471, 1995.
  • Pater J, Palmer M, Zee B, Osoba D, Lofters W, Chin C, Dempsey E. Day of assessment and question time frame affect reported quality of life after moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 375, 1995.
  • Pater J, Zee B, Lofters W, Osoba D, Warr D, Palmer M, Chin C, Dempsey E. Effective anti-emetic therapy improves quality of life after moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 344, 1995.
  • Rusthoven J, Quirt I, Iscoe N, McCulloch P, James K, Lohmann R, Jensen J, Burdette-Radoux S, Bodurtha A, Silver H, Zee B, Bennett K. A randomized, placebo-controlled trial comparing BCNU, dacarbazine, and cisplatin versus BDP and high-dose tamoxifen in the treatment of metastatic melanoma. Proc.Am.Soc.Clin.Oncol. 14, 413, 1995.
  • Sadura A, Fisher B. Improved readability of consent forms for clinical trials. Controlled Clin.Trials 16(3S), 124S, 1995.
  • Shepherd F, Latreille J, Eisenhauer E, Fisher B, Hellmann S, Baker M. Phase I trial of paclitaxel (Taxol) and ifosfamide in previously untreated patients with non-small cell lung cancer. A phase I study of the NCIC Clinical Trials Group and Bristol-Myers Squibb. Proc.Am.Soc.Clin.Oncol. 14, 373, 1995.
  • Swenerton K, Eisenhauer E, Hoskins P, Stuart G, Batist G, Fisher B, Onetto N. Phase I trial of biweekly paclitaxel plus cisplatin in previously untreated patients with advanced ovarian carcinoma. A phase I study of the NCIC Clinical Trials Group and Bristol-Myers Squibb. Proc ISPCC, 1995.
  • Zee B. Analysis of quality of life data in cancer clinical trials using a Cox model with time dependent covariate. Biometric Society ENAR, 1995.
  • Zee B, Pater J, Osoba D. Global health-related quality of life: a direct measurement vs. aggregate scores. Quality of Life Research 4(5), 506, 1995.
  • Zee B. A review of the impact of quality of life in cancer randomized trials. Joint ASA and Biometrics Meeting, 1995.
  • Arnold A, Ayoub J, Douglas L, Hoogendoorn P, Skingley L, Gelmon K, Hirsh V, Eisenhauer E. The combination of 13-cis-retinoic acid + interferon alpha is not active in advanced non-small cell lung cancer. Ann.Oncol. 5(5), 148, 1994.
  • Bacon M. Impact and opportunities of clinical trials for cancer nursing. Canadian Oncology Nursing Journal Part 1[Suppl], 1994.
  • Browman G, Rubin S, Walker I, Sicheri D, Belch A, O'Reilly S, Wilson K, Barr R, Johnston D, James K, Zee B, Pater J. Interferon alpha-2b maintenance therapy prolongs progression-free and overall survival in plasma cell myeloma: results of a randomized trial. Proc.Am.Soc.Clin.Oncol. 13, 408, 1994.
  • Eisenhauer E, Wainman N, Boos G, Macdonald D, Bramwell V. Phase II trials of topotecan in patients with malignant glioma and soft tissue sarcoma. Proc.Am.Soc.Clin.Oncol. 13, 175, 1994.
  • Eisenhauer E, Wainman N, Boos G, Macdonald D, Bramwell V. Phase II trials of topotecan in patients with malignant glioma and soft tissue sarcoma. Ann.Oncol. 5(5), 191, 1994.
  • Eisenhauer E, Lippman S, Arnold A, Massimini G. Combination 13-cis-retinoic-acid and interferon alpha-2a in clinical trials of solid tumors. Ann.Oncol. 5(5), 120, 1994.
  • Eisenhauer E, Lu F, Muldal A, Trudeau M, Latreille J, Mertens W. Predictors and treatment of docetaxel toxic effects. Ann.Oncol. 5(5), 202, 1994.
  • Eisenhauer E, Bacon M, Atri M, Lemort M, Nolan R, Petroons P, Sauerbrei E, Florczyk A, Onetto N. Radiologic review of response in ovarian cancer: Is it useful? Results from a joint European-Canadian trial. Proc.Am.Soc.Clin.Oncol. 13, 257, 1994.
  • Erlichman C, Marsoni S, Seitz J, Skillings J, Shepherd L, Zee B, Milan C, Bedenne L, Giovanni M, Pienkowski P, Torri V, Tardio B, Smerieri F, Pancera G, Martignoni G. Event-free and overall survival is increased by FUFA in resected B and C colon cancer: a prospective pooled analysis of three randomized trials. Proc.Am.Soc.Clin.Oncol. 13, 33, 1994.
  • Findlay B, Myles J, Levine M, Bramwell V, Pritchard K, Ottaway J. Using ideal versus actual weights to calculate chemotherapy doses in premenopausal women with stage 2 breast cancer. Proc.Am.Soc.Clin.Oncol. 13, 63, 1994.
  • Koski B, Wainman N, Bennett K, Muldal A, Fisher B, Ottaway J, Bogues W, Hoogendoorn P. Classification and reduction of queries on multi-centre trials. Controlled Clin.Trials 15(3S), 94S, 1994.
  • Koski T, Hale B, Bacon M. The evolving role of the clinical trials specialty nurse. Canadian Oncology Nursing Journal Part 1[Suppl], 1994.
  • Lhomme C, Eisenhauer E, Swenerton K, Soulie P, Armand J, Ten Bokkel-Huinink W, Gianni L, Winograd B, Chazard M. A European and Canadian randomized trial comparing 2 doses and 2 durations of perfusion of Taxol in patients treated for cancer of the ovaries resistant to platinum. Forum de Cancerologie Maison de La Chimie, 1994.
  • Mandell L, Bow E, Pater J, Zee B, Palmer M. Antibacterial chemoprophylaxis with ofloxacin +/- rifampin versus norfloxacin in neutropenic leukemia patients. Royal College Meeting, 1994.
  • Mertens W, Eisenhauer E, Jolivet J, Ernst S, Moore M, Muldal A. Docetaxel in advanced renal carcinoma: a phase II study. Ann.Oncol. 5(5), 203, 1994.
  • Moore M, Erlichman C, Pillon L, Thiessen J, Eisenhauer E. A phase I clinical and pharmacokinetic study of fostriecin in a daily x 5 schedule. Princess Margaret Hospital, University of Toronto, NCIC Clinical Trials Group. Ann.Oncol. 5(5), 188, 1994.
  • Myles J. Statistical and ethical issues in the design of an oncology pilot study with dose escalation. Statistical Society of Canada, 1994.
  • Myles J, Grechko J, Eisenhauer E, Onetto N. Experience with a factorial design in a pivotal oncology clinical trial. Controlled Clin.Trials 15(3S), 72S, 1994.
  • Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J. Health-related quality-of-life domains are affected by chemotherapy and extent of disease in patients with lung, breast, ovarian and other cancers. Proc.Am.Soc.Clin.Oncol. 13, 454, 1994.
  • Ottaway J, Sadura A, Johnston D. Trial workload measurement tool for study coordinators. Controlled Clin.Trials 15(3S), 90S, 1994.
  • Pritchard K, Zee B, Paul N, Paterson A, Fine S, Shepherd L, Abu-Zahra H, Warr D, Knowling M, Levine M, Bramwell V, Walde D, Norris B, Poljicak M, Perrault D, Ragaz J, Verma S, Bowman D. CMF added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: negative results from a randomized clinical trial. Proc.Am.Soc.Clin.Oncol. 13, 20, 1994.
  • Shepherd F, Eisenhauer E, Latreille J, Fisher B, Hellmann S. Phase I trial of paclitaxel plus ifosfamide in previously untreated patients with non-small cell lung cancer. Ann.Oncol. 5(Suppl.8), 179, 1994.
  • Swenerton K, Eisenhauer E, Hoskins P, Stuart G, Batist G, Fisher B, Onetto N. Phase I trial of biweekly taxel plus cisplatin in previously untreated patients with advanced ovarian carcinoma. Ann.Oncol. 5(Suppl.8), 103, 1994.
  • Zee B, James K, Johnston D. Design and analysis of late randomization trials: information from time to first response in multiple myeloma. Joint ASA and Biometric Meeting, 1994.
  • Bacon M. Central radiology review of responders. Tumour Measurement, Response Assessment Symposium, 1993.
  • Belch A, Osterwalder B, Eisenhauer E, Muldal A, Skingley L, Browman G, O'Reilly S, Michal S. Phase II study of subcutaneous recombinant human interleukin-2 (rHu IL-2) and interferon alfa-2a (rHu IFN alfa-2a) in previously treated patients with multiple myeloma. A study of the National Cancer Institute of Canada Clinical Trials Group A study of the NCIC Clinical Trials Group. Congress of Cytokines and Growth Factors in Cancer, 1993.
  • Brundage M, Pater J, Zee B. Assessing the reliability of two treatment toxicity scales: reason for concern. Proc.Am.Soc.Clin.Oncol. 12, 184, 1993.
  • Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Dropcho E, Fulton D, Stewart D, Schold C, Wainman N, Eisenhauer E. Phase II study of chemotherapy for anaplastic oligodendroglioma (preliminary report). Proc.Am.Soc.Clin.Oncol. 12, 175, 1993.
  • Cormier Y, Eisenhauer E, Gregg R, Ayoub J, Goss G, Stewart D, Muldal A, Tarasoff P. Gemcitabine: an active new agent in patients with previously untreated small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 12, 330, 1993.
  • Eisenhauer E, Ten Bokkel-Huinink W, Swenerton K, Mangioni C, van der Burg M, Kerr I, Gianni L, Buser K, Vermorken J, Onetto N, Winograd B, Canetta R. Toxicity of Taxol: a European-Canadian trial of high vs low dose and short vs long infusion in ovarian cancer. Clinical Oncology Society of Australia, 1993.
  • Grever M, Kopecky K, Head D, Foucar K, Cassileth P, Golomb H, Habermann T, Rai K, Eisenhauer E, Appelbaum F, Cheson B. A randomized comparison of deoxycoformycin versus alpha-2a interferon in previously untreated patients with hairy cell leukemia: an updated report on the NCI-sponsored intergroup study (SWOG, ECOG, CALGB, NCIC CTG). Blood (ASH Annual Meeting Abstracts), 1993.
  • Latreille J, Stewart D, Laberge F, Hoskins P, Rusthoven J, McMurtrie E, Warr D, Yelle L, Walde D, Shepherd F, Dhaliwal H, Findlay B, Mee D, Pater J, Zee B, Johnston D. Dexamethasone improves the efficacy of granisetron in the first 24 hours following high dose cisplatin chemotherapy. Proc.Am.Soc.Clin.Oncol. 12, 133, 1993.
  • Latreille J, Stewart D, Laberge F, Hoskins P, Rusthoven J, McMurtrie E, Warr D, Yelle L, Walde D, Shepherd F, Dhaliwal H, Findlay B, Mee D, Pater J, Zee B, Johnston D. Dexamethasone improves the efficacy of granisetron in the first 24 hours following high dose cisplatin chemotherapy. Eur.J.Can. 29A(Suppl.6), S208, 1993.
  • Macdonald D, Cairncross G, Eisenhauer E. NCIC CTG phase II study of topotecan for malignant glioma. International Conference of Brain Tumour Research and Therapy, 1993.
  • Macdonald D, Cairncross G, Ludwin S, Lee D, Cascino T, Buckner J, Dropcho E, Fulton D, Stewart D, Schold C, Wainman N, Eisenhauer E. NCIC CTG phase II study of chemotherapy for anaplastic oligodendroglioma. International Conference of Brain Tumour Research and Therapy, 1993.
  • Muldal A, Pho L, Eisenhauer E. Establishment of an adverse event reporting database: the NCIC Clinical Trials Group experience. Controlled Clin.Trials 14(5), 428, 1993.
  • Myles J. Design issues of a pilot study to determine equivalent toxicity with G-CSF support. Clinical Trials in Oncology, 1993.
  • Osoba D, Zee B, Pater J, Quirt I. Lessons learned from measuring health-related quality of life in an adjuvant trial of gamma interferon versus levamisole in patients with resected malignant melanoma. Proc.Am.Soc.Clin.Oncol. 12, 434, 1993.
  • Osoba D. for the Quality of Life Committee. Measuring health-related quality of life in clinical trials: the NCIC Clinical Trials Group experience. Clinical Trials in Oncology, 1993.
  • Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.
  • Swenerton K, Eisenhauer E, Ten Bokkel-Huinink W, Myles J, Mangioni C, van der Burg M, Kerr I, Gianni L, Vermorken J, Buser K, Sadura A, Bacon M, Santabarbara P, Onetto N, Canetta R. Taxol in relapsed ovarian cancer: high vs low dose and short vs long infusion: a European-Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 12, 256, 1993.
  • Tallman M, Andersen J, Appelbaum F, Schiffer C, Woods W, Feusner J, Ogden A, Weinstein H, Shepherd L, Wiernik P, Rowe J. Phase III randomized study of all-trans retinoic acid versus ctyosine arabinoside and daunorubicin as induction therapy for patients with previously untreated acute promyelocytic leukemia: preliminary toxicity results. APL International Meeting, 1993.
  • Trudeau M, Eisenhauer E, Lofters W, Norris B, Muldal A, Letendre F, Vandenberg T, Verma S. Phase II study of taxotere as first line chemotherapy for metastatic breast cancer. Proc.Am.Soc.Clin.Oncol. 12, 64, 1993.
  • van der Burg M, Myles J, Hoskins P, Ten Bokkel-Huinink W, Eisenhauer E. CA-125 is an unreliable marker for monitoring response to taxol therapy in patients with relapsed ovarian cancer. Eur.J.Can. 29A(Suppl.6), S133, 1993.
  • Zaniboni A, Erlichman C, Seitz J, Shepherd L, Milan C, Labianca R, Torri V, Pignon J, Zee B, Marsoni S. FUFA increases disease-free survival in resected B2,C colon cancer: results of a prospective pooled analysis of three randomised trials. Proc.Am.Soc.Clin.Oncol. 12, 191, 1993.
  • Zee B, Pater J, Torri V, Marsoni S, Pancera G, Milan C, Pignon J. Salvaging clinical trials forced to terminate early by results of external information. Controlled Clin.Trials 14(5), 439, 1993.
  • Zee B, Pater J, Torri V, Marsoni S, Pancera G, Milan C, Pignon J.Salvaging trials forced to terminate early by external results and a design of pooled-international-trials. Clinical Trials in Oncology, 1993.
  • Zee B, Pho L, Koski B. System for monitoring timing of data review and entry. Controlled Clin.Trials 14(5), 431, 1993.
  • Zee B. Growth curve model for quality of life data with missing and informative right censoring. Joint ASA Biometrics Meeting, 1993.
  • Ciampi A, Zee B, Hendricks L, Pater J. Correcting for confounding in survival analysis: the tree- growing approach. Statistical Society of Canada, 1992.
  • Connors J, Klimo P, Adams G, Burns B, Cooper I, Meyer R, O'Reilly S, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B. MOPP/ABV hybrid versus alternating MOPP/ABVD for advanced Hodgkin's disease. Proc.Am.Soc.Clin.Oncol. 11, 317, 1992.
  • Coppin C, Gospodarowicz M, Dixon P, Tannock I, Zee B, Sullivan L. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or radical radiation. Proc.Am.Soc.Clin.Oncol. 11, 198, 1992.
  • Cormier Y, Eisenhauer E, Gregg R, Stewart D, Muldal A. Gemcitabine is active in patients with previously untreated extensive small cell lung cancer. A phase II study. Cancer Investigation 2(1), 55-56, 1992.
  • Desjardins C, Pater J, Zee B, Torri W, Marsoni S, Colombo N, Bonazzi C. Prognostic factors after a negative second-look laparotomy in ovarian cancer: a Canada-Italy study. Ann.Oncol. 3(Suppl.5), 107, 1992.
  • Egorin M, Reyno L, Sridhara R, Canetta R, Swenerton K, Pater J, Burroughs J, Novak M, Gregory W. Application to ovarian cancer of a mathematical model relating response duration to amount of subclinical resistant disease. Presented: AACR, 1992.
  • Eisenhauer E, Ten Bokkel-Huinink W, Swenerton K, Mangioni C, van der Burg M, Kerr I, Gianni L, Buser K, Vermorken J, Onetto N, Winograd B, Canetta R. Toxicity of taxol: a European-Canadian trial of high vs low dose and short vs long infusion in ovarian cancer coordinated by the NCI Canada Clinical Trials Group. NCI Workshop on Taxol and Taxus, 1992.
  • Eisenhauer E, Cormier Y, Gregg R, Stewart D, Muldal A. Gemcitabine is active in patients with previously untreated extensive small cell lung cancer. A phase II study of the NCIC Clinical Trials Group (NCIC CTG). Proc.Am.Soc.Clin.Oncol. 11, 309, 1992.
  • Eisenhauer E, Belanger K, Erlichman C, Gregg R, Shore T, Dallaire B, Gyves J, Grillo-Lopez A. DUP 937: a new anthrapyrazole in clinical trials. NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1992.
  • Grever M, Kopecky K, Head D, Cassileth P, Golomb H, Habermann T, Rai K, Eisenhauer E, Cheson B. A randomized comparison of deoxycoformycin versus alpha-2a interferon in previously untreated patients with hairy cell leukemia. An NCI-sponsored intergroup study (SWOG, ECOG, CALGB, NCIC CTG). Proc.Am.Soc.Clin.Oncol. 11, 264, 1992.
  • Kaizer L, Warr D, Hoskins P, Latreille J, Lofters W, Geggie P, Palmer M, Zee B, Pater J, Levy M. The effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in patients receiving moderately emetogenic chemotherapy. Proc.Am.Soc.Clin.Oncol. 11, 381, 1992.
  • Koski B, Pater J. Quality assurance and multicentre clinical trials. Controlled Clin.Trials 13(5), 430, 1992.
  • Levitt M, Warr D, Yelle L, Rayner H, Latreille J, Potvin M, Warner E, Pritchard K, Palmer M, Zee B, Pater J. The anti-emetic effect of ondansetron is not superior to dexamethasone plus metoclopramide in CMF chemotherapy for breast cancer. Proc.Am.Soc.Clin.Oncol. 11, 388, 1992.
  • Maroun J, Skillings J, MacCormick R, Potvin M, Davidson J, Eisenhauer E. Phase II study of DUP-937 in colorectal carcinoma. A Canadian National Cancer Institute Clinical Trials Group (NCIC CTG) study. Proc.Am.Soc.Clin.Oncol. 11, 179, 1992.
  • Osoba D, Zee B, Sadura A, Pater J. Measurement of quality of life in a clinical trial of interferon versus levamisole in malignant melanoma. Clin.Invest.Med. 15(4)(Suppl), A87, 1992.
  • Palmer M, Pater J. The parodox of rapid accrual. Controlled Clin.Trials 13(5), 428, 1992.
  • Palmer M, Zee B. The measurement of visual analogue scale data is not a burden. Controlled Clin.Trials 13(5), 435, 1992.
  • Pater J, Darko E, Zee B. Impact of nausea and vomiting on quality of life patients receiving cytotoxic chemotherapy. Ann.Oncol. 3(Suppl.5), 177, 1992.
  • Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.
  • Paul N, Wainman N, Eisenhauer E, Pho L, Koski B, Pieters B. Continuing review of trials by local ethics boards: a reminder system for keeping participating centres on track. Controlled Clin.Trials 13(5), 431, 1992.
  • Paul N, Eisenhauer E, Wainman N, Sadura A, Koski B. Form enhances content: development of a generic protocol. Controlled Clin.Trials 13(5), 395, 1992.
  • Pritchard K, Paterson AHG, Fine S, Paul N, Pater J, Zee B, Warr D, Knowling M, Abu-Zahra H, Levine M, Bramwell V, Walde PD, Norris B, Poljicak M, Perrault D, Ragaz J, Verma S, Bowman D. A randomized trial of CMF chemotherapy added to tamoxifen as adjuvant therapy in post-menopausal women with node-positive estrogen and/or progesterone receptor +ve breast cancer. Clin.Invest.Med. 15(4)Suppl, 1992.
  • Pritchard K, Paterson A, Fine S, Paul N, Pater J, Zee B, Warr D, Knowling M, Abu-Zahra H, Levine M, Bramwell V, Norris B, Poljicak M, Perrault D, Ragaz J, Verma S, Bowman D. A randomized trial of CMF chemotherapy added to tamoxifen as adjuvant therapy in post-menopausal women with node-positive estrogen and/or progesterone receptor positive breast cancer. Proc.Am.Soc.Clin.Oncol. 11, 60, 1992.
  • Pritchard K, Paterson AHG, Fine S, Paul N, Pater J, Zee B, Warr D, Knowling M, Abu-Zahra H, Levine M, Bramwell V, Walde D, Norris B, Poljicak M, Perrault D, Ragaz J, Verma S, Bowman D. A randomized trial of CMF chemotherapy added to tamoxifen as adjuvant therapy in post-menopausal women with node-positive estrogen and/or progesterone receptor breast cancer. Royal College Meeting, 1992.
  • Reyno L, Egorin M, Canetta R, Jodrell D, Swenerton K, Pater J, Burroughs J, Novak M, Sridhara R. Relationships between carboplatin (CBDCA) exposure, response and toxicity in combination with cyclophosphamide (CYC) in the treatment of ovarian cancer. Proc.Am.Soc.Clin.Oncol. 11, 114, 1992.
  • Rusthoven J, Eisenhauer E, Mazurka J, Hirte H, O'Connell G, Jeffrey J, Swenerton K, Muldal A. Phase I clinical trial of escalating doses of interleukin-3 (IL-3) in patients with relapsed ovarian cancer receiving carboplatin. Proc.Am.Soc.Clin.Oncol. 11, 237, 1992.
  • Ten Bokkel-Huinink W, Swenerton K, Eisenhauer E, Onetto N, Winograd B. Toxicity of taxol: a European-Canadian trial of high vs low dose and short vs long infusion in ovarian cancer. Ann.Oncol. 3(Suppl.5), 101, 1992.
  • Vandenberg T, Pritchard KI, Eisenhauer E, Trudeau M, Norris B, Lopez P, Verma S, Buckman RA, Muldal A. Phase II study of weekly 10-EDAM (edatrexate) as first line chemotherapy for metastatic breast cancer. A NCIC Clinical Trials Group (NCIC CTG) study. Proc.Am.Soc.Clin.Oncol. 11, 51, 1992.
  • Verma S, Quirt I, Eisenhauer E, Young V. A phase II study of 10-EDAM in metastatic malignant melanoma. Proc.Am.Soc.Clin.Oncol. 11, 347, 1992.
  • Wainman N, Paul N, Brundage M, Pater J, Eisenhauer E, Koski B, Sadura A, Walsh W. Common toxicity criteria: The NCIC Clinical Trials Group (NCIC CTG) experience. Controlled Clin.Trials 13(5), 435, 1992.
  • Zee B. One-sided test for clinical trials with group sequential design that allow early acceptance of negative result. Controlled Clin.Trials 13(5), 380, 1992.
  • Zee B, Ciampi A, Pater J, Lou Z, Hendricks L. Covariate adjustment in randomized trials incorporating regression tree method. Statistical Society of Canada 1992.
  • Brundage M, Pater J. Reporting of toxicity data in prospective clinical trials: current patterns of practice and implications for analysis. Controlled Clin.Trials 12(5), 681, 1991.
  • Carmichael J, Danjoux C, Fraser R, Krepart G, O'Connell G, Pater J, Roy M, Shelley W, Starreveld A, Swenerton K. Clinical trial comparing abdominal-pelvic radiation versus cyclophosphamide + cisplatinum chemotherapy in patients with epithelial ovarian carcinoma having only microscopic residual disease following surgery (NCIC Trial OV.7). Gyn Oncol Canada Meeting, 1991.
  • Hryniuk W. for the NCI-Canada, Clinical Trials Group. Randomized trial of escalated vs standard BACOP (Bleomycin-Adriamycin-Cyclophosphamide-Oncovin-Prednisone) for intermediate grade lymphoma. Proc.Am.Soc.Clin.Oncol, 1991.
  • Johnston D. Lessons learned from coordinating antiemetic trials. Antiemetics -- Current Status and Future Directions, 1991.
  • Johnston D, Palmer M, Pater J. Interrelationships between anxiety and nausea in cancer patients receiving chemotherapy. Eur.J.Can. 27(S2), S298, 1991.
  • Koski B, Pater J. Does central monitoring of the timeliness of forms result in a decrease in the quality of data. Controlled Clin.Trials 12(5), 708, 1991.
  • Lu HX, Pater J, Zee B, Evans WH, Feld R, Coy P, Murray N, Ciampi A. Disease extent influences the impact of other prognostic factors in patients with small cell lung cancer. Eur.J.Can. 27(2), 1991.
  • Maroun J, Belanger K, Jolivet J, Stewart D, Wong B, Grillo-Lopez A, Eisenhauer E. Phase I trial of the anthrapyrazole DUP-937 given weekly x3 every 5 weeks. Proc.Am.Assoc.Cancer Res, 1991.
  • Murray N, Coy P, Pater J, Hodson I, Arnold A, Kostashuk E, Dixon P, Zee B, Sadura A, Ayoub J, Levitt M, Wierzbicki R, Payne D, Maroun J, Wilson K. The importance of timing for thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 10, 243, 1991.
  • Palmer M, Pater J. Does participation on concurrent clinical trials compromise the quality of the data or its timely submission? Controlled Clin.Trials 12(5), 713, 1991.
  • Palmer M, Koski B, Goodlow J, Zee B. So clean it squeaks -- comparison of data collected by two independent groups on the same trial. Controlled Clin.Trials 12(5), 693, 1991.
  • Pater J, Smaldone L, Zee B, Goodlow J, Rusthoven J, Rozencweig M. Simultaneous randomization to multiple dose levels and an active comparator as a means of determining the minimal effective dose of an investigational agent. Controlled Clin.Trials 12(5), 696, 1991.
  • Pater J. Prognostic factors in emesis. Antiemetics -- Current Status and Future Directions, 1991.
  • Paul N. Implementing the European Community good clinical practice guidelines in Canada: a national cooperative group's report. Controlled Clin.Trials 12(5), 682, 1991.
  • Paul N, Pater J, Whitehead M, Sadura A. Methods of toxicity data collection: an evaluation of the relative effectiveness of the case report flow sheet, the patient symptom diary, and the quality of life questionnaire. Controlled Clin.Trials 12(5), 648, 1991.
  • Sadura A, Pater J, Levine M, Osoba D. Quality of life assessment: patient complicance with questionnaire completion. Controlled Clin.Trials 12(5), 708, 1991.
  • Shepherd F, Rusthoven J, Goss P, Eisenhauer E. A phase I-II trial of high dose cisplatin, etoposide and GM-CSF for small cell lung cancer. Proc.Am.Soc.Clin.Oncol, 1991.
  • Slamet L, Pater J, Zee B, Osoba D, Warr D, Rusthoven J. Inconsistency of prognostic factors and post chemotherapy nausea and vomiting. Eur.J.Can. 27(2), 1991.
  • Stewart D, Eisenhauer E, McDonald D, Cairncross G, Lopez P. NCI Canada phase II study of tiazofurin in the treatment of glioblastoma multiforme. International Conference of Brain Tumour Research and Therapy, 1991.
  • Stewart D, Verma S, Eisenhauer E, Pritchard K, Buckman R, Skillings J, Vandenberg T. NCI Canada phase II study of weekly oral menogaril as first line chemotherapy for recurrent breast cancer. Proc.Am.Soc.Clin.Oncol, 1991.
  • Warr D. Phase I/II 5-HT3 antagonist trials. Antiemetics -- Current Status and Future Directions, 1991.
  • Weinerman B, Shepherd F, Eisenhauer E, Stewart D, Mertens W, MacCormick R, Venner P, Cormier Y, Belanger K, Ayoub J, Tannock I, Spaulding R. NCI Canada phase II studies of sulofenur in untreated small cell lung and renal cell cancers. Proc.Am.Soc.Clin.Oncol. 10, 251, 1991.
  • Zee B. Assessing quality of life in antiemetic studies: preliminary results. Antiemetics -- Current Status and Future Directions, 1991.
  • Zee B, Pater J. Recursive structural model: an approach to analyze data with treatment adherence problem in randomized clinical trials. Controlled Clin.Trials 12(5), 625, 1991.
  • Eisenhauer E, Johnston J, Cassileth P, Kraut E. Durability of 2-Deoxycoformycin induced remissions in patients with hairy cell leukemia. International Cancer Congress, 1990.
  • Eisenhauer E, Wierzbicki R, Venner P, Skillings J, Letendre F. Phase II trial of recombinant tumour necrosis factor (rTNF) in patients with renal cell carcinoma. Proc.Am.Soc.Clin.Oncol. 9, 139, 1990.
  • Erlichman C, Moore M, Kerr I, Wong B, Eisenhauer E. Phase I trial of the anthrapyrazole CI-937. Proc.Am.Soc.Clin.Oncol, 1990.
  • Fine S, Rusthoven J, Erlichman C, Wilson K, Johnston D, Zee B, Pater J, Smaldone L. Dose Response in the control of nausea and vomiting with batanopride. A multicentre double-blind randomized trial of the Clinical Trials Group of the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol. 9, 1316, 1990.
  • Johnston D. Coordinating a pivotal clinical trial: an educational experience. Controlled Clin.Trials 11(4), 306, 1990.
  • Koski B. Impact of the monitoring of center performance. Controlled Clin.Trials 11(4), 304, 1990.
  • Loomer S. Does center size affect protocol compliance on multicentered clinical trials? The NCIC Clinical Trials Group's Experience. Controlled Clin.Trials 11(4), 297, 1990.
  • Moertel CG, Loprinzi CL, Witzig TE, Wieand H, Gonchoroff NJ, Reiman HM, Galandiuk S, Fitzgibbons R, Barlow JF, Donohue JH. The dilemma of stage B-2 colon cancer. Is adjuvant therapy justified? A Mayo Clinic/North Central Cancer Treatment Group study. Proc.Am.Soc.Clin.Oncol. 9, 108, 1990.
  • Murray N, Coppin C, Rapp E, Pater J, Cormier Y, Evans W, Hodson I, Clark D, Feld R, Arnold A, Ayoub J, Wilson K, Latreille J, Wierzbicki R, Hill D. The Canadian multicenter trial in non-small cell lung cancer: an analysis of drug delivery. Proc.Am.Soc.Clin.Oncol. 9, 225, 1990.
  • Pater J. For the Ovarian Cancer Trials Committee of the NCIC CTG. Cyclophosphamide/cisplatin (CDDP) versus cyclophosphamide/carboplatin (CBDCA) in macroscopic residual ovarian cancer. Initial results of a NCIC Clinical Trials Group Trial. Proc.Am.Soc.Clin.Oncol. 9, 602, 1990.
  • Paul N. Industry involvement in cooperative group trials: effects on data management. Controlled Clin.Trials 11(4), 280, 1990.
  • Rusthoven J. On behalf of the NCIC Clinical Trials Group and Bristol Myers Squibb. Randomized, double blind controlled trial testing the dose response and overall efficacy of batanopride in patients receiving moderately emetogenic chemotherapy. Ann.Oncol. 1(Suppl, abstr W9:18, 1990.
  • Rusthoven J, Levin L, Eisenhauer E, Carmichael J. A phase I study of GM-CSF, cyclophosphamide, and escalating doses of carboplatin (CBDCA) in chemotherapy-naive patients with ovarian cancer. Ann.Oncol. 1 (Suppl, abstr W1:12), 1990.
  • Rusthoven J, O'Connell G, Mazurka J, Eisenhauer E, MacFarlane D, Levin L, Hirte H. A phase I study of GM-CSF, cyclophosphamide, and escalating doses of carboplatin (CBDCA) in chemotherapy-naive patients with ovarian cancer. Ann.R.Coll.Phy.Surg.Can, 1990.
  • Sadura A. Determining ineligibility: the role of central review of supporting documentation. Controlled Clin.Trials 11(4), 288, 1990.
  • Venner P. Granisetron for high dose cisplatin induced emesis: a randomized double blind study. Proc.Am.Soc.Clin.Oncol. 9, 320. 1990.
  • Weinerman B, Shah A, Fields A, Kerr I, et al. A randomized trial of continuous systemic infusion vs bolus therapy with 5 fluorouracil in metastatic measurable colorectal cancer. Proc.Am.Soc.Clin.Oncol. 9, 399, 1990.
  • Zee B, Pater J. Sample size for trials where survival depends on first response rate. Controlled Clin.Trials 11(4), 301, 1990.
  • Bergsagel D, Belch A, Wilson K, O'Reilly D, Zee B. A controlled trial of daily etidronate disodium (Didronel) in the management of bone disease of multiple myeloma. International Workshop of Advances in Biology and Therapy of Myeloma, 1989.
  • Blackstein M, Eisenhauer E, Wierzbicki R. Epirubicin in extensive small cell lung cancer: a phase II study in patients without prior chemotherapy. Proc.Am.Soc.Clin.Oncol, 1989.
  • Eisenhauer E. Novel anticancer drugs in phase I development: the anthrapyrazoles and a diarylsulfonylurea. International Congress of Chemotherapy, 1989.
  • Eisenhauer E, Evans W, Blackstein M. New agent testing in untreated patients with extensive small cell lung cancer: the NCI Canada experience. NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1989.
  • Evans W, Wierzbicki R, Ayoub J, Cormier Y, Laberge F, Shepherd F, Eisenhauer E. Amonafide in previously untreated extensive small cell lung cancer: treatment results and lessons learned by the NCI Canada Clinical Trials Group. Ann.R.Coll.Phy.Surg.Can, 1989.
  • Evans W, Wierzbicki R, Ayoub J, Cormier Y, Laberge F, Shepherd F, Eisenhauer E. Amonafide in previously untreated extensive small cell lung cancer: treatment results and lessons learned by the NCI Canada Clinical Trials Group. Proc.Am.Soc.Clin.Oncol, 1989.
  • Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Rapp E. Counting the costs of chemotherapy in a randomized trial in non-small cell lung cancer. Proc Am Soc Clin Oncol 8[abstr 858], 221, 1989.
  • Maroun J, Stewart D, Verma S, Eisenhauer E. Phase I study of didemnin B given in a weekly schedule. Proc.Am.Assoc.Cancer Res, 1989.
  • Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.
  • Pater J, Coy P, Murray N, Hodson I, Payne D, Ayoub J, Dixon P. Safety of concurrent chemotherapy and thoracic irradiation in patients with small cell lung cancer: results of a NCIC Clinical Trials Group trial. Proc.Am.Soc.Clin.Oncol, 1989.
  • Pritchard K, Pater J, Paul N, Paterson AHG, Fine S. Thromboembolic complications related to chemotherapy in a NCIC Clinical Trials Group randomized trial of tamoxifen versus tamoxifen plus chemotherapy in postmenopausal women with axillary node positive receptor positive breast cancer. Proc.Am.Soc.Clin.Oncol. 8, 25, 1989.
  • Warr D. A double-blind randomized comparison of the novel antiemetic BRL43694A versus dexamethasone plus prochlorperazine. Eur.J.Can, 1989.
  • Wierzbicki R, Venner P, Skillings J, Stewart D, Eisenhauer E. Phase II study of recombinant tumor necrosis factor (TNF) in renal cell carcinoma. Symposium on Immunobiology in Clinical Oncology, 1989.
  • Zee B, Redmond C. Exact variance and simulation model for kappa statistic. Biometric Session in ASA and Biometrics Joint Statistical Meeting, 1989.
  • Eisenhauer E, Quirt I, Cairncross G, Iscoe N, Swenerton K. Phase II evaluation of trimetrexate in four solid tumors. Eur.Soc.Med.Oncol., 1988.
  • Evans W, Eisenhauer E, Wierzbicki R, Kocha W, Wilson K, Murray N. A phase II trial of VP-16 and cisplatin in patients with unresectable mesothelioma. Ann.R.Coll.Phy.Surg.Can, 1988.
  • Feld R, Pater J, Coy P. Restaging of responding patients with limited disease small cell lung cancer -- is it really necessary? Proc.Am.Soc.Clin.Oncol, 1988.
  • Goodwin P, Feld R, Evans WK, Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a Canadian randomized trial in small cell lung cancer. World Conference on Lung Cancer, 1988.
  • Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Rapp E. Combination chemotherapy for advanced non-small lung cancer -- effective but at what cost? Lung Cancer 4 (suppl), 1988.
  • Johnston D, Bogues W. The innovative role of study coordinator in the Clinical Trials Group. Controlled Clin.Trials 9(3), 266, 1988.
  • Koski B. The use of participant surveys in the estimation of annual accrual for four multicenter controlled clinical trials. Controlled Clin.Trials 9(3), 270, 1988.
  • Louie T, Mandell L, Feld A, Chow A, Robson H, Bow E, Miedzinski L, Nicolle L, Rachlis A, Phaneuf D, Pater J. Multicenter comparison of aztreonam plus cloxacillin, aztreonam plus tobramycin or moxalactam plus tobramycin as empiric therapy of febrile neutropenic episodes. Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988.
  • Pater J. Designing clinical trials of anti-emetics: who should be studied and how? Emesis Symposium, Ottawa, 1988.
  • Pater J, Johnston D, Bogues W. Multicentre antiemetic trials - the NCIC Clinical Trials Group experience. Emesis Symposium, Ottawa, 1988.
  • Quirt I, Eisenhauer E, Knowling M, Warr D, Bramwell V, Rusthoven J, Wierzbicki R, Verma S. A phase II study of trimetrexate in metastatic soft tissue sarcoma: a cooperative study of the Canadian Sarcoma Group and the NCIC Clinical Trials Group. Proc.Am.Soc.Clin.Oncol, 1988.
  • Carmichael J, Shelley W, Kirk M, Krepart G, Levitt M, Fraser R, Roy M, Wilson K. Factors predictive of persistent disease in patients N.E.D. at the completion of a course of cisplatin containing chemotherapy. Gynecol.Oncol. 26, 416, 1987.
  • Eisenhauer E, Pritchard K, Perrault D, Verma S, Pater J. Phase II study of intravenous menogaril as first line chemotherapy for patients with breast cancer. Proc.Am.Soc.Clin.Oncol. 6, 1987.
  • Klaassen D, Shelley W, Starreveld A, Boyes D, Gerulath A, Levitt M, Fraser R, Carmichael J, Methot Y. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate -- all programs included pelvic radiotherapy. Proc.Am.Soc.Clin.Oncol. 6, 117, 1987.
  • Logan D, Perrault DJ, Eisenhauer E, Stewart D, White D. Phase I-II study of flutamide in metastatic breast cancer. Proc.Am.Soc.Clin.Oncol, 1987.
  • Rapp E, Pater J, Willan A, Cormier Y, Murray N, Evans W, Hodson I, Clark D, Feld R, Arnold A, Ayoub J, Wilson K, Latreille J, Wierzbicki R, Hill DP. A comparison of best supportive care to two regimens of combination chemotherapy in the management of advanced non-small cell lung cancer. A report of a Canadian multicentre trial. Proc.Am.Soc.Clin.Oncol. 6, 168, 1987.
  • Yelle L, Willan A, Pater J. Trial of chemotherapy and radiotherapy in advanced Hodgkin's disease. Clin.Invest.Med. 10(4), 1987.
  • Band P, Maroun J, Pritchard K, Coppin C, Wilson K, Eisenhauer E. Phase II study of lonidamine in advanced breast cancer. NCI Canada Clinical Trials Group. Proc.Am.Soc.Clin.Oncol, 1986.
  • Band P, Weinerman B, Eisenhauer E, Murray N. Lonidamine, a new anticancer agent: overview of Canadian trials. International Cancer Congress, 1986.
  • Eisenhauer E, Johnston JB, Barr R, Feldman L, Maksymiuk A, Scott G, Sutton D, Venner P, Walde D, Zaentz D. 2'-Deoxycoformycin (DCF) in hairy cell leukemia. NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1986.
  • Evans W, Murray N, Feld R, Coy P, Levitt M, MacDonald A, Cormier Y, Young V, Osoba D, Shelley W, Willan A. Canadian multicenter randomized trial comparing standard and alternating combination chemotherapy in extensive small cell lung cancer. Proc.Am.Soc.Clin.Oncol. 5, 169, 1986.
  • Johnston J, Eisenhauer E, Barr R, Feldman L, Maksymiuk A, Scott G, Sutton D, Venner P, Walde D. 2'-deoxycoformycin in hairy cell leukemia: a Canadian phase II trial. Proc.Am.Soc.Clin.Oncol, 1986.
  • Jolivet J, Landry L, Pinard MF, Eisenhauer E. Daily bolus x 9 trimetrexate: a phase I clinical pharmacokinetic and pharmacodynamic study. Proc.Am.Assoc.Cancer Res, 1986.
  • Louie T, Mandell L, Feld R, Chow A, Robson H, Bow E, Miedzinski L, Nicolle L, Rachlis A, Phaneuf D, Pater J. Multicentre comparison of aztreonam plus cloxacillin, aztreonam plus tobramycin, or moxalactam plus tobramycin as empiric therapy of febrile neutropenic episodes. International Symposium on Infections in the Immunocompromised Host, 1986.
  • O'Dwyer P, Eisenhauer E, Hoth D. Deoxycoformycin in lymphoid malignancies, an overview. NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1986.
  • Pater J, Elliott C. The effect of different measures of outcome on the results of studies of empiric antiobiotic therapy in febrile neutropenic patients. International Symposium on Infections in the Immunocompromised Host, 1986.
  • Perrault DJ, Logan D, Bramwell V, Eisenhauer E, Pritchard K, Stewart D, White D. Phase I-II study of flutamide in metastatic breast cancer. Breast Cancer Research and Treatment 8, 90, 1986.
  • Quirt I, Shelley W, Bodurtha A, McCulloch P, McPherson A, Paterson A, Prentice R, Silver H, Willan A, Wilson K. Adjuvant levamisole improves survival and disease-free survival in patients with poor prognosis malignant melanoma. Proc.Am.Soc.Clin.Oncol. 5, 130, 1986.
  • Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.
  • Belch A, White D, Bergsagel D, Wilson K, Shelley W. Remission duration in multiple myeloma. Proc.Am.Soc.Clin.Oncol. 4, 215, 1985.
  • Feld R, Evans WK, Coy P, Hodson I, MacDonald AS, Osoba D, Payne DG, Pater JL. Canadian multicentre randomized trial comparing sequential and alternating administration of two non-cross resistant chemotherapy combinations in patients with limited small cell carcinoma of the lung. Proc.Am.Soc.Clin.Oncol. 4: 177, 1985.
  • Osoba D, Erlichman C, Willan A, Levitt M, Pater J. Superiority of methylprednisolone sodium succinate over conventional dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy. Proc.Am.Soc.Clin.Oncol. 4, 268,1985.
  • Pater JL, Willan AR, Erlichman C, Osoba D, Levitt M. A validation of self-reported measures of nausea and vomiting. Proc Am Soc Clin Oncol 4[abstr C-1032], 265, 1985.
  • Pater J, Willan A, Erlichman C, Osoba D, Levitt M. A validation of self-reported measures of nausea and vomiting. Clin.Invest.Med. 8, 1985.
  • Pritchard K, Meakin J, Sawka C, Thomson D, Myers R, Sutherland D, Mobbs B, Malkin A, Shelley W, Paterson A. The role and mechanism of action of tamoxifen in premenopausal women with metastatic carcinoma of the breast: an update. Proc.Am.Soc.Clin.Oncol. 4, 54, 1985.
  • Willan A. Choosing the largest test statistic in the two-period crossover trial. American Statistical Association, 1985.
  • Belch A, White D, Bergsagel D, Wilson K, Shelley W, Koch M. Analysisof progression patterns of multiple myeloma. Ann.R.Coll.Phy.Surg.Can. 17, 343, 1984.
  • Belch A, White D, Bergsagel D, Wilson K, Shelley W. The role of maintenance chemotherapy for multiple myeloma. Proc.Am.Soc.Clin.Oncol. 3, 268, 1984.
  • Bow E, et al. The effect of prophylactic antibiotics on outcome of infection in granulocytopenic patients receiving trimethoprim/sulfamethoxazole. International Symposium on Infections in the Immunocompromised Host, 1984.
  • Maroun J, Maksymiuk A, Eisenhauer E, Stewart D, Young V, Pater J. A phase II trial of acivicin (AT-125, NSC 163501) (A) in metastatic non-small cell lung cancer. A Canadian National Cancer Institute Study. Proc.Am.Soc.Clin.Oncol. 3, 1984.
  • Pater J, Louie T, Mandell L, et al. Factors influencing outcomes of febrile episodes in granulocytopenic patients -- a multivariate analysis. Internation Symposium on Infections in the Immunocompromised Host, 1984.
  • Pater J, Shelley W, Willan A, Kirk M, Carmichael J, Krepart G, Levitt M, Roy M. The effect of histologic subtype, grade and residual tumor diameter on survival and negative second look rates in patients with Stage III and IV carcinoma of the ovary. Proc.Am.Soc.Clin.Oncol. 3, 166, 1984.
  • Quirt I, Shelley W, Bodurtha A, McCulloch P, McPherson A, Paterson A, Prentice R, Silver H, Wilson K. A controlled trial of adjuvant immunotherapy for malignant melanoma. Proc.Am.Soc.Clin.Oncol. 3, 48, 1984.
  • Weinerman B, Eisenhauer E, Maroun J, Coppin C, Armitage G. Phase II evaluation of lonidamine in advanced renal cell carcinoma. Proc.Am.Soc.Clin.Oncol 3, 1984.
  • Willan A, Pater J. Carryover and the two-period crossover clinical trial. International Biometric Conference, 1984.
  • Willan A, Pater J. Using baseline measurements to eliminate carryover in the two- period crossover clinical trial. Presented: 12th International Biometric Conference, 1984.
  • Willan A, Pater J. Carryover and the two-period crossover clinical trial. American Statistical Association, 1984.
  • Feld R, Louie TJ, Mandell L, Robson H, Chow A, Bow E, Belch A, Goldsand G, Pater J. A multicentre comparative trial of moxalactam and ticarcillin vs tobramycin and ticarcillin in febrile neutropenic patients. Proc.Am.Soc.Clin.Oncol. 2, 87, 1983.
  • Feld R, et al. The use of combination beta-lactam therapy in febrile neutropenic patients. International Conference of Chemotherapy, 1983.
  • Mandell L, Louie T, Feld R, et al. A prospective randomized trial of ticarcillin and tobramycin in the treatment of febrile neutropenic patients. International Conference of Chemotherapy, 1983.
  • Willan A, Pater J. The mixed benefits of subtracting baseline measurements in crossover trials. Clin.Invest.Med. 6 (Suppl 2), 49, 1983.
  • Belch A, Ronald AR, Feld R, Pater J. Efficacy of lithium during remission induction of acute myelogenous leukemia (AML). Blood (ASH Annual Meeting Abstracts) 58[5 Suppl, abstr 447], 1981.
  • White D, Bergsagel D, Rapp E, Khaliq A, Shelley W, Pater J. Failure of cyclophosphamide to produce response in melphalan resistant multiple myeloma. Blood (ASH Annual Meeting Abstracts) 58[5 Suppl 1, abstr 586], 1981.